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Abstract 
The objective of this doctoral research was two-fold: 1) to estimate inequalities with regard to a) 
social determinants of health (SDoH) and health-related quality of life, and b) substance use 
between women living with HIV and the general population of women in Canada; and 2) to 
assess the impact of the SDoH clusters/classes on a) illicit drug use and b) heavy alcohol 
drinking among women living with HIV. For the first objective, prevalences of social 
determinants, self-rated health status, and substance use were estimated from 1,422 women with 
HIV aged 16+ in the 2013-2015 Canadian HIV Women’s Sexual and Reproductive Health 
Cohort Study (CHIWOS, time-point 1), and then compared with their counterparts estimated in 
46,831 general population women in the 2013-2014 Canadian Community Health Survey 
(CCHS), standardized to the age/ethnoracial group distribution of women with HIV. For the 
second objective, we used longitudinal data from the 2013-2017 CHIWOS at time-point 1 
(N=1,422) and time-point 2 (N=1,252). Findings showed that compared to general population 
women, a higher proportion of women with HIV reported a) adversities regarding the social 
determinants (e.g., poverty, food insecurity, poor social support), poor/fair self-rated health 
status [manuscript 1], and b) greater cigarette smoking and illicit drug use, but similar to lower 
likelihood of binge drinking [manuscript 2]. Latent class analysis was used to determine the 
clustering of SDoH. We identified four distinct classes: no/least SDoH adversities, 
discrimination/stigma, economic hardship, and most SDoH adversities. Inverse-probability 
weighted regression models showed a substantial difference in a) illicit drug use [manuscript 3], 
and b) heavy alcohol drinking [manuscript 4] between no/least SDoH class and other SDoH 
classes. These findings underscore the need for novel approaches to address socio-structural 
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adversities and substance use among women with HIV. We also discuss additional implications 
and future research directions.  
Keywords: Social determinants of health; Substance use; Disparities; Women; HIV; Canada 
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Summary for lay audience 
People with HIV now live longer. This is due to advances in HIV care and treatment services. 
But, these people continue to face challenges in their life. The two most important challenges are 
substance use and social adversities. In this study, we compared several social factors between 
women with and without HIV. We also compared the patterns of substance use between these 
two populations. We used two data sets: 1) 1,422 women with HIV and 2) 46,851 women 
without HIV. We showed that a higher proportion of women with HIV reported living with low 
income (70.3% versus 28.1%). Severe food insecurity was more common among women with 
HIV (54.1% versus 10.2%). Poor social support, gender discrimination, and race discrimination 
were also more common among women with HIV. Poor/fair health status was more frequent 
among women with HIV. Except for alcohol, the use of other substances was more prevalent 
among women with HIV.  As shown, a higher proportion of women reported living with these 
challenges. In the next step, we examined whether social factors tend to co-occur among women 
with HIV. To do this, we used data of 12 social factors. Using statistical models, we identified 
four unique groups: a) no social adversities (group 1; 6.6%), b) mainly stigma and discrimination 
(group 2; 18.0%), c) mainly economic difficulties (group 3; 30.2%), and d) most social 
adversities (group 4; 45.2%). We finally examined the association of these groups with substance 
use. We found that illicit drug use was significantly lower among women in group 1 versus the 
other three groups. The same findings were observed for heavy alcohol use. Social 
vulnerabilities were shown to be significantly associated with a greater risk of substance use. To 
reduce harms due to substance use, social adversities are required to be addressed.
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1. Chapter 1: Objectives, introduction, and literature review  
1.1. Thesis Objectives 
The overall objective of this doctoral research work was to study the inequalities with regard to 
social determinants of health (SDoH) and the impact of the clusters of SDoH on substance use 
among women living with HIV in Canada. Specifically, this thesis had two main objectives: 
Objective 1: To explore the inequalities associated with SDoH and substance use among women 
living with HIV comparing with women in the general population in Canada. To this end, we 
used data from the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study 
(CHIWOS, at baseline 2013/15) and comparable information from the Canadian Community 
Health Survey (CCHS, 2013/14). This objective had 2 sub-objectives:  
1a. To compare age- and ethnoracial-standardized prevalence of SDoH and self-rated 
quality of life between women living with HIV and the general population of women.  
1b. To compare age- and ethnoracial-standardized prevalence of substance use between 
women living with HIV and the general population of women. 
Objective 2: To investigate the clustered impact of SDoH on substance use among women living 
with HIV in Canada. To do this objective, we used data from CHIWOS for two time-points 
(Wave 1 in 2013/15 and Wave 2 in 2015/17) to explore the clustered impact of 12 SDoH on 
substance use. Specifically, this objective had two sub-objectives: 
2a. To investigate the impact of the clusters of SDoH on drug use (opioid/stimulant use) 
among women living with HIV in Canada.  
2b. To investigate the impact of the clusters of SDoH on heavy alcohol consumption 
among women living with HIV in Canada.   
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1.2. Thesis organization 
Chapter 1: This chapter consists of a comprehensive review of the literature in line with the main 
objectives of this thesis. 
Chapter 2: This chapter addresses Objective 1a: comparing SDoH between women living with 
HIV and the general population of women. A version of this chapter has been published in PloS 
One (Manuscript 1). 
Chapter 3: This chapter addresses Objective 1b: comparing substance use between women living 
with HIV and the general population of women. A version of this chapter has been published in 
Drug and Alcohol Dependence (Manuscript 2). 
Chapter 4: This chapter addresses Objective 2a: The clustered impact of SDoH on drug use 
among women living with HIV. A version of this chapter has been published in Addiction 
(Manuscript 3). 
Chapter 5: This chapter addresses Objective 2b: The clustered impact of SDoH on heavy 
drinking among women living with HIV. A version of this chapter has been published in AIDS 
and Behavior (Manuscript 4). 
Chapter 6: This chapter provides an integrated discussion, conclusions, and future directions.  
Appendices: This section consists of questionnaires, and data sharing agreements. 
1.3. Introduction 
1.3.1 HIV profile, a global perspective  
The human immunodeficiency virus (HIV) infection continues to be a major public health 
problem worldwide.
1
 Since the beginning of the HIV epidemic, more than 77 million individuals 
have become infected with HIV and more than 35 million people have died from AIDS/HIV-
related illnesses globally. Estimates from the Joint United Nations Programme on HIV/AIDS 
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(UNAIDS) in 2017 showed that approximately 36.9 million people were living with HIV 
globally, with 1.8 million people newly infected with HIV.
2
 Women constitute approximately 
half of all people living with HIV globally; with 18.2 million women living with HIV in 2017. In 
2017, approximately one million people died from AIDS-related illnesses, which was half of the 
estimate since the epidemic’s peak in 2004 (i.e., 1.9 million).3 The advent of combined 
antiretroviral treatment (cART) has been considered as the key reason for the significant 
reduction in HIV-related deaths worldwide.
4
  
Since its introduction in 1996, treatment with cART has significantly improved such that 
cART regimens have become more effective, less toxic, and simpler with regard to pill burden 
and frequency; consequently, adherence to HIV treatment regimens has also been enhanced.
5-7
 
Both observational research
5
 and randomized trials
6
 have supported the improved treatment 
adherence due to advances in treatment regimens. The availability of cART has brought about 
sustained virologic (i.e., referring to viral load suppression) and immunological (i.e., mainly 
referring to CD4 cell count) responses.
4,8,9
 Research shows that cART effectively reduces the 
plasma HIV-1 viral load to its undetectable level (i.e., HIV RNA < 50 copies/mL or less; a limit 
of detection of the most sensitive available clinical tests), leading to a significant immunological 
recovery through an increase in circulating CD4+ T-lymphocytes.
10,11
 Viral load and CD4 cell 
counts are the two common clinical measures of HIV progression. Viral load refers the amount 
or concentration of HIV virus in the blood, with a level less than 50 copies/mL indicating 
undetectable/suppressed viral load (this limit may differ by clinical assays/tests, but 50 
copies/mL is the most common limit used in the literature). CD4 cell count assesses the function 
of the immune system, with a CD4 count below 500 cells per mm
3 
indicating increased 
vulnerabilities to immune suppression and associated opportunistic infections and diseases. 
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However, treatment adherence – typically defined as the extent to which individuals take their 
medication as prescribed
12,13
 – is an important measure in determining undetectable HIV viral 
load,
14
 with taking ≥ 95% of the medications defined as optimal adherence.12  
Progress in viral load suppression and immunological function reconstitution have 
translated into significant improvements in life expectancy (as an important population health 
indicator) of people living with HIV,
4,7,15-18
 particularly in high-income nations where 
individuals living with HIV have access to health care and cART.
4,19-23
 For example, 
Teeraananchai et al. (2017) in a meta-analysis using data from eight cohort studies of individuals 
on cART aged ≥ 14 years found that the overall life expectancy in high-income countries was an 
additional 43.3 years and 32.2 years at ages 20 and 35 years, respectively, versus 28.3 and 25.6 
additional years, respectively, in low/middle-income countries.
24
 Research has also documented 
that life expectancy among individuals on cART is approaching that in the general 
population.
19,20
 For example, a study in Switzerland showed that life expectancy at age 20 years 
increased from 11.8 years in the monotherapy era (1988–1991, where combination therapy was 
not yet introduced) to 54.9 years in the most recent cART era of the study (2006–2013), 
compared with 62.3 to 63.0 years, respectively, in the general population.
20
  
While advances in HIV treatment have substantially improved the life expectancy, 
individuals with HIV are still experiencing lower quality of life. A study in the United Kingdom 
assessing health-related quality of life among individuals with HIV aged ≥ 18 years who were 
mostly virologically and immunologically stable found a lower level of quality of life for people 
with HIV compared with the general population; it has been hypothesized that a substantial part 
of this gap might be due to the higher levels of psychiatric symptoms such as anxiety and 
depression in people with HIV.
25
This hypothesis is consistent with evidence from studies 
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conducted in the United States (US) indicating that people living with HIV are approximately 
three times more likely to experience depression than do individuals without HIV.
26
  
In general, existing evidence indicates that despite the notable improvements in their life 
expectancy, people living with HIV still experience greater morbidity and mortality in 
comparison to the general population.
27
 In addition to the role of HIV itself and aging-associated 
conditions, behavioural or lifestyle factors such as substance use
27-29
 and socio-structural 
conditions
27,30-36
 (e.g., socioeconomic status, social support, employment status, and HIV stigma) 
have been introduced as the key contributing factors that negatively affect health-related quality 
of life of individuals with HIV, either independently or in combination.
27
  
1.3.2 Global strategies to end the HIV/AIDS epidemic  
To end the HIV/AIDS epidemic by 2030, UNAIDS and partners in 2014 launched three 
ambitious goals/targets that called on countries to reach by 2020:
37
 i) to diagnose 90% of all HIV 
cases, ii) to provide cART for 90% of all persons diagnosed with HIV, and iii) to achieve viral 
suppression for 90% of people with HIV on cART. The UNAIDS 90-90-90 targets are a 
commitment to increase access to cART treatment, prevent AIDS-related deaths, prevent HIV 
transmission, and meet the goals in line with human rights. The end target is to achieve an 
undetectable viral load in 73% of people with HIV.
37-39
 While this strategy is a crucial step in 
eliminating the HIV epidemic, reports from the global HIV programmes indicate that greater 
efforts are required to help end the epidemic by 2030.
39
 Actions should particularly focus on the 
challenges that individuals typically face along with all stages of the HIV treatment (i.e., the HIV 
care cascade). Recent updates show that out of an estimated 36.9 million living with HIV 
globally, only 75% were aware of their HIV status, 59% were on cART, and 47% were virally 
suppressed,
40
 with the highest rates in resource-rich nations.
41
 These estimates imply that while 
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enormous efforts have been made to control HIV/AIDS, national programs are still far from 
meeting the global targets.  
To achieve the UNAIDS targets, evidence suggests that an effective HIV medical care 
program such as the “HIV care cascade” (or “HIV treatment continuum”), an internationally-
recognized framework, is required. This framework forms the basis of the UNAIDS 90-90-90 
targets. While various steps (stages) can be reported, this framework primarily focuses on the 
modeling of five main successive dynamic steps of HIV care, including HIV diagnosis, linkage 
to care, retention in care, adherence to cART, and viral load suppression.
42-45
 Such a sequence of 
HIV medical care and delivery is commonly used to gauge the effectiveness of cART.
44
 The 
success of this framework in preventing new HIV cases, HIV complications and HIV/AIDS-
related morbidity and mortality rely on addressing each of these steps, from scaling up HIV 
testing to diagnose those not yet known to be infected with HIV, to linkage to care and treatment 
programmes to achieve viral suppression.
46,47
 This framework aims to help depict estimates (i.e., 
proportions) for the successive steps from HIV diagnosis through viral suppression.
45
 While 
addressing all steps along the HIV care continuum framework is highly important,
44
 researchers 
have focused on those steps in the middle of this framework (i.e., linkage to and retention in 
care, and adherence to treatment), underscoring their significance in optimizing health and 
clinical outcomes among diagnosed individuals.
42,45,48,49
  
With remarkable advances in the management of HIV and improved knowledge regarding 
the optimized practices for HIV care and treatment, reasons for people with HIV receiving poor 
linkage to and retention in care as well as suboptimal treatment adherence are not justifiable.
42
 
Despite the success attributable to the cART expansion and uptake, suboptimal HIV treatment 
remains a public health challenge worldwide. The findings of a meta-analysis of studies of 
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people with HIV in North America and Africa showed that only 55% and 77%, respectively, 
achieved over 80% adherence.
50
 A global meta-analysis in 2011 among individuals on cART 
showed that, on average, 62% of individuals achieved optimal HIV treatment adherence.
51
 The 
fact is that the complexity of the HIV care models as well as multiple social and structural 
factors may limit the ability of people with HIV to remain engaged in care, highlighting the need 
for a social determinants of health (SDoH) framework when addressing the challenges 
attributable to suboptimal treatment outcomes.
42,52
 Such socio-structural-level barriers along with 
individual-level factors such as illicit drug use and heavy alcohol consumption have the potential 
to negatively impact coverage of each step along with the HIV care cascade.
46
 These challenges 
and their associated consequences in the context of HIV are discussed in greater detail below. 
1.4. Epidemiological profile of HIV in Canada 
1.4.1 Prevalence and incidence 
The national HIV statistics showed that there were an estimated 63,110 people living with 
HIV/AIDS in Canada at the end of 2016, an approximate 5% increase since 2014 (i.e., 2,945 new 
HIV infections since 2014).
53,54
 This estimate corresponds to a prevalence of 173 per 100,000. 
Almost half (N = 32,762; 51.9%) of individuals living with HIV in Canada are gay, bisexual and 
other men who have sex with men (gbMSM), with a large number of cases (N = 30,980) 
attributed to having sex with men and a small number (N = 1,782) through either having sex with 
men and/or injection drug use (IDU) (these are based on the reporting categories). Other main 
modes of HIV transmission in Canada are: heterosexual sex (N = 20,543, 32.6%), and IDU (N = 
10,986 (17.4%)), including 9,204 people whose HIV was attributed to IDU and 1,782 men 
whose HIV status could be attributed to either sex with men or IDU. The populations impacted 
by HIV infection vary from province to province. For example, based on the available estimates 
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in 2011,
55
 the HIV epidemic is concentrated mainly in gbMSM in British Columbia (45.5% of 
people with HIV), and Ontario (56.0%), and Quebec (54.2%). Estimates also show that an 
estimated 14,520 females were living with HIV, representing approximately 23% (prevalent 
cases) of all individuals living with HIV in Canada.  
HIV infection has slightly increased in Canada recently.
54-56
 Estimates in 2016 showed that 
there were 2,165 new HIV infections (incident cases) in Canada, with a slight increase over the 
estimated 1,960 new cases in 2014. The national estimates in 2016 indicate that the number of 
new HIV cases slightly increased among females since 2014: from 436 new HIV infections 
(22.2% of all new cases in 2014) to 507 (23.4% of all new cases in 2016). The HIV incidence 
rate was 6.0 per 100,000 population in Canada in 2016, with 3.3 per 100,000 for females (based 
on available data in 2014).
54,56,57
 According to the 2016 national estimates, heterosexual sex and 
injection drug use are the main drivers of HIV infection among females, with 78% and 22% of 
all new HIV cases among females attributed to heterosexual sex and injection drug use, 
respectively. According to the same data from the national estimates in 2016, females aged 20 to 
49 (years) comprised almost three-quarters of all new HIV diagnoses among women. Black, 
Indigenous and white females (women and girls) constituted 37%, 36% and 21% of all new HIV 
diagnoses among women in 2016. 
1.4.2 Treatment cascade and targets  
In line with global commitments, Canada has made substantial progress in the control of HIV 
and AIDS. At the end of 2014, approximately 80% of all estimated 65,040 individuals with HIV 
knew their HIV status (i.e., an estimated 52,220 were diagnosed). Of individuals diagnosed with 
HIV, 76% were on HIV treatment (i.e., 39,790 individuals with HIV received cART). Of all 
individuals on treatment, 89% had achieved viral suppression (i.e., 35,350 individuals on 
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treatment were virally suppressed). Reports show that only 61% of all estimated individuals 
living with HIV in Canada received appropriate HIV treatment (the global expected percentage 
is 81%), and only 54% of all individuals living with HIV were virally suppressed
58
 (the global 
target is 73%).
59
According to the Public Health Agency of Canada (PHAC),
58
 achieving the first 
90 target (i.e., 90% of all individuals with HIV know their HIV status) necessitates greater 
actions to enhance HIV test uptake and diagnosis through identifying and addressing the main 
barriers associated with HIV testing (e.g., increasing community knowledge, improving access to 
services). The low estimate for the second 90 target (i.e., 90% of all people with diagnosed HIV 
receive sustained cART) is assumed to be partly related to the “treat all” recommendation (i.e., 
treat all people with HIV at diagnosis
60
) being relatively new in 2016 when these targets were 
set. In other words, implementing this policy and adjusting to this recommendation may require 
more time for both clinicians and individuals with HIV.  
1.4.3 Life expectancy  
Reports indicate that mortality among Canadian people with HIV has declined considerably.
4,22
 
PHAC in 2016 reported that HIV-related deaths decreased by half between 1997 and 2011, and 
5-year survival rates among individuals with AIDS increased from 7% in 1981–1986 to 65% in 
1997–2012.61 Notable improvements in life expectancy have also been reported among people 
with HIV in Canada. For example, Samji et al. (2013) using data from the United States and 
Canada suggested that life expectancy at age 20 increased from approximately 36 years in 2000-
2002 to 51 years in 2006-2007, an estimate that is approaching that of a 20-year-old person in the 
general population.
22
 Patterson et al. (2015), in a study in Canada in 2015, demonstrated a steady 
increase in life expectancy at age 20 from the calendar period 2000-2003 to 2008-2012 (31 vs. 
54 years).
23
 Using data from British Columbia, Eyawo et al. (2017)
62
 found a remarkable 
10 
 
reduction in all-cause age-standardized mortality rates (ASMR) among individuals with HIV: 
approximately 127 per 1000 population in 1996 to 22 per 1000 population in 2011-2012 (83% 
decline), compared with 7.9 per 1000 population in 1996 to 6.8 per 1000 population among HIV-
uninfected individuals (14% decline). These findings indicate that even though mortality rates 
have been significantly reduced over time among Canadians with HIV, mortality rates still 
remained in excess of that of HIV-uninfected individuals.  
1.4.4 Women living with HIV 
Globally, the intersection of various factors (e.g., biological, social, structural, and political 
factors) that contributes to women’s increased vulnerability to HIV may also contribute to 
greater vulnerabilities to worse HIV- and treatment-related outcomes among women with HIV,
63-
65
 a phenomenon that is called the “feminization of HIV”.63,66,67 The unique challenges that 
women experience with regard to HIV may hamper or disrupt access to care, retention in care, 
and service utilization. Such challenges among women oftentimes result from their greater 
biological susceptibility to HIV acquisition, increased vulnerability to sexual and physical 
violence, and lower socioeconomic participations (e.g., lower educational achievement, lower 
participation in paid work, and lower income opportunities).
2,68,69
 In Canada, the complex 
intersection of discrimination based on gender with other dimensions of identity (e.g., racism, 
and sexism) can also pose critical challenges to their engagement in HIV care.
63,70-72
 
Consistent with international literature,
68,73-79
 research in Canada, where individuals have 
universal access to health care, has also documented gender inequalities/differences, with women 
reporting a lower engagement along the HIV care cascade as well as subsequent poorer HIV 
outcomes over time than their male counterparts.
64,76,79-81
 For example, Carter et al. (2014) 
documented gender inequalities in quality of HIV care during the first year after initiation of 
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treatment, and found that female gender predicted poorer quality of care (adjusted odds ratio 
(aOR) = 1.22†). Among women, the likelihood of poorer quality of care was greater among those 
with injection drug use history.
79
 Based on data from British Columbia, Lourenço et al. (2104) 
documented the high levels of heterogeneity in the HIV cascade of care across different 
population subgroups, with women having greater attrition at every step of the cascade than 
men.
80
 They found that a lower proportion of women than men achieved virologic suppression 
(73% vs. 87%), transitioned from linked to care to retained in care (20% loss vs. 11% loss), 
transitioned from retained in care to on cART treatment (15% loss vs. 8% loss), and from on 
cART to viral suppression (27% loss vs.13% loss). Puskas et al. (2011) reviewed comparative 
data on treatment adherence stratified by gender in developed countries, with eight studies from 
Canada, and found that women were less likely to report optimal treatment adherence.
76
 Using a 
population-based HAART Observational Medical Evaluation and Research (HOMER; N = 
4,534) cohort in British Columbia,
64
 Puskas et al. found that a lower proportion of women 
reported optimal treatment adherence than men (57.0% vs. 77.1%, respectively). Women were 
45% less likely to be optimally adherent to cART treatment in the adjusted analyses (aOR = 
0.55). Furthermore, a Canadian longitudinal study of injection drug users living with HIV (N = 
545) identified female gender as an independent factor associated with a greater likelihood of 
suboptimal treatment adherence (aOR = 0.70).
82
 Using data from the Canadian Observational 
Cohort (CANOC; N = 5442) collaboration, a multisite cohort study of individuals with HIV, 
Cescon et al. (2013)
81
 also documented gender differences in poor clinical outcomes, with 
women at heightened vulnerabilities. Using Kaplan-Meier methods, the estimated probability of 
virologic suppression by 6 and 12 months post-ART initiation was respectively 38% and 52% for 
                                                          
† To report the measures of associations such as odds ratio and risk ratio, this rule was followed: aa.a for estimates greater than 10 (e.g., 12.3), a.a 
for estimates between 2 and 10 (e.g., 7.4), a.aa for estimates between 1 and 2 (e.g., 1.43), and .aa for estimates less than 1 (e.g., 0.89). For very 
small estimates, we followed this rule: a.aaa such as 1.003 and .aaa such as 0.006.  
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women, and respectively 47% and 65% for men. Adjusted analyses showed that women were 
13% less likely to achieve virologic suppression than men (aHR = 0.87) and were 55% more 
likely to have virologic rebound (aHR = 1.55).  
Traumatic and stressful events owing to socio-structural conditions have resulted in 
substantial inequalities in attrition across the cascade of care among women with HIV in Canada. 
For example, Kerkerian et al. using the baseline data of the Canadian HIV Women’s Sexual and 
Reproductive Health Cohort Study (CHIWOS; N = 1,424) found that 83% of women were on 
cART, of whom 68% were adherent and 72% were virally suppressed, with a considerable 
variability among those who experienced greater disadvantages concerning the social and 
structural determinants.
83
 In fact, social determinants were found to be the main factors 
associated with attritions from one stage to another. For example, the greatest attrition between 
linkage to care and cART initiation occurred among women with unstable housing; and attrition 
between cART use and cART adherence happened mostly among women with illicit drug use 
and recent incarceration. Household annual income, racial discrimination, and incarceration 
history were among the significant contributing factors of attrition at viral suppression stage. 
According to the same data from Canadian women with HIV, Kronfli et al. (2017) documented 
that unstable housing, history of recreational drug use, and experiences of everyday racism were 
the main barriers to access to HIV care.
84
  
Consistent with the evidence from developed countries,
4,20
 life expectancy among 
Canadians living with HIV has also improved as mainly the result of the scale up of cART. 
While there are differences, available evidence in Canada indicates that life expectancy of 
individuals living with HIV on cART are approaching that of the general population,
22
 with a 
considerable gap between men and women with HIV. Samji et al. in a study involving data from 
13 
 
the U.S. and Canada found that while life expectancy at age 20 years increased with calendar 
time in both men and women with HIV, it was lower among women. Life expectancy among 
men with HIV at age 20 years was estimated as 35.9 years in 2000/02 to 53.4 years in 2006/07 
vs. women with HIV from 36.6 years in 2002/03 to 47.3 in 2006/07.
22
 The 2009 estimate of life 
expectancy in the general population of Canada at age 20 years was 59.7 years for men and 63.9 
years for women, indicating that life expectancy of men and women with HIV lags behind the 
life expectancy of men and women in the general population up to 6.3 and 16.6 years, 
respectively.
22
 Other research in Canada using data from the Canadian Observational Cohort 
(CANOC) collaboration, including people with HIV aged ≥18 years receiving cART reported a 
lower life expectancy at age 20 among women with HIV versus men with HIV (32.4 vs. 39.2 
years) and for participants with injection drug use history versus those without injection drug 
history (23.9 vs. 52.3 years).
23
 A global systematic review of the literature in 2016, in which 
three studies from Canada were also included, showed that life expectancy among women with 
HIV was higher than that among men with HIV in all resource-rich settings, except for Canada.
85
  
Research in Canada has found that women with HIV have a lower life expectancy 
compared to men,
23,86
 a difference that may be due to variations in risk factors for HIV 
acquisition rooted in social and structural inequities, resulting in poor or suboptimal HIV-related 
health outcomes among women compared with men.
64,65
 Analyses of data from British Columbia 
using a retrospective cohort study (2003-2011) of 3,653 people with HIV on treatment aged ≥ 20 
years demonstrated that life expectancy of individuals living with HIV at age 20 years was 34.5 
years, and it increased to 48.7 years (41% increase) when researchers considered only those who 
were alive after the first year follow-up.
86
 The overall life expectancy at age 20 years among 
females was lower than males with HIV (27.2 vs. 37.5 years). Individuals with HIV were 3.2 
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times more likely to die than the general population (mortality rates: 28.8 vs. 8.9 deaths per 1000 
person-years), with greater mortality among females with HIV (34.6 vs. 8.6 deaths per 1000 
person-years) than males with HIV (27.6 vs. 9.3 deaths per 1,000 person-years). Another study 
based on data from British Columbia consisted of electronic health records from 9,310 
individuals with HIV and 510,313 adults without HIV (1996-2012) found that health-adjusted 
life expectancy (HALE) at age 20 years was approximately 31 and 58 years among men with and 
without HIV, respectively.
87
 Such estimates were approximately 27 and 63 years among women 
with and without HIV, respectively. The findings of these studies indicate much shorter overall 
life expectancies among women with HIV than among men with HIV, as well as their female 
counterparts in the general population.  
1.4.5 Contributing factors in gender inequalities   
These findings show that despite universal access and availability to cART in the Canadian 
context, the fact is that not all individuals with HIV have equally benefited from the available 
HIV treatment and care programs. Disparities in care engagement, HIV outcomes, and life 
expectancy across background (e.g., sex) and baseline characteristics (e.g., history of drug use) 
remain.
22
 Multiple barriers may negatively impact the degree to which women with HIV remain 
engaged in HIV care and treatment services. Canadian research has consistently highlighted the 
contribution of social, economic and structural determinants – collectively known as the social 
determinants of health (SDoH) – to the poor HIV care and treatment outcomes among women. 
Suboptimal health-related outcomes are particularly overrepresented among those who face or 
continue to face socio-structural adversities and stressful events in their daily lives (e.g., poverty, 
discrimination, HIV-related stigma, violence). In addition to daily living conditions, other 
factors, more importantly, substance use (e.g., illicit drug use) and difficulties in accessing HIV 
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and support services are amongst significant barriers that may hinder access to HIV care, 
initiation or continuation of HIV care and treatment services, and retention in HIV care; 
consequently, they may negate the efforts in ending the HIV/AIDS epidemic. Of particular 
concern is that marginalized women in Canada are disproportionately infected with HIV, which 
underscores the necessity of understanding the social adversities as well as behavioural factors 
driving the disproportionate impact of HIV among women in Canada.
88
 
Identification of these adversities that women with HIV may experience in excess of what 
their counterparts do in the general population (i.e., those who are or assumed to be without 
HIV) is an essential step in dealing with these barriers. PHAC’s HIV strategy states that, “It is 
critical to continue to work towards creating supportive environments that address social 
determinants, decrease stigma and discrimination, and reduce barriers to prevention, treatment, 
care and support.”58 Therefore, it is essential to further investigate the individual/behavioural as 
well as socio-structural determinants that continue to negatively affect the health and well-being 
of Canadians with HIV, particularly women. The importance of these determinants and their role 
in poor HIV-related outcomes are further discussed below. 
1.5. Social determinants of health  
1.5.1 Definitions and importance 
Over the recent decades, growing attention has been paid to understanding and addressing the 
social environment factors (e.g., income), physical environment factors (e.g., housing), structural 
factors (e.g., stigma), and access to health services, collectively known as the social determinants 
of health (SDoH).
89-91
 These are the social and structural conditions that people typically 
experience in their daily life and impact their health and well-being.
91
 Greater insights into SDoH 
have been gained as of 2005 when the Commission on Social Determinants of Health (CSDH) 
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was set up by the World Health Organization (WHO) to accumulate the evidence on health 
equity and how to promote it.
91
 WHO provides a holistic SDoH conceptual framework
92
 in 
which the principle of health inequality is explicitly articulated. Under this framework, WHO 
defines SDoH as, “The conditions in which an individual is born, grows, works, lives, ages, as 
well as the wider set of forces and systems shaping the conditions of daily life”.91 The unequal 
distributions of these determinants play a significant role in overall health and give rise to greater 
inequalities in the health of individuals. WHO underlines that understanding the social 
determinants helps identify the processes interacting to create avoidable inequities in health 
outcomes.
91
 That being said, dealing with the social impacts on health is considered as a way to 
reduce health inequalities and improve the health and well-being of individuals and 
populations.
93
 
The proposed WHO framework provides two levels of the SDoH, and the link between the 
determinants and health status. These two levels are: a) structural mechanisms (determinants), 
which stem from the key institutions and processes of the socioeconomic and political context 
(e.g., macroeconomic policies, social policies, public policies, and culture and societal values). 
As this framework asserts, these structural mechanisms are responsible for stratification and 
social class divisions in the society and that define socioeconomic status of individuals within 
hierarchies of power, prestige and access to resources. Income, education, occupation, social 
class, gender, and ethnoracial identity are among the most important structural stratifiers. 
Together, context, structural mechanisms and the resultant socioeconomic status are “structural 
determinants”, which are, in fact, referred to as the “social determinants of health inequities.” 
These inequities operate through a set of intermediary determinants of health to cause health 
outcomes; and b) intermediary determinants: This level directly determines the vulnerability to 
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factors that affect health. These determinants include material circumstances (e.g., housing, food 
availability); psychosocial circumstances (e.g., lack of social support); behavioural factors (e.g., 
substance use), biological factors (e.g., genetic factors); and the health system (e.g., access to 
healthcare services).  
In the Canadian context, the concept of SDoH is seen as the social and economic 
circumstances that contribute to the health of individuals, communities, and jurisdictions as a 
whole. Dennis Raphael, the author of Social Determinants of Health: Canadian Perspectives,
94
 
provides two definitions for SDoH: i) A narrow definition as, “the primary determinants of 
whether individuals stay healthy or become ill”, and ii) A broad definition as, “the extent to 
which a person possesses the physical, social, and personal resources to identify and achieve 
personal aspirations, satisfy needs, and cope with the environment.” Raphael adds that SDoH 
“are about the quantity and quality of a variety of resources that a society makes available to its 
members.”94 While a wide range of SDoH have been developed over time, the most important 
ones  in the Canadian setting, proposed by Dennis Raphael, include: Aboriginal status, gender, 
disability, housing, early life, education, income and income distribution, race, employment and 
working conditions, social exclusion, food insecurity, social safety net, health services, 
unemployment and job security.
94,95
  
A social determinants of health  (SDoH) approach is seen as an approach moving beyond a 
medical model, in which the body is seen as a mechanism that is either running well or in need of 
repair, and a lifestyle approach, in which the causes of diseases are to be found in individuals’ 
unhealthy choices.
94
 Said differently, the two approaches of biomedical and behavioural factors 
are relatively poor indicators of health status in comparison with a social-determinants approach. 
This does not mean that SDoH approach undermines the importance of the medical care models 
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that influence health, instead, the SDoH perspective emphasizes that medical care is not the only 
influence on health.
90,94,96
 For example, in 2000, the number of deaths in the US attributable to 
three social factors of low education, racial segregation, and low social support was shown to be 
comparable with the number of deaths attributable to three medical conditions of myocardial 
infarction, cerebrovascular disease, and lung cancer, respectively.
97
 Additionally, studies in the 
United States showed that medical care was responsible for only 10-15% of avoidable deaths.
98
 
Other studies have also consistently shown the leading role of daily living conditions (e.g., 
income, employment) on health-related outcomes.
99,100
  
1.5.2 Social determinants and HIV  
Despite substantial advances in HIV prevention and treatment strategies, people continue to be 
infected with HIV, and people with HIV continue to experience poor health-related outcomes, 
with considerable inequalities across population subgroups. While the reasons for such 
inequalities are complex, evidence has documented the interplaying role of the multifaceted 
factors impacting the effectiveness of HIV care and treatment programs. A set of social and 
structural determinants are among those contributing to health inequalities.
101-103
  
In the context of HIV, the Centers for Disease Control and Prevention’s (CDC’s) National 
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) defines SDoH as, 
“the complex, integrated, and overlapping social structures and economic systems that include 
the social environment, physical environment, health services and structural and societal 
factors.”104 In this definition, structural, cultural, and societal determinants are responsible for 
inequalities in health, which in turn influence individuals’ ability to fight against HIV. Morin in 
1988 described HIV as three separate but linked epidemics: HIV (viral) epidemic, AIDS 
(disease) epidemic as well as a set of epidemics defined as “the social, cultural, economic, and 
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political reactions to the HIV and AIDS”.105 The last one – that is termed as SDoH – has played a 
significant role in expanding the infection and changing the profile of the infection. Even after 
the acquisition of the infection, people with HIV are more likely to experience inequalities with 
regard to these determinants. As the effectiveness of HIV treatment is now heavily contingent on 
consistent linkage to and retention in care as well as sustained adherence,
44,106-108
 recognizing 
these determinants and their overlapping nature is key to designing effective HIV care and 
treatment programs.
90,101,109
  
The connection between SDoH and HIV is complex and multi-directional.
110
 Despite the 
significant role the social determinants of health play in increasing vulnerabilities to HIV 
infection, living with HIV can itself elevate vulnerability to experiencing greater inequalities 
with regard to these daily life conditions. For example, living with HIV may reduce the income-
generating opportunities or may exacerbate the extent of the socio-structural adversities through 
experiencing the unfair or unjust discriminatory behaviours due to their HIV status (i.e., HIV-
related stigma).
110
 In Canada, while the individuals most affected by HIV (e.g., men who have 
sex with men, heterosexual route, injection drug use) may have different life experiences, they 
may, however, share the experience of being socio-economically marginalized and victims of 
various forms of stigma and discrimination (e.g., homophobia, racism, and sexism, HIV-related 
stigma).
110
 Inequalities with regard to social determinants not only add an additional burden of 
health problems, but they also impact the ability of individuals to seek care, treatment and 
support,
111
 and then restrict individuals from access to resources that have potential to reduce 
their HIV-related complications. The negative impacts of socioeconomic and structural 
adversities on HIV outcomes are discussed in more detail below 
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1.5.3 Socioeconomic marginalization and HIV outcomes  
Despite the substantial improvements in the survival and clinical outcomes of individuals living 
with HIV since the advent of cART, these individuals continue to experience difficulties in their 
livelihood. While consistent linkage in and retention to HIV care and optimal adherence to HIV 
treatment are necessary for individuals to gain the maximum benefits from the HIV 
programs/intervention, adversities with socioeconomic status are among the central challenges 
that individuals with HIV still face in the post-cART era.
112
 Poverty, income insecurity, 
unemployment, and food insecurity are among the significant socioeconomic cofactors that not 
only affect the distribution of HIV infection,
103,113
 but also increase the vulnerabilities to HIV-
related clinical and health outcomes among individuals with HIV. Beyond their influence on a 
wide range of health problems, the health problems created by these determinants can result in 
conditions that, in turn, deteriorate social determinants as well as other health 
determinants.
94,114,115
 For example, poverty has been linked with increased vulnerabilities to HIV 
infection which, in turn, reduces opportunities to engage in a secure employment condition, 
thereby exacerbating poverty itself as well as poverty-related outcomes.  
The link between socioeconomic status (SES) and health inequalities in HIV infection does 
not seem to be similar to other chronic health conditions. While in many chronic conditions there 
is an SES-health disparities gradient, HIV infection has predominantly impacted individuals who 
face socioeconomic adversity or marginalization;
34
 this is particularly pronounced for women 
with HIV. For example, the US Center for Disease Control reported that HIV infection occurs 
mostly among socioeconomically disadvantaged people (i.e., those at or below the poverty 
level).
116
 In Canada, HIV infection occurs predominantly among marginalized subpopulations 
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with histories of drug use/injection, sex work involvement, incarceration, and other 
socioeconomic adversities.
61,63,85,86
  
Adversity with respect to socioeconomic factors such as low education and unemployment 
has contributed to the HIV epidemic and HIV outcomes; for example, a high prevalence of HIV 
is seen among those with lower education and/or those without an occupation.
116,117
 Research has 
demonstrated worse HIV related outcomes with lower socioeconomic positions.
118-120
 Research 
examining HIV-related outcomes has found a set of socio-structural determinants that influence 
the risk of suboptimal HIV care and treatment outcomes, clinical outcomes, and morbidity and 
mortality. Extant research has shown that a large proportion of individuals living with HIV 
experience difficulties with achieving economic security or attaining employment as well as the 
subsequent suboptimal HIV care and treatment outcomes. In a review study in 2015 aiming at 
documenting factors associated with treatment initiation and adherence in Australia, Canada, and 
the United Kingdom, the economic factors were found to be the leading but under-reported 
barriers of HIV care.
121
 A meta-analysis including 28 studies published between 1996 and 2014 
from 14 countries (N = 8,743) showed a statistically significant association between being 
employed and cART adherence (overall pooled odds ratio = 1.27), and the association remained 
significant for studies from low-income and high-income countries (subgroup overall OR = 1.85 
and 1.33, respectively).
122
 Income, education, and employment were found to be independently 
associated with the level of HIV medication adherence in a systematic review.
123
 Data from the 
Women’s Interagency HIV Study (WIHS; N = 1,481), a multicenter cohort study in the United 
States, demonstrated that insured women with higher annual income (i.e., a yearly income of > 
$18,000) were 21% less likely to have a detectable viral load than those in the least annual 
income category (i.e., < $6000/yr).
124
 Another study from the same cohort of women with HIV 
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(WIHS; N = 1,115) comparing socioeconomic data between women with and without HIV found 
that a higher proportion of women with HIV reported a low income level (69% vs. 64%) and not 
having an employment (77% vs. 57%).
125
  
Evidence from Canada and internationally has consistently linked the socioeconomic 
indicators with HIV clinical indicators, including suboptimal cART treatment, elevated failure in 
immunological and virologic responses, and increased mortality rates.
118,126-131
 For example, 
individuals with lower education in comparison with those with higher education reported 
experiencing delayed diagnosis (40.5% vs. 22.0%); reported lower immunological (68% vs. 
84%) and virologic (76% vs. 86%) responses to HIV treatment; and higher risk of mortality 
(adjusted hazard ratio (aHR) = 2.3);
126
  economically poor individuals had a significantly higher 
risk of mortality (aHR = 1.50), and that poverty (aHR = 1.60) and hunger (aHR = 1.70) 
continued to predict mortality after excluding the potential mediators;
127
 individuals with no net 
wealth versus individuals with > $50,000 and individuals with an education less than high school 
versus those with college degree had greater hazard of mortality (aHR = 1.81, and 1.52, 
respectively);
128
 in comparison with individuals who had tertiary education, the risk of mortality 
was significantly higher among those with secondary (aHR = 1.30), primary (aHR = 1.68), and 
incomplete primary education (aHR = 1.93), respectively,
130
 and that the risk of HIV virologic 
success was lower among those with primary (aHR = 0.93) and incomplete primary (aHR = 
0.80) education.
130
 
Food insecurity is another key SDoH, and is defined as, “limited or uncertain availability 
of nutritionally adequate, safe foods or the inability to acquire personally acceptable foods in 
socially acceptable ways.”132,133 Food insecurity is prevalent among individuals with HIV,132,134-
137
 and is considered as one of the main barriers to optimal care and treatment outcomes.
135
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Research has linked food insecurity with HIV outcomes among individuals with HIV. For 
example, in a study of 1,213 men and women with HIV in British Columbia, 48% were 
identified as food insecure (i.e., 27% as food insecure without hunger and 21% as food insecure 
with hunger), with greater prevalence among women than men.
132
 Data from the Longitudinal 
Investigations into Supportive and Ancillary Health Services (LISA, N = 457) cohort in British 
Columbia documented food insecurity among 71% of individuals with HIV.
136
 Weiser et al. 
presented a conceptual framework and theorized that adverse HIV outcomes may be linked with 
food insecurity through nutritional, mental health and behavioural pathways.
137
 Studies among 
people with HIV receiving HIV treatment have found that food insecurity is associated with 
suboptimal adherence to HIV treatment, and incomplete HIV RNA suppression, and 
mortality.
134,135,138
 Data from British Columbia found a high prevalence (48%) of food insecurity 
among 1,119 individuals living with HIV (1998-2007). Adjusted analyses showed that 
individuals who were food insecure and underweight were 94% more likely to die than those 
who were not food insecure or underweight (adjusted hazard ratio = 1.94).
135
 Anema et al. in a 
study in British Columbia among 254 injection drug users living with HIV who initiated cART 
documented a high prevalence of food insecurity (71.3%), and found an independent association 
of food insecurity with mortality (aHR = 1.95).
134
  
1.5.4 Stigma and discrimination 
While evidence has consistently demonstrated that the advancements in HIV care and treatment 
have changed the profile of HIV from an acute to a chronic health condition, many other 
challenges such as HIV-related stigma and discrimination continue to exist and have potential to 
endanger attempts to manage HIV/AIDS in the post cART-era. Since the beginning of the HIV 
epidemic, HIV-related stigma has continued to occur globally, and has been considered as one of 
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the most serious and prevalent challenges for controlling the epidemic.
139-141
 A systematic review 
in 2014 found that the prevalence of the experience of some types of stigma among individuals 
with HIV who were on HIV treatment varied from 42% in resource-rich nations to 82% in 
resource-limited nations.
142
  
Erving Goffman, a Canadian sociologist, defines the term stigma as the “situation of the 
individual who is disqualified from full social acceptance.”143 Goffman further describes stigma 
as a term referring to an attribute or a characteristic (e.g., race/ethnicity, gender) that is deeply 
discrediting such that reduces a person in our minds “from a whole or usual person to a tainted, 
discounted one”.143 In the context of HIV, stigma is defined as discounting, discrediting and 
discriminating against individuals who are living with HIV and AIDS. The UNAIDS defines 
HIV-related stigma as “the negative beliefs, feelings and attitudes towards people living with 
HIV, groups associated with people living with HIV (e.g. the families of people living with HIV) 
and other key populations at higher risk of HIV infection, such as people who inject drugs, sex 
workers, men who have sex with men and transgender people.”140,144 Peter Piot, the former 
Executive Director of UNAIDS, in a viewpoint paper entitled AIDS: from crisis management to 
sustained strategic response published in The Lancet in 2006, introduced combating stigma and 
discrimination as one of five key imperatives for a sustained response to the HIV/AIDS 
epidemic.
145
 Piot emphasized that wide access to antiretroviral therapy is helpful in combatting 
stigma and discrimination, but insufficient. Different types of HIV-related stigma have been 
introduced and been associated with worse HIV outcomes. Some of these types include: a) 
perceived stigma, which refers to the awareness of individuals with HIV from negative attitudes 
of other people in the society, and involves expectations of discrimination and prejudice from 
others owing to their HIV status; b) internalized stigma, which refers to negative beliefs, views 
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and feelings towards themselves and those with HIV/AIDS; c) enacted stigma, which refers to 
acts of discrimination (e.g., violence, exclusion) toward individuals with HIV because they are 
infected with HIV, and involves the experience of such discriminative behaviours.
141,146-151
 
HIV-related stigma has been one of the most common barriers to HIV care and treatment 
programs. Various observational and review studies have shown the detrimental impact of HIV-
related stigma and discrimination on multiple HIV and health-related outcomes.
33,141,142
 While 
the reduction of HIV-related stigma is a crucial step toward reducing HIV inequalities and health 
inequities,
152
 its complexity has been introduced as one of the main reasons for the insufficient 
response to this prevalent phenomenon.
141,146
 Mahajan et al. believe that lack of a clear 
definition, difficulties in measuring the extent of HIV stigma, difficulties in assessing the impact 
of stigma on HIV outcomes and the effectiveness of HIV programs, and difficulties in 
developing interventions to reduce stigma are amongst those challenges that have hindered 
universal efforts to appropriately respond to HIV-related stigma.
141
 The complexity in defining 
this phenomenon may partly originate from its interaction with a range of cross-cultural 
differences, socio-structural disparities, discriminative behaviours from health care providers, 
and social processes that are not usually measured in common practice.
146,153,154
 HIV-related 
stigma can be particularly complex when compounded by marginalized behaviours (e.g., 
substance use, sex work) and demographic characteristics (e.g., gender and race/ethnicity).
141,146
  
Women with HIV have frequently reported experiencing multiple forms of stigma beyond 
those related to their gender and HIV itself;
152
 for example, stigma due to sexual minority 
orientation, transgender identity, substance use, history of sex work involvement, incarceration, 
and violence. Logie et al.
88
 developed an “intersectional model of stigma and discrimination” in 
which intersectional stigma refers to mutually constitutive relationships between disadvantaged 
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societal attributes and inequities such as HIV-related stigma, discrimination due to gender (i.e., 
sexism), discrimination due to ethno-racial status (i.e., racism), and discrimination due to sexual 
orientation or gender minority status (i.e., homo/transphobia). These stigmas have been the key 
issues identified in previous research with populations at elevated risk for HIV infection in 
Canada.
88
 While each type of stigma and discrimination can be studied independently,
152
 they 
may also tend to co-occur and create clusters or combinations in which a group of individuals 
may follow certain patterns. The identification of the distinct pattern of these stigmas can help 
better understand the impact of these societal stigmas. This is a concept similar to what Logie et 
al. called “intersectional stigma and discrimination,” referring to the overlapping, multilevel 
forms of stigma and discrimination that concomitantly pose barriers to health and wellbeing of 
women with HIV.
88
 
Stigma can negatively impact the ability of individuals with HIV to manage their disease 
and multiple health and HIV outcomes,
33,155-158
 ranging from its interfering impact on 
engagement in HIV care and treatment to inferior clinical indicators of HIV progression.
146,158-160
 
Previous studies have suggested that individuals who experience high levels of HIV-related 
stigma have lower access to, retention in and utilization of medical and HIV care as well as 
poorer treatment adherence and HIV clinical indicators. In a systematic review and series of 
meta-analyses (64 studies included), Rueda et al. found significant associations between HIV-
related stigma and lower levels of medication adherence, and lower access to and usage of health 
and social services.
33
 
The interlinked nature of HIV-related stigma with other social and mental health indictors 
in influencing the health and clinical outcomes among people with HIV have been well 
documented. For example, using data from a national cohort of women with HIV in Canada 
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(CHIWOS; N = 1,425), Logie et al. found a significant direct association between HIV-related 
stigma and gender discrimination on mental health-related quality of life (HR-QoL). In addition 
to their direct effects, these two indicators indirectly impacted HR-QoL through social support 
(acting as mediators) such that low social support accounted for 22.7% of the effect between 
HIV-related stigma and mental HR-QoL and 41.4% of the effect between gender discrimination 
and mental HR-QoL. For the impact of HIV-related stigma and racial discrimination on physical 
HR-QoL, economic insecurity accounted for 14.3% and 42.4% of the effect, respectively.
155
 In 
another study, Logie et al. found that depressive symptoms mediated the association between 
personalized stigma and cART adherence as well as the association between negative self-image 
and both cART use and adherence.
161
 Rao et al. in a cross-sectional study of individuals with 
HIV (N = 720) found that much of the effect of stigma on HIV treatment adherence was 
explained by depressive symptoms, suggesting the mediating role of depressive symptoms on the 
association between HIV-related stigma and HIV medication adherence.
156
 Based on data from 
the Women's Interagency HIV Study (WIHS; N = 1168), Turan et al. found that depressive 
symptoms and low social support (or loneliness) each separately mediated the association 
between internalized stigma and suboptimal HIV treatment adherence;
162
 meaning that a part of 
this association was explained by depressive symptoms and low social support. They also found 
that low social support operated through depressive symptoms to explain the indirect association 
between internalized HIV stigma and lower HIV adherence. Turan et al.
163
 in another study in 
the same population (N = 1356) found that perceived discrimination in healthcare settings 
significantly reduced the likelihood of optimal cART adherence (aOR = 0.81). Through serial 
mediation analyses, they documented that internalized HIV-related stigma and depressive 
symptoms mediated the perceived discrimination-adherence association, suggesting the indirect 
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impact of perceived discrimination in healthcare settings on cART adherence, first through 
internalized HIV stigma, and then through depressive symptoms. 
1.6. Substance use  
Substance use (e.g., illicit drugs, alcohol use) is prevalent among individuals with HIV. 
Inequality in substance use between individuals with HIV and their counterparts in the general 
population has been documented, suggesting a higher prevalence among individuals with HIV. 
Previous research has also estimated the prevalence of use of various substances and examined 
their association with multiple HIV and health outcomes as well as mortality.
35
 Substance use is 
not only a common driver of HIV infection, but also is directly and indirectly associated with 
suboptimal HIV care and treatment outcomes.  
There is limited research focusing on the patterns of substance use specifically in women 
with HIV, who appear to be of particular vulnerability to poorer HIV outcomes attributable to 
substance use
164-166
 owing to elevated burdens of psychiatric comorbidity, underdiagnosed 
alcohol use disorder, and greater difficulties accessing substance use treatment due to greater 
socioeconomic, cultural and structural adversities.
166-168
 Given such additional burdens of daily 
life adversities, women with concomitant HIV infection and substance use are indeed of 
particular vulnerability to poorer HIV outcomes.
168
 In addition to inequalities with regard to 
income-producing opportunities, women with HIV experience a greater level of stress and 
stressful events such as posttraumatic stress disorder (PTSD) and intimate partner violence 
(IPV),
169
 or are at greater risk for depression in their daily life.
169-172
 Research suggests that 
substance use is one coping strategy through which individuals tend to escape or avoid their 
everyday stresses or stressful events.
173
 Substance use, coupled with socioeconomic 
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marginalization and structural adversities, can bring about greater vulnerabilities toward 
suboptimal HIV outcomes among women with HIV. 
Substance use is, in fact, one of the most frequently studied correlates of HIV treatment 
non-adherence.
174
 Greater focus on substance use in the current era of cART is warranted for 
multiple reasons. One of the key reasons is due to the preponderant co-existence of HIV and 
substance use.
175
 Vagenas et al.
175
 reported that HIV and alcohol use, for example, “are 
intricately intertwined and mutually reinforcing epidemics” that have the potential for poor 
outcomes. Skalski et al.
176
 also added other reasons such as: i) the direct and indirect 
contributions of substance use to the circulation of HIV infection, ii) their association with 
health-seeking behaviours and HIV care and treatment interventions such as non-adherence to 
cART treatment, and iii) their interference with virologic and immunologic responses to cART, 
and subsequently accelerating disease progression, and mortality. Identifying and remediating 
such common barriers to treatment adherence are major priorities of behavioural HIV 
research
177,178
 and of particular importance for people with HIV themselves, as well as those 
bodies (e.g., care providers, policy-makers) that are committed to improve treatment outcomes 
and the health and well-being of these individuals.
175
 Evidence suggests that optimal adherence 
can be improved via either the facilitation of interventions that improve adherence directly or 
through the mitigation of the key challenges at each step along the HIV treatment cascade.
179-183
 
Substance use is one of these challenges that has substantially contributed to suboptimal 
engagement of individuals with HIV at each step of the HIV cascade; consequently, it has 
negated the efforts in improving HIV treatment programs. Given the modifiable nature of this 
behavioural practice, interventions targeting substance use and its predictors can potentially 
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improve the management of HIV and then enhance treatment outcomes. Below, the importance 
of these behavioural practices is discussed in detail.  
1.6.1 Alcohol consumption   
Alcohol consumption, particularly heavy use (or hazardous use), is considered a major public 
health challenge among individuals with HIV due to its high prevalence as well as its 
contribution to worse HIV outcomes.
184-187
 The World Health Organization (WHO) defines 
heavy/hazardous drinking as, “quantity or pattern of use that places patients at risk for adverse 
consequences,” and heavy drinking is defined as, “quantity of pattern of use that exceeds a 
defined threshold.”184,188,189 The National Institute on Alcohol Abuse and Alcoholism (NIAAA) 
has also provided specific definitions for different measures of heavy/hazardous alcohol use, 
specifically, a) Hazardous (or, high-risk) drinking, defined as 7 drinks or more per week for 
women.
190
 While hazardous drinking is not considered as alcohol use disorder (AUD), 
individuals who are involved in such hazardous practices are at elevated risk for the worse 
outcomes attributed to alcohol use;
191
 and b) Binge drinking, defined as “a pattern of drinking 
that brings blood alcohol concentration levels to 0.08 g/dL,” where typically happens after 4 
drinks for women in about 2 hours.
192
 A woman then can be considered as a binge drinker if she 
drinks 4 or more alcoholic drinks on the same occasion on at least 1 day within 30 days.
193
 
Heavy drinking can impact the HIV outcomes through a) behavioural mechanisms: by 
diminishing health-seeking behaviours of individuals with HIV and negate retention in care and 
treatment adherence (discussed below); and b) biochemical mechanisms: by its potential impact 
on the acceleration of disease progression.  
Multiple studies have demonstrated the preponderance of heavy/hazardous alcohol 
consumption among individuals with HIV. For example, data from a nationally representative 
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sample of people with HIV in the United States in 2002 (N = 2,864) estimated that more than 
half (53%) of individuals with HIV who were in HIV care reported last-month alcohol 
consumption, with 8% of entire sample and 15% among those who reported alcohol drinking 
identified as heavy drinkers (defined as the weekly consumption of ≥ 5 drinks/day). No statistical 
difference was observed for heavy drinking between men vs. women with HIV (15.0% vs. 
15.5%, respectively). Another study in the United States estimated a high prevalence of past-
month alcohol use (60.6%), with binge drinking reported by 27.2% of the whole sample.
194
 
Studies of women with HIV have also suggested a high prevalence of alcohol consumption; for 
example, Cook et al. identified five distinct drinking trajectories among women with HIV: 
continued heavy drinking (3%), reduction from heavy to non-heavy drinking (4%), increase from 
non-heavy to heavy drinking (8%), continued non-heavy drinking (36%), and continued non-
drinking (49%), indicating that almost 15% of the sample were involved in heavy drinking at 
some point during the follow-up.
195
 Cook et al. in an 11 year follow-up study found that 
approximately half of women reported drinking alcohol and 14% to 24% reported past-year 
hazardous drinking, suggesting that approximately 1 in 5 met criteria for hazardous drinking.
185
 
Cook et al. in a qualitative research identified that women with HIV reported drinking alcohol to 
cope with multiple adversities, including biological (e.g., addiction, to manage pain), 
psychological (e.g., coping, to escape negative experiences, to feel in control), and social (e.g., 
peer/family pressure, to socialize).
196
 Studies comparing the patterns of alcohol drinking between 
men and women have documented mixed findings. While some epidemiological research
197,198
 
found a higher prevalence among men vs. women, data from other studies
199
 indicated that a 
higher proportion of women who classified as heavy drinkers than men (7% vs. 5%, 
respectively). 
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Both in vitro and epidemiological studies have shown the negative impact of heavy 
drinking on subsequent HIV outcomes. In vitro studies demonstrated that alcohol accelerate HIV 
disease progression through impacts on key inflammatory markers (e.g., elevation in plasma 
CD4, a marker of monocyte activation),
200
 or alteration of the virus infectivity, the immune 
response of the host, and tissue injury.
201
 Epidemiological studies have also introduced heavy 
drinking as an important barrier to every step of the HIV care cascade.
187,202
 For example, a 
2010-2015 systematic review
175
 including 53 clinical studies examining the impact of alcohol 
use on each step of the HIV treatment cascade found that 77% of the included studies 
documented a negative association of alcohol consumption with at least one step of the treatment 
cascade. Other observational and review research have shown such negative impact of heavy 
alcohol consumption on the HIV care cascade outcomes; for example, retention in HIV care,
203
 
health care utilization,
204
 and suboptimal adherence to treatment.
177,202,204,205
 Aside from impacts 
on each step at the HIV care cascade, alcohol use has also been associated HIV progression 
indicators and mortality; for example, different patterns of heavy alcohol consumption have been 
associated with failing to achieve immunological response (i.e., CD4 cell count ≤ 200/mm3)206,207 
and virologic failure (i.e., detectable viral load)
208-210
 as well as a higher risk of hospitalization
211
 
and mortality.
186
 
1.6.2 Cigarette smoking  
Cigarette smoking is also prevalent among people with HIV,
212,213
 with its high prevalence 
contributes to a variety of poor outcomes.
194,213 For example, Mdodo et al. in a nationally 
representative cross-sectional study in the United States in 2009 demonstrated that individuals 
with HIV receiving medical care were approximately twice as likely to be current smokers 
compared with adults in the general population (37.6% vs. 20.6%), with a higher prevalence 
33 
 
among both men and women with HIV (40.9% and 34.6%, respectively) compared to their 
counterparts in the general population (23.3% and 18.0%, respectively).
213
 Other epidemiological 
studies, mainly from the United States, have shown the high prevalence of current cigarette 
smoking among individuals with HIV.
194,214
   
Cigarette smoking contributes to both HIV-related and non–HIV-related health outcomes 
among individuals with HIV.
213
 Beyond its contribution to the elevated risk of non-
communicable diseases such as chronic obstructive pulmonary disease (COPD),
215
 
cardiovascular disease,
215
 and cancers,
216
 cigarette smoking has been also shown to have a 
deleterious impact on HIV outcomes, such as health and treatment outcomes as well as mortality 
among individuals with HIV. Nicotine, the active ingredient in tobacco, and HIV have 
synergistic interaction to negatively regulate the synaptic plasticity gene expression and spine 
density which may contribute to the elevated risk of HIV-associated neurocognitive disorder 
(HAND),
217
 as characterized by development of cognitive, behavioural and motor abnormalities, 
and reported among almost half of individuals with HIV.
218
 Epidemiological research indicates 
that such lifestyle factors continue to negate advances in HIV outcomes.
219
 For example, 
multiple studies have reported the negative impact of cigarette smoking on outcomes among 
individuals with HIV; e.g., suboptimal adherence.
220
  
In addition to its impact on treatment interruption and non-adherence, smoking has also 
been associated with worse clinical indicators and increased risk of mortality. Such elevated 
vulnerability has been reported to be due mainly to a) biochemical mechanisms through which 
smoking can negatively influence immune and virological response, regardless of cART 
use,
221,222
 and b) behavioural mechanisms in which smoking can potentially increase cART non-
adherence.
223,224
 Research shows that individuals with HIV who reported cigarette smoking are 
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at a greater vulnerability to poor immunological and virologic responses, as well as greater risk 
of developing AIDS and all-cause mortality.
214,225-227
 Data from individuals with HIV enrolled in 
European and North American cohorts (N = 17,995) suggested a high prevalence of smoking 
(60%), and that smokers had a higher mortality rate than non-smokers (mortality rate ratio = 
1.94; with 1.84 among men and 2.41 among women).
227
 This study showed that mortality 
attributed to smoking is higher than mortality due to HIV itself. Furthermore, a lower level of 
quality of life has also been reported among individuals with HIV who were current smokers 
versus never smokers.
228
 
1.6.3 Illicit drug use  
Illicit drug use is also prevalent among individuals with HIV. Despite its substantial contribution 
to driving HIV acquisition and transmission, drug use – both injection and non-injection – has 
the potential to threaten the significant clinical benefits obtained in the control of HIV in the 
cART era.
229,230
 Illicit drug use is of particular concern among people with HIV given its high 
prevalence and the negative effects on HIV treatment outcomes and morbidity and mortality. 
Prior research from different contexts has suggested that a high proportion of individuals 
with HIV meet criteria for illicit drug use alone or in combination with other substances, alcohol 
use in particular. For example, Pence et al. reported a high prevalence of marijuana (12%) and 
crack (5%), with 11% reporting using a non-marijuana drug and 7% reporting polysubstance use 
(i.e., multiple substances at one time) at least weekly.
198
 Gurung et al. reviewed electronic 
medical records of 4,965 individuals with HIV in New York City and reported that 12.7% had an 
alcohol use diagnosis and 26.4% had a recorded drug use diagnosis, with 8.7% having co-morbid 
alcohol and drug-use diagnoses.
231
 Hartzler et al. using data from the Center for AIDS Research 
Network of Integrated Clinical Systems (CNICS; N = 10,652), a multi-regional U.S.-based data, 
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estimated the prevalence of any substance use disorders (SUDs) at 48% (50% for men vs. 36% 
for women), with 31% marijuana use, 19% alcohol use, 13% methamphetamine use, 11% 
cocaine use, and 4% opiate use, and 20% having polysubstance use disorder.
232
 Of the limited 
research among women with HIV, Cook et al. found a high prevalence of illicit drug use among 
heavy drinkers: 30.2% cocaine use, 39.5% crack use, 42.1% marijuana use, and 21.5% heroin 
use.
185
 Kuo et al. examined data from the HIV Prevention Trials Network (HPTN 064; analytic 
N = 1,882) Study, and found that 76.1% reported using one or more substances or binge drinking 
in the past six months (i.e., 37.5% as frequent users [i.e., daily or less than weekly] and 38.6% 
infrequent user), with 63.3% reported binge drinking (of them, 54.5% being as frequent users), 
followed by 25.0% cocaine use (of them, 29.5% as being frequent users) and 16.5% opioid use 
(of them, 54.5% being as frequent users).
233
  
Illicit drug use can also negatively impact the pathobiology of HIV. Xu et al. investigated 
in vitro effects of cocaine and found that a direct effect of cocaine on four major immune 
competent cells (i.e., T cell function such as helper T cells [CD4], B cell function, natural killer 
[NK] cell function, and monocyte-macrophage function).
234
 In vitro and animal models have 
documented that illicit drugs may impact the pathobiology of HIV through altering immune 
functions (e.g., NK cells, T cells, neutrophils and macrophages) and the ability of such immune 
cells to secrete immunoregulatory cytokines, and also enhancing the infectivity and/or replication 
of HIV virus.
235,236
  
Apart from the biochemical mechanisms explaining such heightened risk of HIV 
outcomes, drug use negatively impacts on health seeking behaviours, treatment utilization and 
adherence, and subsequent outcomes among individuals with HIV.
237,238
 Sohler et al. examined 
patterns of drug use (at baseline only, 6-month follow-up [i.e., starters], both periods [i.e., 
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consistent user], and nonuse) and health care utilization, and found that any drug users were 
more likely to miss HIV medical appointments (aOR = 2.2 for starters [who newly started] vs. 
nonusers, aOR = 2.9 for consistent users vs. nonusers), more likely to use emergency services 
(aOR = 4.9 for starters vs. nonusers, aOR = 2.2 for consistent users vs. nonusers), less likely to 
use antiretroviral medication (aOR = 0.23 for starters vs. nonusers, aOR = 0.19 for consistent 
users vs. nonusers), and more likely to report unmet support services need (aOR = 1.8 for 
consistent users vs. nonusers).
239
 Individuals who stopped using drugs within the follow-up did 
not significantly differ from nonusers with regard to these outcomes. Individuals reporting the 
use of hard drugs (i.e., cocaine, amphetamines, or heroin) were more likely to be cART non-
adherent (aOR = 2.1), and had higher risk of AIDS progression or death with (aHR = 2.1) or 
without (aHR = 2.5) adjusting for non-adherence, suggesting a possible adherence-independent 
mechanism of harm associated with illicit drug use.
238
 Research also showed that concurrent 
illicit drug use with other substance, e.g., alcohol use, exacerbated the negative impacts on HIV 
treatment outcomes. For example, concurrent hazardous drinking and active drug use was 
significantly negatively associated with the lowest odds of cART use (aOR = 0.40), cART 
adherence (aOR = 0.32), and viral suppression (aOR = 0.50).
240
 Limited data on women with 
HIV also showed that substance users were 20% more likely to be suboptimal cART adherent 
(adjusted prevalence ratio (aPR) = 1.20).
241
 They found that both marijuana use and non-
marijuana illicit drug use predicted suboptimal adherence.   
Epidemiological research showed that the association of illicit drug use with HIV treatment 
nonadherence has led to elevated likelihood of failure to achieve viral suppression and reduced 
CD4 cell recovery,
242
 and consequently resulting in greater risk of HIV disease progression, 
opportunistic infections, and mortality.
243-246
 In fact, illicit drug use facilitates HIV progression 
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through either curtailing treatment adherence among those receiving cART or independent of 
cART use. For example, compared to nonusers, abstinent heroin/cocaine intermittent users (aOR 
= 1.4); active intermittent users (aOR = 2.3); and persistent users (aOR = 2.1) were at greater risk 
of opportunistic infection. Persistent crack cocaine using women were at greater risk than non-
users to die from AIDS-related causes (aHR = 3.6) and to develop newly acquired AIDS-
defining illness (aHR = 1.65).
246
 Both pattern and type of illicit drug use were associated with 
HIV progression and mortality. Kapadia et al. showed an elevated risk of progression to AIDS 
among consistent (aHR = 2.5), inconsistent (aHR = 1.63) and former (aHR = 1.56) illicit drug 
using women than never users, and an increased risk of progression for stimulant users (aHR = 
2.0) and polydrug users (aHR = 1.65) compared with non-users. They also found that consistent 
drug users had greater risk of all-cause mortality (aHR = 1.43) and AIDS-related mortality (aHR 
= 1.42) than never users.
247
 
1.7. Social determinants and substance use 
As made clear above, evidence has well documented that individuals with HIV reported a higher 
prevalence of illicit drug use
248
 than their counterparts in the general population, with mixed 
findings for heavy alcohol consumption.
249,250
 Substance use as a public health problem is of 
particular concern among people with HIV due to its direct and indirect impacts.
251,252
 Substance 
use impacts individuals’ cognitive capacity and impairs their decision making and judgment, 
resulting in other risky practices.
253-255
 The co-occurrence of substance use and care and 
treatment interruptions attenuates the public health benefits of HIV treatment.
256
 As noted above, 
a large body of evidence has identified strong associations of substance use with HIV outcomes 
such as low retention in care, treatment non-adherence, poorer immunological and virologic 
responses, and elevated burdens on health systems.
28
 For example, illicit stimulant drugs (e.g., 
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crack-cocaine use) enhance viral replication, resulting in unsuppressed viral load, and blunt 
effector function of cytotoxic T lymphocytes.
257
 In addition to such direct impacts, individuals 
with HIV who use substances have elevated prevalence and frequency of medical, psychiatric, 
and substance use disorders. The resulting complications contribute to multiple key challenges in 
the provision of HIV care. In addition, drug using individuals under care for HIV and taking 
cART have increased age-matched morbidity and mortality than do their counterparts who do 
not use substances.
258
 
Few studies have explored the patterns of substance use among women with HIV and little 
research has compared such patterns with their counterparts in the general population to explore 
the inequalities associated with substance use. Given the fact that an increasing number of 
women become infected with HIV, the need to address modifiable barriers that directly or 
indirectly accelerate disease progression and negatively impact survival becomes more 
essential.
185
 This is particularly important among women with HIV who are also at greater 
vulnerabilities for their daily living conditions. While there have been appreciable progresses in 
the understanding of the epidemiology of HIV and risk factors among women over the recent 
decade, epidemiological data remain limited with respect to the key modifiable risk factors that 
have potential to diminish the efforts made to control and manage the HIV epidemic. Substance 
use is one such modifiable risk factor; however, evidence indicates that less attention has been 
paid to substance use disorders given the fact that it is an important aspect of HIV care and 
treatment.
208
 While the optimal benefits of HIV treatment are strongly tied to treatment 
adherence, substance use has the potential to interfere with treatment through non-adherence and 
then lead to poorer subsequent HIV treatment outcomes. In addition to inadequate evidence 
concerning substance use among women with HIV, the literature has also inadequately addressed 
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the modifiable risk factors associated with substance use, particularly through the SDoH 
perspective.  
The SDoH perspective highlights the leading role that the social and structural 
environments play in determining health outcomes and health status.
91,94,114,259
 According to this 
framework, certain groups are at greater risk for poor health outcomes due mainly to inequitably 
experiencing adversities with respect to the social and structural determinants.
259
 Even though 
the contribution of these determinants in the spread of the HIV epidemic has been well 
recognized, a relatively small number of studies have demonstrated the role of these 
determinants in the initiation or continuation of substance use among women with HIV. While 
evidence from different fields of research has suggested that the etiology of substance use is 
multifactorial, such that genetic, psychological, and social factors all contribute to substance use, 
Galea et al. believe that greater attention needs to be paid to the social aspects of substance 
use.
260
 In addition to the fact that people are biologic and social organisms, these researchers 
believe that there are few biologic processes or behaviours that are not mediated through social 
context. In the case of substance use behaviour in particular, evidence indicates that the 
experiences have consistently been rooted in the social context.
260,261
 In other words, social 
determinants have a direct impact on the patterns of substance use as well as the resultant levels 
of harms.
262
 Marmot and Allen in support of the leading role of social determinants believe that 
investigators “need to understand and improve the social determinants of [unhealthy] behaviours 
to reduce health inequalities and improve health while simultaneously trying to facilitate and 
support better existing behaviours.”263 A better understanding of these key determinants of health 
and their association with substance use is imperative for identifying and developing effective 
interventions in the course of HIV management among women.
262
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Evidence, predominantly US-based research, has linked substance use with social 
determinants among individuals with HIV, with a substantial focus on social stratification 
characteristics such as gender, race/ethnicity, and socioeconomic status. For example, Chander et 
al.
191
 investigated the contribution of gender, education, and race/ethnicity to both any alcohol 
use and hazardous drinking among a sample of individuals with HIV at 14 HIV primary care 
sites in the United States. They found the significant contribution of gender (aOR = 1.52 for male 
sex) and education (aOR = 1.87 for those with a college education vs. < high school) with any 
alcohol use, while no significant difference was observed across race/ethnicity groups. No 
significant association was observed between these three determinants and hazardous alcohol 
use. Crane et al.
264
 using a sample of 8,567 people with HIV from seven U.S. sites from 2013–
2015 found a significant contribution of gender (aOR = 0.77 for females vs. males) and 
race/ethnicity (e.g., aOR = 0.81 for Black vs. White) to binge drinking, and race/ethnicity to 
hazardous drinking (e.g., aOR = 0.74 for Black vs. White). Analyses stratified by sex showed 
that certain race/ethnic groups had different risk for heavy/hazardous alcohol consumption 
among males and females with HIV. Bilal et al. in a prospective sample of 7,906 people with 
HIV receiving care assessed clinical and sociodemographic predictors of alcohol misuse and 
alcohol use trajectory separately for men and women.
197
 The only available SDoH indicator in 
their model was race/ethnicity, a non-modifiable SDoH measure. While certain race/ethnic 
groups had different risk for alcohol misuse among males, no difference was observed across 
race/ethnic groups in the sample of females. Alcohol consumption trajectories were also not 
different across race/ethnic groups for males and females. Kelso-Chichetto et al. using data from 
two cohorts of men and women with HIV in their model explored the role of only two SDoH 
indicators of annual income and race on heavy alcohol use separately for male and female 
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samples. Among women, those with lower annual income levels: < $10,000 (aOR = 0.76) and 
$10,000-$30,000 (aOR = 0.72) non-significantly had lower risk of heavy drinking vs. those in 
the higher income level (≥ $ 30,000), with significant differences observed across racial groups. 
Compared with individuals in higher income levels, those with < $10,000 annual income had a 
significantly increased risk of heavy drinking (aOR = 1.97).
199
  
Research focusing on data from women living with HIV has also documented the 
contribution of a few social determinants to alcohol use. For example, Cook et al. found that 
women were significantly less likely to report hazardous drinking if they were employed (aOR = 
0.80) and had higher education (aOR = 0.72 for those with more than high school education vs. 
those with high school or less), with no significant difference for race groups and marital status 
in the adjusted analysis.
185
 Cook et al. in another study showed that among women without 
heavy drinking at baseline, those with more than high school education had a lower risk of heavy 
drinking trajectory than those with high school or lower education (aOR = 0.65), with no 
difference across racial groups, employment and marital status. Ghebremichael et al.
265
  found a 
higher odds of alcohol use among women with a higher education (aOR = 1.53 for those with 
more than high school education vs. high school or less), with no significant difference for those 
with different income levels.  
The same patterns of association between social determinants and illicit drug use have also 
been documented. For example, Pence et al.
198
 found that women with HIV were less likely to 
report frequent non-marijuana drug use (aOR = 0.88) and polysubstance use (aOR = 0.46) than 
heterosexual males with HIV. No significant difference was observed for racial groups (minority 
vs. majority) and educational levels (beyond high school vs. high school or less). In addition to 
these determinants, these authors also assessed the association of other social determinants 
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including experienced trauma, stressful life, and social support on illicit drug use. Lifetime 
trauma increased the risk (per number of traumatic experiences) of frequent non-marijuana drug 
use by 13%, frequent crack use by 9%, and polysubstance use by 30%. In addition, stressful life 
events increased the risk of frequent non-marijuana drug use by 38% per event. Higher social 
support levels decreased the risk of frequent crack use by 18% and increased the risk of 
polysubstance use by 39%, even though these estimates were not statistically significant. Studies 
focusing specifically on data from women with HIV and assessing social determinants of illicit 
drug use is limited. Carter et al.
266
 in a Canadian context found six distinct classes of substance 
use: abstainers (26.3%), tobacco users (8.8%), alcohol users (31.9%), ‘socially acceptable’ poly-
substance users (13.9%), illicit polysubstance users (9.8%) and illicit poly-substance users of all 
types (9.3%). They also found a complex pattern for women with an annual household income < 
$20,000 vs. those with ≥ $20,000: women were significantly more likely to be illicit poly-
substance users of all types (aOR = 2.8) while less likely to be alcohol users (aOR = 0.59). 
Violence as a key social determinant also significantly increased the odds of substance use. 
These studies have also found that recent experience of violence was independently associated 
with all classes of substance use, e.g., alcohol use (aOR = 2.6), illicit polysubstance use (aOR = 
7.3), illicit poly-substance users of all types (aOR = 9.4). The contribution of social determinants 
to illicit drug use is even stronger among other subgroups living with HIV. For example, a cross-
sectional sample of 2,216 youth (ages 12-26) living with HIV found that individuals with 
lifetime unstable housing reported a higher odds of non-marijuana illicit drug use (aOR = 2.2).
267
  
As noted, research has generally focused on non-modifiable social stratification 
characteristics/positions such as ethnoracial identity in assessing the role of social and structural 
determinants and their inequalities on substance use. This might be since that disparity in the 
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United States is often referred to racial/ethnic differences in health, while this concept 
(commonly termed inequality) in the United Kingdom and European countries has referred to 
differences in health across individuals with different socioeconomic classes.
263
 Undoubtedly, 
these groups of social determinants can highlight the significance of the social context of 
substance use; however, these do not provide enough help in recognizing the specific patterns of 
social determinants in relation to substance use. Therefore, to better address substance use and its 
associated harms, greater actions are required. Beyond the role of the social stratification 
characteristics, there is also a need for research on identifying the comprehensive social 
determinants that substantially influence and shape the behaviours of individuals with HIV. This 
is particularly important in the current context of HIV where effective care and treatment are 
available and accessible, and treatment has brought about significant advances in the life of 
individuals with HIV.
263
 From the social determinants of health perspective, there is indeed a 
need to address larger environmental and social factors – also called the upstream level268 – that 
influence individuals’ behaviours.268,269 The extent to which substance use is influenced by a 
comprehensive set of social and structural factors warrants additional study, particularly among 
women with HIV. Studying socio-structural factors and assessing their role in substance use have 
implications for HIV care and treatment.
270
 
1.8. The current research  
The current research was informed by the social determinants of health (SDoH) framework, a 
conceptual framework around the social and structural context of health. We aimed to document 
inequalities in daily life conditions and lifestyle factors among women with HIV in comparison 
to the general population. Informed by a social determinants of health framework, we first 
examined how social determinants of health may cluster together, and then how the identified 
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clusters of social determinants may have the differential influence on illicit drug use and 
heavy/hazardous drinking among women with HIV in Canada. In fact, this framework was used 
to help explain how substance use, that itself substantially contributes to poor HIV treatment 
outcomes, are patterned by social and structural environments. We hypothesized that the choices 
women with HIV make (here, substance use) are shaped by the choices they have (here, daily 
living conditions), which are themselves shaped by structural policies and processes. Growing 
interest in the socio-structural determinants of health has led to an increasing emphasis on 
understanding these fundamental causes (or upstream factors) and their contributions to health 
inequities.
271
 Exploring a broad range of social, economic and structural determinants can help 
understand how these determinants play a fundamental role in lifestyle-related outcomes, 
substance use in particular in the present research, among women with HIV. There is a lack of 
research among women with HIV analyzing these determinants and exploring their contribution 
to substance use, as key lifestyle or individual-level factors that have the potential to negate the 
HIV treatment outcomes and mortality. 
Studies of individuals with HIV have typically treated these social, economic and structural 
determinants as separate (or, independent) conditions or indicators when assessing their impacts 
on subsequent health outcomes, including substance use. For example, research has explored the 
independent impact of food insecurity on heavy alcohol use
272
 and illicit drug use
273,274
 as well as 
other HIV- and health-related outcomes such as treatment non-adherence,
275,276
 and 
immunological and virologic responses to HIV treatment;
277-279
 or the independent impact of 
HIV-related stigma on substance use,
280-282
 late linkage to HIV care,
283
 cART initiation and 
treatment uptake, and suboptimal ART adherence,
33,158,161,162
 mental health conditions, access to 
and usage of health and social services;
33
 or the independent impact of perceived discrimination 
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such as unfair treatment on cART adherence;
163,284
 or the independent impact of social support 
on substance use,
285
 risk behaviours;
286
 or the independent impact of under-housing or unstable 
housing, as a structural determinants of health, on substance use,
267
 medical care, and health 
outcomes;
287
 or the independent impact of incarceration, as a structural determinants of health, 
on substance use,
288,289
 treatment adherence.
290,291
  
Although assessing the independent impact of these indicators – i.e., using regression 
modeling with food insecurity, for example, as separate statistical predictors – may also have 
implications for HIV programs and interventions, methodologically, such an approach is not 
without limitation.
292
 Social determinants have the potential to co-occur (i.e., co-present) and 
then may follow certain clusters/patterns (i.e., tend to be positively correlated). Therefore, such 
analytic approaches assessing the independent impacts may fail to account for the dependency 
and overlap of these social determinants.
292
 While uncovering overlapping patterns of social 
determinants has been a challenge, other statistical approaches such as latent class analyses 
(LCA) enable researchers to account for the dependency across a set of overlapped 
indicators.
293,294
 In the context of SDoH, this method offers an important methodological step 
forward for empirically considering the inter-relationships between social, economic and 
structural factors and their joint associations with substance use. We, therefore, used LCA to first 
identify the distinct groups of women with similar patterns of social determinants, and then 
assessed the impact of the clusters of these determinants on the study outcomes (a brief 
description of LCA can be found in Appendix A). This is in line with the available 
recommendations with respect to the use of dimensions to characterize SDoH, rather than 
separate assessment of such overlapping indicators.   
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2. Chapter 2: Social Determinants of Health and Self-Rated Health Status: 
A Comparison between Women with HIV and Women without HIV from 
the General Population in Canada
1
 
 
2.1. Introduction  
Research has shown substantial improvements in health outcomes of people living with HIV 
(PLWH) since the introduction of combination antiretroviral therapy (cART); for example, life 
expectancy for those who receive cART has been approaching that of the general population.
1,2
 
Despite the remarkable successes achieved in HIV outcomes, they are still not ideal, particularly 
among women living with HIV. A recent Canadian study demonstrated that reductions in health-
adjusted life expectancy among those living with HIV were larger for women than men.
2
 In 
addition, Canadian studies have documented that a higher proportion of women experience 
poorer “quality of care” in Canada, indicating the existence of gender inequities in access and 
adherence to HIV treatment even in a universal healthcare system.
3,4
 
Although HIV is now widely known as a chronic but manageable illness where appropriate 
care and treatment services are accessible,
5
 multiple interpersonal and structural factors – 
situated within social determinants of health (SDoH), continue to limit HIV care and treatment 
efforts. The World Health Organization (WHO) defines the SDoH as “the conditions in which 
people are born, grow, live, work, and age.”6 Researchers have described the contribution of 
these socio-structural disadvantages in shaping the HIV epidemic among PLWH.
7-9
 
                                                          
1
 A version of this chapter has been published: Shokoohi M, Bauer GR, Kaida A, et al. Social Determinants of 
Health and Self-Rated Health Status: A Comparison between Women with HIV and Women without HIV from the 
General Population in Canada. PLoS One. 2019;14(3):e0213901. doi:10.1371/journal.pone.0213901  
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In turn, living with HIV can also cause greater vulnerability to socio-structural 
disadvantages; for example, PLWH experience food insecurity even after an HIV diagnosis, and 
employment loss, particularly among women.
10,11
 Despite advances in HIV interventions, PLWH 
continue to experience challenges to maintaining their health due to the barriers linked with 
SDoH.
8,9,12
 For example, socioeconomic inequities, housing instability, food insecurity, HIV-
related stigma, and discrimination have been correlated with poorer HIV care, treatment 
responses, and clinical outcomes.
10,12-17
 Women living with HIV are a population that face 
relatively lower socioeconomic status, and broader, systemic inequities that impact their health 
and wellbeing.
3,4
 
In Canada, women now represent nearly one-quarter of the estimated 75,500 PLWH.
18
 
Women living with HIV in Canada are disproportionately from communities that experience 
marginalization. For example, according to 2014 national surveillance data, 35.6% and 30.6% of 
new HIV diagnoses in women were identified as Black and Indigenous (Aboriginal), 
respectively.
18
 Canadian women living with HIV were shown having higher vulnerabilities to 
substance use, particularly cigarette smoking and illicit drug use, than Canadian women with a 
similar age/ethnoracial background.
19
 Additional experiences of disadvantage, with regard to 
social determinants in particular, can result in poorer health outcomes, even in countries where 
cART is widely available.
9
 However, the magnitude of inequalities in underlying socio-structural 
barriers among WLWH compared with the broader population have not yet been investigated as 
general population studies do not accurately identify HIV status, and HIV cohort studies often do 
not include enough women to ensure robust comparison to the broader population to assess 
differences. Understanding socio-structural barriers that WLWH face in excess of what would be 
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expected is essential to minimize vulnerability to HIV, eliminate inequities in the HIV care 
cascade, reduce vulnerabilities to poor outcomes, and improve health and well-being.  
Therefore, this study took advantage of comparable measures in two large data sets— the 
Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS) for women 
living with HIV (WLWH) and the Canadian Community Health Survey (CCHS) for women of 
the general population—to investigate socio-structural determinants and self-rated health status 
among WLWH, and then compare them with the assumed HIV-negative general population of 
women, standardizing for age and ethnoracial variables.  
2.2. Methods 
2.2.1 Study cohorts 
CHIWOS: We used data from the Canadian HIV Women’s Sexual and Reproductive Health 
Cohort Study (CHIWOS) of WLWH enrolled at time-point 1 between 2013 and 2015. As a 
community-based research study, CHIWOS applied the Greater Involvement of People Living 
with HIV/AIDS (GIPA) and Meaningful Involvement of Women Living with HIV/AIDS 
(MIWA) principles such that WLWH were integral to all steps of the research process.
20,21
 
CHIWOS enrolled 1,422 WLWH aged ≥ 16, residing in British Columbia (BC), Ontario, and 
Quebec. Participants were recruited through peers, HIV clinics, AIDS Service Organizations, 
and online networks.
20
 The survey was completed during an in-person interview at clinic or 
community sites or participants’ homes, or via phone/Skype if this was not possible. Information 
was collected using structured questionnaires, administered by trained Peer Research Associates 
(PRA) in English or French. Participants provided written or oral informed consent at enrolment. 
CHIWOS was approved by the Research Ethics Boards of Simon Fraser University, University 
of British Columbia/Providence Health, Women’s College Hospital and McGill University 
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Health Centre. CHIWOS was approved by the Research Ethics Boards of Simon Fraser 
University, University of British Columbia/Providence Health, Women’s College Hospital and 
McGill University Health Centre.  
CCHS: The Canadian Community Health Survey (CCHS) is a nation-wide population-
based survey administered by Statistics Canada that collects self-reported data on various health-
related information of approximately 65,000 Canadian residents annually.
22
 Briefly, the CCHS 
uses a multistage, stratified cluster sampling design to target ~98% of Canadians aged ≥12 for 
inclusion in all provinces and territories. The CCHS excludes people living on reserves, full-time 
members of the Canadian Forces, the institutionalized residents, and residents of some remote 
areas. For the purpose of the present research, we used Statistics Canada’s Public Use Microdata 
Files to create a combined CCHS dataset within two years of 2013/2014. For consistency with 
CHIWOS, we limited the CCHS’s analytic sample to women aged ≥16 years old, residing in the 
three provinces (analytic sample = 46,851). To study day-to-day discrimination, we used the 
CCHS-Rapid Response on the Everyday Discrimination Scale (EDS) performed separately in 
2013 (analytic sample = 6,936). CCHS collects data using both computer-assisted personal and 
telephone interviews. Statistics Canada’s Research Data Centre at the University of Western 
Ontario provided researchers of the current study with access to the CCHS microdata. 
2.2.2 Measures  
The most widely used Canadian SDoH framework recognizes that the following socio-structural 
determinants can help elucidate existing health differences: Aboriginal status, disability, early 
life events, education, employment and working conditions, food insecurity, health services, 
gender, housing, income and income distribution, race, social exclusion, social safety net, and 
unemployment and job security.
23
 We chose only those measures whose content and/or wording 
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were similar in the question stems allowing the measures to be comparable between the two 
surveys.  
The following measures were compared: relationship status (single, living common-law or 
married, and separated/widowed/divorced), education level (below high school, completed high 
school, above high school to non-university degree, and obtained university degree), yearly 
personal income (<$20,000, $20,000 to $39,999, ≥ $40,000, and Not Stated), yearly household 
income (<$20,000, $20,000 to $39,999, and ≥ $40,000), and the main source of income 
(wages/salaries [paid jobs], employment insurance/compensation/welfare, others [e.g., Dividends 
and interest, Benefits from Pension Plan, no income, etc.], and don’t know/not stated). 
CHIWOS examined food sufficiency and food security using Statistics Canada’s 4-item 
adult measure from the Household Food Security Survey Module.
24
 The matched items were also 
found in CCHS. Food sufficiency was measured with a question about past-year household food 
sufficiency, with responses recoded into three categories:  always had enough of the kinds of 
food they wanted to eat, had enough but not always the kinds of food they wanted to eat, and 
sometimes/often did not have enough to eat. Household food security over the last 12 months 
was measured by three items, “worried that food would run out,” “The food did not last, and 
there was no money to get more,” and “could not afford to eat balanced meals.” Binary response 
options for each item were created as 1 for “Sometimes/Often true” and 0 for “Never true.” We 
summed these three items to form a four-category ordinal measure: 0: food secure, 1: mildly 
food insecure, 2: moderately food insecure, and 3: severely food insecure. CCHS did not 
measure food security in BC; for comparability, we provided estimates for only Ontario and 
Quebec in CHIWOS. 
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Perceived social support was measured using a 4-item abbreviated version of the Medical 
Outcome Study Social Support Survey (MOS-SSS),
25
 measuring four domains of 
emotional/informational, tangible, affectionate, and positive social interaction. Possible 
responses included strongly disagree (score 0), disagree, agree, and strongly agree (score 3) in 
CCHS and a five-point Likert scale, with responses recoded into four categories as none of the 
time (score 0), a little of the time, some or most of the time, and all of the time (score 3). Items 
were summed (range 0–12 points), with higher scores implying greater perceived social support. 
For the purpose of comparison, we created a binary measure with ≤6 indicating poorer social 
support. The analysis was limited to data from Quebec as CCHS did not measure social support 
in BC and Ontario. 
Racial discrimination and gender discrimination measures were quantified using a 
modified version of the Everyday Discrimination Scale,
26
 with 5-item version in CCHS and 6-
item version in CHIWOS. CCHS respondents were asked to specify how often they had 
experienced various forms of day-to-day mistreatments “because of your race” or “because of 
your gender.” Items included “You are treated with less courtesy or respect than other people,” 
“You receive poorer service than other people at restaurants or stores,” “People act as if they 
think you are not smart,” “People act as if they are afraid of you,” and “You are threatened or 
harassed.” CHIWOS asked the first question in two separate items, “You are treated with less 
courtesy,” and “You are treated with less respect.” The CCHS’s items were on a five-point scale 
(at least once a week, a few times a month, a few times a year, less than once a year, never), 
while they were on a six-point scale in CHIWOS (never, almost never, not that often, sometimes, 
frequently, almost every day). Two three-category measures were created for racial and gender 
discrimination, representing: never or almost never experienced any of the mistreatments, 
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infrequent experience indicating less than once a year or not that often for any of the 
mistreatments, and frequent experience indicating more than once, or sometimes, or more in a 
year for any of the mistreatments.  
Self-rated health status was measured in both surveys using a single question, “In general, 
would you say that your health is…?” We included an ordinal variable with five possible 
responses (excellent, very good, good, fair, and poor), and a binary recoded variable (poor/fair 
vs. good/very good/excellent). 
2.2.3 Statistical analyses  
Proportions and associated 95% confidence intervals (CIs) for each measure were first estimated 
in CHIWOS (i.e., observed estimates). Then, the proportion of the same measure was estimated 
in the CCHS. Survey weights were incorporated into the analyses to account for the survey 
complexity and provide population-level estimates. The 95% CIs were constructed through the 
bootstrap variance estimation technique using a set of 500 replicates to account for the complex 
survey design effects.
27
 Standardization method was used to account for the differences in 
population structure by age and ethnoracial group (S Table 2.1). These two variables are 
considered as important confounders representing non-modifiable characteristics that differ 
between the study samples but are not a result of HIV status. To do this, we first produced a 16-
category variable representing CHIWOS’s age and ethnoracial group structure (i.e., age with 
four categories: 16-35, 36-45, 46-55, or >55; and ethnoracial statues with four categories: white, 
African, Caribbean, Black (ACB), Indigenous, or other/multi-ethnicities. We applied CHIWOS’s 
combined age and ethnoracial distribution to the CCHS sample to make the two study 
populations of CHIWOS and CCHS identical with regard to the distribution of these two 
variables. After controlling the confounding impact of these two variables, we then provided the 
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age-/ethnoracial-standardized estimates (i.e., expected estimates) of the SDoH measures and self-
rated health. Standardization combines stratum-specific prevalence into a single summary 
estimate through taking a weighted average.
28
 
We reported the standardized prevalence differences (SPDs) to quantify the differences 
between the two study samples for each SDoH measure as well as self-rated health. The SPDs 
were calculated as the proportion of the observed estimates in CHIWOS minus the expected 
estimates from the CCHS adjusted for age/ethnoracial group identity; with the SPDs > 0 
indicating a greater proportion of the given determinant among WLWH and can be interpreted as 
the proportion of WLWH experiencing an excess above what would be expected based on the 
general population women. The 95% CIs were calculated using the methods of variance 
estimates recovery (MOVER).
29
 CIs excluding 0 are indicative of statistical significance at 
p<0.05. All analyses were performed using Stata version 15. 
2.3. Results 
2.3.1 Demographics 
Women in the general population (CCHS data) were older than those in the CHIWOS sample: 
34.4% of the general population women versus only 12.0% of WLWH were >55 years old. 
Around three-quarter of general population women were White (75.2%) and the rest were either 
Black (3.2%), Indigenous (2.4%) or other/multi ethnicities (19.2%). However, the ethnoracial 
identities of CHIWOS sample were White (41.1%), African/Caribbean/Black (29.4%), 
Indigenous (22.3%), and other ethnicities (7.2%). The distribution of age and ethnoracial groups 
for both CHIWOS and CCHS is presented in (S Table 2.1).  
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The mean age of all WLWH at time-point 1 was 42.8 (standard deviation [SD]: 10.6). The 
majority identified as cisgender/non-transgender women (sex-labeled-at-birth and gender identity 
congruent) (96%) while the rest identified as transgender women. Almost one-quarter (25.1%) 
were living with HIV for 5 years or less, 40.2% were living with HIV for 6-14 years, and less 
than one-third were living with HIV for more than 14 years. Overall, 61.0% were optimally on 
HIV treatment (i.e., treatment adherence ≥ 95%), 22.0% were sub-optimally on HIV treatment 
(treatment adherence < 95%), while the rest at time-point 1 of the survey were not engaged in 
HIV treatment. Among those who were on treatment (either optimally or sub-optimally), 87.0% 
reported an undetectable viral load (i.e., <50 copies/mL). The history of lifetime injection drug 
use, sex work involvement, and incarceration was reported by 30.9%, 16.6%, and 36.9% of 
WLWH, respectively (S Table 2.2).  
2.3.2 Relationship, education, income and source of income  
Proportions of indicators of relationship status, education, poverty, and main source of income 
differed significantly between WLWH and estimates expected based on the age-/ethnoracial-
standardized general population. The proportion who were single was higher among WLWH 
compared with the general population (48.7% vs. 26.6%; SPD 22.1% [95% CI: 18.8, 25.4]), 
while a lower proportion of WLWH reported being married or in a common-law relationship 
status than their general population counterparts (32.1% vs. 55.3%; SPD -23.2% [95% CI: -26.7, 
-19.6]). A lower proportion of WLWH had a university education than the general population 
(14.1% vs. 27.9%; SDP -13.7% [95% CI: -16.8, -10.6]), whereas a higher proportion had an 
education level of less than high school (16.1% vs. 12.3%; SPD 3.8% [95% CI: 1.5, 6.1]). More 
than two-thirds (70.3%) of WLWH versus less than one-third (28.1%) of women of the general 
population reported a personal income <$20,000 annually, yielding an SPD 42.2% (95% CI: 
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39.1, 45.2). A higher proportion of WLWH also reported a household income <$20,000 than the 
estimate expected in the general population sample (65.3% vs. 10.9%; SPD 54.4% [51.5, 57.3]). 
Finally, 22.1% of WLWH compared with 69.9% of their counterparts in the general population 
reported having wages/salaries (i.e., paid jobs) as their main source of income (SPD -47.8% [-
50.9, -44.6]), while a high proportion of WLWH (62.2%) reported having an employment 
insurance/compensation/welfare as their main source of income versus only 9.5% of the general 
population women (SPD 52.7% [95% CI: 49.5, 55.8]) (Table 2.1).  
Table 2.1: Comparing Sociodemographic Variables of Women Living with HIV 
(CHIWOS; 2013-2015) and the General Population of Women in Canada (CCHS; 2013-
2014) 
 CHIWOS
* 
 
(1) 
CCHS estimates
*
  SPD
¥ 
 
(1) – (2) 
CCHS
£
 
AER Std.
† 
(2) 
Relationship status      
Single  48.7 
(46.1, 51.3)
‡
 
24.3 
(23.7, 24.8) 
26.6 
(24.6, 28.7) 
22.1 
(18.8, 25.4) 
Married or common-law 32.1 
(29.7, 34.6) 
58.0 
(57.3, 58.7) 
55.3 
(52.7, 57.9) 
-23.2 
(-26.7, -19.6) 
Separated/divorced/widowed  19.2 
(17.2, 21.3) 
17.7 
(17.2, 18.3) 
18.1 
(15.8, 20.4) 
1.1 
(-1.9, 4.2) 
Education      
Less than high school  16.1 
(14.2, 18.1) 
15.4 
(14.9, 16.0) 
12.3 
(11.0, 13.6) 
3.8 
(1.5, 6.1) 
High school completed  37.6 
(35.1, 40.2) 
24.7 
(24.0, 25.4) 
23.9 
(21.9, 25.9) 
13.7 
(10.5, 16.9) 
Diploma/trade/college  32.2 
(29.8, 34.7) 
30.6 
(29.8, 31.3) 
35.9 
(33.4, 38.4) 
-3.7 
(-7.1, -0.11) 
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University degree 
(≥Bachelor’s degree) 
14.1 
(12.4, 16.1) 
29.3 
(28.6, 30.1) 
27.9 
(25.4, 30.4) 
-13.8 
(-16.8, -10.6) 
Yearly personal income 
a
     
<20,000 CAD 
b
 70.3 
(67.8, 72.6) 
29.1 
(28.4, 29.9) 
28.1 
(26.1, 30.0) 
42.2 
(39.1, 45.2) 
20,000 to <40,000 CAD 17.2 
(15.3, 19.3) 
24.8 
(24.1, 25.5) 
24.5 
(22.4, 26.7) 
-7.3 
(-10.1, -4.1) 
≥ 40,000 CAD 10.1 
(8.7, 11.8) 
30.0 
(29.2, 30.8) 
33.1 
(30.4, 35.8) 
-23.0 
(-26.1, -19.5) 
Not stated  2.4 
(1.7, 3.3) 
16.1 
(15.5, 16.8) 
14.3 
(12.3, 16.3) 
-11.9 
(-14.0, -9.7) 
Yearly household income      
<20,000 CAD 65.3 
(62.8, 67.8) 
9.3 
(8.9, 9.8) 
10.9 
(9.5, 12.3) 
54.4 
(51.5, 57.3) 
20,000 to <40,000 CAD 20.6 
(18.5, 22.8) 
20.4 
(19.7, 21.0) 
18.9 
(16.8, 21.1) 
1.7 
(-1.29, 4.74) 
≥ 40,000 CAD 14.1 
(12.3, 16.0) 
70.3 
(69.6, 71.1) 
70.2 
(67.8, 72.6) 
-56.1 
(-59.1, -53.0) 
Main source of income      
Wages/salaries (paid jobs) 22.1 
(20.0, 24.3) 
59.2 
(58.4, 60.1) 
69.9 
(67.6, 72.2) 
-47.8 
(-50.9, -44.6) 
Employment insurance/ 
compensation / welfare  
62.2 
(59.6, 64.7) 
4.8 
(4.40, 5.1) 
9.5 
(7.6, 11.4) 
52.7 
(49.5, 55.8) 
Others (ex. dividends and 
interest, pension, no income, 
etc.)) 
15.0 
(13.3, 17.0) 
29.4 
(28.7, 30.0) 
17.0 
(15.7, 18.3) 
-2.0 
(-4.1, 0.4) 
Don’t know or not stated 0.70 
(0.38, 1.30) 
6.6 
(6.2, 7.1) 
3.6 
(2.6, 4.6) 
-2.9 
(-3.9, -1.7) 
*
 The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS; N=1,422) and the 
Canadian Community Health Survey (CCHS; analytic N=46,851);  
‡ 
Data are % (95% Confidence Intervals (CIs)); 
£
 
Unstandardized weighted estimates are reported from CCHS; 
† 
AER Std.: Age- and ethnoracial-standardized 
expected estimates from CCHS; 
¥
 SPD: standardized prevalence difference (% (95% CIs)), with positive (negative) 
84 
 
values indicating higher (lower) prevalence in WLWH in excess of (less than) what would be expected of Canadian 
women of similar ages/ethnoracial backgrounds; 
a
 aged > 17 years old; 
b
 Canadian dollar (CAD) 
 
2.3.3 Food security   
Proportions of food insufficiency and food insecurity were substantially higher in WLWH 
compared with expected estimates from the general population women. A higher proportion of 
WLWH reported sometimes or often their household did not have enough to eat over the last 12 
months (15.7% vs. 2.6%; SPD 13.1% [95% CI: 10.9, 15.7]), and had enough but not always the 
kinds of food (53.7% vs. 15.3%; SPD 38.4% [95% CI: 34.4, 42.4]). The analysis of the 
individual items of food security scale showed that a higher proportion of WLWH reported their 
household sometimes/often “worried that food would run out before you got money to buy 
more” (65.7% vs. 17.9%), “the food bought didn’t last and there wasn’t any money to get more” 
(62.9% vs. 14.3%), and “couldn’t afford to eat balanced meals” (62.7% vs. 14.0%). Overall, a 
higher proportion of WLWH reported experiencing severe (54.1% vs. 10.2%; SPD 43.9% [95% 
CI: 40.2, 47.5]), moderate (10.3% vs. 5.3%; SPD 5.0% [95% CI: 2.6, 7.6]), and mild (8.2% vs. 
5.2%; SPD 3.0% [95% CI: 1.1, 5.1]) food insecurity than the expected values in the general 
population (Table 2.2).  
Table 2.2: Comparing Food Sufficiency and Food Security between Women Living with 
HIV (CHIWOS; 2013-2015) and the General Population of Women in Canada (CCHS; 
2013-14) 
 CHIWOS
* 
 
(1) 
CCHS estimates
*
 SPD
¥ 
 
(1) – (2) 
CCHS
£
 
AER Std.
† 
(2) 
Food sufficiency     
Always had enough of 30.5 89.6 82.0 -51.5 
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the kinds of food (27.8, 33.4)
‡
 (88.9, 90.2) (79.2, 84.8) (-55.4, -47.5) 
Had enough, but not 
always the kinds of food 
53.7 
(50.7, 56.7) 
9.1 
(8.5, 9.7) 
15.3 
(12.7, 18.0) 
38.4 
(34.4, 42.4) 
Sometimes or often did 
not have enough to eat 
15.7 
(13.7, 18.1) 
1.3 
(1.1, 1.6) 
2.6 
(1.7, 3.6) 
13.1 
(10.9, 15.7) 
Food security items      
Item 1) Food run out      
Never  34.3 
(31.5, 37.2) 
90.8 
(90.2, 91.4) 
82.1 
(79.5, 84.7) 
-47.8 
(-51.5, -43.8) 
Sometimes/often  65.7 
(62.7, 68.5) 
9.2 
(8.6, 9.8) 
17.9 
(15.3, 20.5) 
47.8 
(43.8, 51.5) 
Item II) Food did not last      
Never 37.1 
(34.3, 40.1) 
93.3 
(92.7, 93.9) 
85.7 
(83.3, 88.0) 
-48.5 
(-52.2, -44.7) 
Sometimes/often 62.9 
(59.9, 65.7) 
6.7 
(6.1, 7.2) 
14.3 
(12.0, 16.7) 
48.5 
(44.7, 52.2) 
Item III) Could not afford 
for balanced meal  
    
Never  37.3 
(34.4, 40.3) 
92.8 
(92.2, 93.3) 
86.0 
(83.5, 88.4) 
-48.6 
(-52.4, -44.8) 
Sometimes/often  62.7 
(59.7, 65.5) 
7.2 
(6.6, 7.7) 
14.0 
(11.6, 16.5) 
48.6 
(44.8, 52.4) 
Overall Food security 
a
     
Food secure 27.4 
(24.8, 30.2) 
88.6 
(88.0, 89.3) 
79.3 
(76.7, 82.0) 
-51.9 
(-55.6, -48.0) 
Mildly food insecure 8.2 
(6.7, 10.0) 
4.1 
(3.7, 4.5) 
5.2 
(4.1, 6.4) 
3.0 
(1.1, 5.1) 
Moderately food insecure 10.3 
(8.6, 12.3) 
2.7 
(2.4, 3.0) 
5.3 
(3.6, 6.9) 
5.0 
(2.6, 7.6) 
Severely food insecure 54.1 4.5 10.2 43.9 
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(51.0, 57.0) (4.0, 5.0) (8.1, 12.2) (40.2, 47.5) 
*
 CHIWOS-Ontario/Quebec (N=1,066) and CCHS-Ontario/Quebec (N=33,704); 
‡ 
Data are % (95% Confidence 
Intervals (CIs)); 
£
 Unstandardized weighted estimates are reported from the Canadian Community Health Survey 
(CCHS); 
†
 AER Std.: Age- and ethnoracial-standardized expected estimates from CCHS; 
¥
 SPD: standardized 
prevalence difference (% (95% CIs)), with positive (negative) values indicating higher (lower) prevalence in 
WLWH in excess of (less than) what would be expected of Canadian women of similar ages/ethnoracial 
backgrounds; 
a
 The summation of three binary items (0, indicating Never true and 1, indicating sometimes/often 
true) of the scale produced an index ranging from 0 to 3; 0: food secure, 1: mild food insecurity, 2: moderate food 
insecurity, and 3: severe food insecurity. 
2.3.4 Social support and discriminations 
Analyzing the overall binary measure of perceived social support showed that a higher 
proportion of WLWH reported poorer social support compared with the general population 
women adjusted for age and ethnoracial group status (30.3% vs. 2.9%; SPD 27.4% [95% CI: 
22.2, 33.0]). WLWH reported experiencing frequent racial discrimination (46.4% vs. 9.6%; SPD 
36.8% [95% CI: 31.9, 41.8]) and frequent gender discrimination (54.4% vs. 8.4%; SPD 46.0% 
[95% CI: 42.6, 51.6]) than the expected values of the general population women (Table 2.3). 
Table 2.3: Comparing Social Support, and Racial and Gender Discrimination between 
Women Living with HIV (CHIWOS; 2013-2015) and the General Population of Women in 
Canada (CCHS; 2013-2014) 
 CHIWOS 
 
(1) 
CCHS estimates  SPD
¥ 
 
(1) – (2) 
CCHS
£
 
AER Std.
† 
(2) 
Perceived social support
*,a
     
Poor  30.3 
(25.6, 35.5)
‡
 
1.9 
(1.5, 2.3) 
2.9 
(0.7, 5.1) 
27.4 
(22.2, 33.0) 
Good 69.7 
(64.5, 74.4) 
98.1 
(97.7, 98.5) 
97.1 
(94.9, 99.3) 
-27.4 
(-33.0, -22.2) 
Race discrimination
**
     
Never  45.6 93.5 87.1 -41.5 
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(43.0, 48.2) (92.2, 94.8) (82.2, 92.1) (-47.1, -36.0) 
Infrequent 8.0 
(6.7, 9.6) 
1.1 
(0.65, 1.48) 
3.3 
(0.5, 6.1) 
4.7 
(1.7, 7.9) 
Frequent  46.4 
(43.8, 49.0) 
5.4 
(4.1, 6.6) 
9.6 
(5.3, 13.8) 
36.8 
(31.9, 41.8) 
Gender discrimination
**
     
Never  37.5 
(35.0, 40.0) 
89.3 
(88.2, 90.5) 
89.4 
(87.0, 91.7) 
-51.9 
(-55.3, -48.4) 
Infrequent  8.2 
(6.9, 9.7) 
2.6 
(2.1, 3.1) 
2.2 
(1.2, 3.2) 
6.0 
(4.3, 7.8) 
Frequent  54.4 
(51.8, 56.9) 
8.1 
(7.0, 9.0) 
8.4 
(6.2, 10.6) 
46.0 
(42.6, 51.6) 
*
 CHIWOS-Quebec (N=355) and CCHS-Quebec (N=11,780); 
**
 CHIWOS-all N=1,422 and CCHS rapid survey 
(N=6,936); 
‡ 
Data are % (95% Confidence Intervals (CIs)); 
£
 Unstandardized weighted estimates are reported from 
the Canadian Community Health Survey (CCHS); 
†
 AER Std.: Age- and ethnoracial-standardized expected 
estimates from CCHS; 
¥
 SPD: standardized prevalence difference (% (95% CIs)), with positive (negative) values 
indicating higher (lower) prevalence in WLWH in excess of (less than) what would be expected of Canadian women 
of similar ages/ethnoracial backgrounds; 
a
 The summation of four items, each having four options (0 to 3), produced 
an index ranging from 0 to 12; with a lower score indicating lower level of social support. A binary measure was 
created based on the mid-point threshold score: score mid-point or below (i.e., ≤ 6) indicated poor/low perceived 
social support, and scores above mid-point (i.e., > 6) indicated better/good perceived social support.  
 
2.3.5 Overall health status  
A higher proportion of WLWH reported poor and fair overall health status than the estimates 
expected based on the age-/ethnoracial-standardized assumed HIV-negative women. The 
aggregated proportion of these two options (i.e., fair/poor health condition), indicating a lower 
level of overall health status, was higher among WLWH than the general population women 
(24.8% vs. 12.6%; SPD: 12.2% [95% CI: 9.4, 15.0]) (Table 2.4).  
Table 2.4: Comparing Self-rated Overall Health Status between Women Living with HIV 
(CHIWOS; 2013-2015) and the General Population of Women in Canada (CCHS; 2013-
2014) 
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Self-rated health 
CHIWOS 
 
(1) 
CCHS estimates  SPD
¥ 
 
(1) – (2) 
CCHS
£
 
AER Std.
† 
(2) 
A five-category measure     
Excellent  8.3 
(6.9, 9.8)
‡
 
20.7 
(20.0, 21.4) 
21.9 
(19.5, 24.2) 
-13.6 
(-16.3, -10.8) 
Very good  26.9 
(24.6, 29.3) 
37.5 
(36.7, 38.3) 
35.8 
(33.6, 37.9) 
-8.9 
(-12.0, -5.7) 
Good  40.1 
(37.5, 42.6) 
30.0 
(29.1, 30.8) 
29.7 
(27.3, 32.1) 
10.3 
(6.8, 13.8) 
Fair  19.0 
(17.1, 21.2) 
8.8 
(8.3, 9.2) 
8.9 
(7.5, 10.2) 
10.2 
(7.8, 12.7) 
Poor  5.7 
(4.6, 7.1) 
3.0 
(2.8, 3.3) 
3.7 
(2.8, 4.7) 
2.0 
(0.51, 3.6) 
A binary measure      
Excellent/v. good/good 75.2 
(72.9, 77.4) 
88.2 
(87.6, 88.7) 
87.4 
(85.8, 89.0) 
-12.2 
(-15.0, -9.4) 
Fair/poor  24.8 
(22.6, 27.1) 
11.8 
(11.3, 12.3) 
12.6 
(11.0, 14.2) 
12.2 
(9.4, 15.0) 
*
 The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS; N=1,422) and the 
Canadian Community Health Survey (CCHS; analytic N=46,851); 
‡ 
Data are % (95% Confidence Intervals (CIs)); 
£
 
Unstandardized weighted estimates are reported from CCHS; 
†
 AER Std.: Age- and ethnoracial-standardized 
expected estimates from CCHS; 
¥
 SPD: standardized prevalence difference (% (95% CIs)), with positive (negative) 
values indicating higher (lower) prevalence in women living with HIV (WLWH) in excess of (less than) what would 
be expected of Canadian women of similar ages/ethnoracial backgrounds.  
 
2.4. Discussion 
Drawing on data from the largest cohort study of WLWH in Canada, we found that 42.2% and 
43.9% of WLWH respectively reported an annual personal income <$20,000—a low income cut-
off indicating poverty—and severe food insecurity, in excess of what would be expected of 
Canadian women of similar ages/ethnoracial backgrounds. Additionally, a higher proportion of 
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WLWH reported experiencing the proxy indicators for social exclusion including poor perceived 
social support, and racial and gender discriminations compared with what would be expected. 
The self-rated health, as a proxy but holistic measure of health, was also lower in WLWH. While 
previous research highlighted the greater socio-structural disadvantages and economic hardships 
among WLWH, we are not aware of previous comparisons between these two populations. 
Although this analysis did not permit assessment of whether living with HIV exacerbated 
inequities in SDoH or whether such inequities increase risk of acquiring HIV or (likely) a 
mixture of both, a large proportion of WLWH in Canada are living with multiple and 
overlapping disadvantages with regard to social and economic participation is unjust and of huge 
concern. The concentration of financial hardship, food insecurity, and social exclusion – with 
having the potential for exposure to increased magnitude of chronic and acute stressors, poses a 
wide range of barriers that negate the ability of individuals to consistently engage in the HIV 
care/treatment cascade, e.g., retention in care
30
 and cART initiation and continuation,
12
 and 
further undermine attempts to optimize treatment outcomes. Recent studies have documented the 
role of food insecurity, for example, on cART non-adherence and incomplete HIV viral 
suppression.
10,15
 Such level of risk has also been realized for social exclusion determinants
14
 as 
found notably prevalent in WLWH in the present study. These findings highlight the need for 
multi-component interventions targeted at SDoH inequity reduction, particularly in those women 
with an increased risk for treatment interruptions, discontinuation, and non-adherence due to 
limited socio-structural resources.  
The substantial differences in the study determinants and self-assessed health identified 
between the two samples would provide evidence on the socio-structural determinants of 
WLWH to aid with policy development and resource allocation. Given the concern surrounding 
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the growing proportion of WLWH in Canada,
18
 our findings have implications for evoking calls 
for gender-specific tailored service, a complex and multidimensional model of care and service 
delivery, as the current care approaches appear to be inadequate to address women's 
comprehensive needs. The women-centered model of HIV care that has already been envisioned 
by target population is recommended to be a useful model of care for guiding policy and practice 
to improve care and health outcomes.
31
 Such models of care require targeting the persistent 
health inequalities in women with HIV, relative to either men with HIV
3,4
 or women of the 
general population, through a social-determinants framework, an approach in which a wide range 
of disciplines contribute to addressing the underlying barriers and reducing health inequities.
32
 
The socio-structural approach of addressing the fundamental causes of health inequities are 
imperative to achieve the UNAIDS “90-90-90 targets”—the universal commitments of HIV 
epidemic elimination by 2030.
33
 
This analysis has also significant implications for designing strategies that support WLWH 
through social service programs, and reinforcing social support and resilience with the objective 
of facilitating women’s access to care, promoting health and wellbeing, health equity, and social 
justice. Programs supporting social service delivery have important implications, especially now 
that HIV care has shifted toward chronicity. The provision of transportation supports, financially 
accessible complementary services, and providing flexible program schedules can facilitate 
access to care among women with socio-economical disadvantages.
34
 The integration of social 
programs into health service delivery can help address socio-structural adversities and facilitate 
women's participation in HIV care.  
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2.4.1 Strengths and Limitations  
To our knowledge, this is the first research investigating the inequities with socio-structural 
determinants of health and the self-rated health between WLWH and assumed HIV-negative 
women of the general population. However, this study is not without limitations. First, we 
compared the health determinants among WLWH with the assumed HIV-negative women of the 
general population. However, due to small population estimates of WLWH in Canada—97 per 
100,000 females
18—we believe the inclusion of WLWH in the comparison group would not 
substantially impact on our findings. Furthermore, the substantial differences identified between 
the two surveys may be partly due to differences in population structure other than 
age/ethnoracial group, factors which were not accounted for in standardization. Moreover, self-
report data may be prone to social desirability bias, particularly in CCHS data. CHIWOS 
attempted to mitigate the impact of this bias using trained peer research associates (PRAs), who 
shared an experience of living with HIV, to administer the surveys. Also, CHIWOS’s non-
random sampling design may undermine the generalizability of these findings. 
2.4.2 Conclusion  
These findings provide information on the upstream determinants of health inequalities in 
WLWH indicating that a high proportion of WLWH in Canada experienced much worse 
economic hardships, food insecurity, social exclusions as well as poor/fair self-reported health, 
in excess of what would be expected. These findings support the need for the integration of 
socio-structural approaches and health equity into practice to address women’s unique needs. 
These findings also advocate for social service delivery and programming as well as further 
resource allocation to reduce socially constructed, unjust, and avoidable inequalities in health in 
this population. Addressing these needs when providing individual-tailored HIV care and 
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treatment services will promote the clinical care of a sizable proportion of women with HIV 
living in poverty. Future research needs to focus on targeted exclusion-reduction interventions, 
e.g., poverty- and discrimination-reduction strategies, in this population. Future research could 
also assess the independent and/or clustered impact of these social determinants of health (e.g., 
race discrimination, gender discrimination) plus other relevant social determinants in the field of 
HIV such as HIV-related stigma on health outcomes of WLWH. Applying advanced statistical 
techniques such as decomposition analysis
35
 – a technique to assess health inequalities through 
decomposing the overall inequality in the study outcomes into the inequality in each contributing 
determinants, and latent class analysis (LCA)
36
 – a method to identify the latent class/clusters of 
individuals who experience the unique adversities with respect to the social determinants, can 
help researchers better explore the association of these determinants with HIV outcomes. This 
data on SDoH inequalities can help investigators develop interventions to address disparities 
experienced by WLWH to improve their health outcomes, and identify mechanisms through 
which these determinants may reinforce or directly contribute to inequitable vulnerabilities 
among WLWH.  
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2.5. Supplementary Tables  
S Table 2.1: Age-Ethnoracial Distributions of both the CHIWOS (2013-2015) Cohort of 
Women Living with HIV and the CCHS (2013-2014) Data of the Corresponding General 
Population Women in Canada. 
 CHIWOS estimates  
(N=1,422) 
CCHS estimates 
(N=46,851)
a
 
 
% 
Unstandardized  
% 
Standardized
 
 
%  
Ethnoracial and age groups     
 White  16-35 (years)  10.2
b
 21.1
c
 10.2
d
 
   36-45  11.4 11.2 11.4 
   46-55  12.5 13.9 12.5 
   > 55  7.0 29.0 7.0 
Black  16-35  7.5 1.1 7.5 
   36-45  11.5 0.7 11.5 
   46-55  7.8 0.8 7.8 
   > 55  2.6 0.7 2.6 
Indigenous  16-35  7.0 1.0 7.0 
  36-55  8.4 0.4 8.4 
  36-45  5.2 0.4 5.2 
  46-55  1.7 0.6 1.7 
Others 16-35  1.4 7.9 1.4 
  36-45  2.4 4.4 2.4 
  46-55  2.6 3.1 2.6 
  > 55  0.8 3.7 0.8 
a
 Out of 128,310 respondents, 46,851 (36.5%) were the corresponding general population women for the current 
study: women aged 16+ residing in three provinces of BC, ON, QC; 
b 
Data are presented as percentages; 
d 
Chi 
Square test showed a significant difference between the two samples of CHIWOS and unstandardized CCHS (P-
value < 0.001); 
c 
Standardization made the two study populations of CHIWOS and CCHS identical with regard to 
the distribution of age and ethnoracial group.  
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S Table 2.2: Characteristics of Women Living with HIV (WLWH) – the Baseline Survey of 
the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS), 
2013-2015  
Variables  n (%) or mean [SD] 
Age, year (mean [SD]) 42.8 [10.6] 
Age groups (years) (N = 1,422)  
 16-35  372 (26.2) 
 36-45  479 (33.7) 
 46-55  400 (28.1) 
 > 55  171 (12.0) 
Ethno-racial group (N = 1,422)  
 White 584 (41.1) 
 African/Caribbean/Black 418 (29.4) 
 Indigenous 318 (22.3) 
 Other 102 (7.2) 
Study province (N = 1,422)  
 Ontario  717 (50.4) 
 British Columbia  356 (25.0) 
 Quebec   349 (24.6) 
Years living with HIV (N = 1,374)  
 < 6 years 345 (25.1) 
 6-14 years  552 (40.2) 
 > 14 years  477 (34.7) 
Taking treatment (N = 1,415)  
 Yes, optimal (≥ 95%) 863 (61.0) 
 Yes, suboptimal (< 95%) 312 (22.0) 
 Not engaged in treatment  240 (17.0) 
Undetectable (50 copies/mL) viral load among WLWH on 1018 (87.0) 
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treatment (N=1,170) 
History of injection drug use (N = 1,421) 439 (30.9%) 
History of sex work involvement (N=1,321) 219 (16.6) 
History of incarceration (N=1,420) 5246.9) 
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3. Chapter 3: Substance use patterns among women living with HIV 
compared with the general female population of Canada
1
 
 
3.1. Introduction  
Substance use is a common health risk behaviour among people living with HIV (PLWH), who 
have a demonstrated greater prevalence than their general population counterparts.
1-3
 Substance 
use is considered a major barrier to successful HIV care and treatment
4-9
 despite the substantial 
advances obtained from combination antiretroviral therapy (cART), e.g., improved life 
expectancy in PLWH.
10
 Substance use independently or by interaction with other factors such as 
psychiatric disorders and socioeconomic marginalization has the potential to limit the remarkable 
benefits of cART and pose additional barriers to HIV prevention efforts and medical care.
6-9,11-14
 
Previous studies have reported the negative impacts of tobacco smoking,
12
 problematic 
alcohol consumption,
13
 and illicit drug use (e.g., heroin)
4,8
 on HIV care cascade outcomes. The 
optimal levels of these outcomes such as retention in care and adherence to HIV treatment are 
critical in promoting the health of PLWH and maintaining treatment as prevention (TasP) 
targets.
15
 Beyond its interruption of care and treatment, substance use can also interfere with 
cART metabolism and virological response,
16,17
 and contribute to excess mortality.
12,18
 For 
example, in a study of 17,995 PLWH on treatment, smoking increased the rate of death by 1.94 
times, with 1.84 and 2.41 times in men and women with HIV, respectively.
18
 
                                                          
1
 A version of this chapter has been published: Shokoohi M, Bauer GR, Kaida A, et al. Substance use patterns 
among women living with HIV compared with the general female population of Canada. Drug Alcohol Depend. 
2018 Oct 1;191:70-77. doi: 10.1016/j.drugalcdep.2018.06.026. 
100 
 
Substance use vulnerability appears to have greater impacts on HIV and clinical outcomes 
among women than men with HIV. For example, women with injection drug use (IDU) history 
and Indigenous ancestry had lower optimal adherence to treatment (47.8%) relative to their male 
HIV-positive counterparts with (57.7%) and without (83.8%) such vulnerabilities.
19
 Women with 
IDU history were also found to be 18% less likely to achieve HIV RNA viral suppression than 
their male counterparts.
20
 Other than the unique experiences of HIV infection among women 
(e.g., pregnancy), drug use along with greater experiences of other psychosocial, economic and 
structural challenges may account for gender-related differences in HIV outcomes.
20-22
 
However, substance use prevalence among women living with HIV (WLWH) has not been 
well-characterized, particularly in Canada. Population-based research has either overlooked 
collecting data on WLWH, or has not had adequate sample size to provide estimates for WLWH 
and comparisons to the broader population.
23,24
 Women now constitute more than half of all 
individuals living with HIV worldwide
25
 and represent nearly one-fourth of the estimated 75,500 
PLWH in Canada; almost doubled from the 1990s.
26
 Understanding the prevalence of substance 
use in a geographically diverse sample of WLWH relative to general population women is 
important because of the profound implications for HIV management and to assess the need for 
harm reduction and socio-structural supports for women who use substances.  
Therefore, the objective of this research was to characterize the prevalence of cigarette 
smoking, alcohol consumption, non-prescribed cannabis use, and illicit drug use from the 
Canadian HIV Women’s Sexual and Reproductive Cohort Study (CHIWOS), a large 
community-based study of WLWH in Canada. We estimated the prevalence for substance use in 
CHIWOS, and compared them with data from HIV-negative women of the general population, 
standardized to the age/ethnoracial distribution of WLWH. Our aim was to document substance 
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use disparities among WLWH, to explore differences based on HIV status and to identify needs 
with regard to resource allocation, particularly given the implications of substance use in the 
context of HIV-related medical care. 
3.2. Methods  
3.2.1 Participants 
CHIWOS sample: We used data from the baseline survey of the Canadian HIV Women’s Sexual 
and Reproductive Health Cohort Study (CHIWOS) conducted between 2013 and 2015. 
CHIWOS is a large community-based study of WLWH (≥16 years; 3.8% trans women), residing 
in British Columbia (BC), Ontario, and Quebec. Study design and sampling procedure were 
published elsewhere.
27
 Briefly, we applied the Meaningful Involvement of Women Living with 
HIV/AIDS principle, reflecting the recognition of the rights and responsibilities of individuals 
living with HIV as equal partners to actively engage throughout the design and delivery of 
HIV/AIDS services to strengthen the responses to HIV/AIDS epidemics.
28
 A sample of 1,422 
WLWH were recruited from HIV clinics, AIDS Service Organizations, peers, and online 
networks.
24
 The survey was administered by Peer Research Associates (PRAs), many of whom 
also shared the experience of living with HIV, who were hired and trained in community-based 
research conduction.
27
 The average 120-minute-long surveys were administered either through 
in-person interviews at clinic, community sites, or participants’ homes, or via phone/Skype. 
CHIWOS was approved by the Research Ethics Boards of Simon Fraser University, University 
of British Columbia/Providence Health, Women’s College Hospital and McGill University 
Health Center.  
CCHS sample: We used data from the 2013-2014 cycle of the Canadian Community 
Health Survey (CCHS), a nation-wide cross-sectional survey administered by Statistics Canada. 
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Detailed documentation is available elsewhere.
29
 Briefly, CCHS is designed to provide 
nationally representative estimates on health status, health care utilization, and health 
determinants of Canadians aged 12 years or older residing in private dwellings of all provinces 
and territories (~98% coverage), excluding populations living on reserves/Indigenous 
settlements, institutions, Canadian Force Bases, and some remote regions. Data are collected 
using computer assisted personal and telephone interview software. Consistent with CHIWOS, 
CCHS analyses were restricted to women aged ≥16 years old, residing in the three provinces 
(analytic sample = 46,851). Measures of cigarette smoking, alcohol consumption, non-prescribed 
cannabis use and illicit drug use with similar content and wording were compared between the 
two surveys.  
3.2.2 Measures  
Although cigarette smoking and alcohol consumption were collected from all CCHS 
respondents, measures of drug use were not collected in Ontario and Quebec; for comparability, 
we provided estimates of drug use for only BC participants in CHIWOS.  
Cigarette smoking: In CHIWOS, cigarette smoking history was measured as, “What is 
your cigarette (tobacco) smoking history?” with four response options (regular, occasional, 
former, and never). In CCHS, the same question was asked with three response options (daily, 
occasionally, not at all). To be consistent with the CCHS definition, we categorized WLWH who 
reported at least one cigarette/day (equivalently, at least 30 cigarettes/month) as “daily” smokers 
irrespective of how they were self-identified. As such, 67 self-identified occasional smokers 
were recoded as daily smokers and two cases who reported cigarette smoking regularly were 
recoded as occasional smokers. Two measures were created to compare the two surveys: a) 
nonsmokers at the time of interview (i.e., former or none) versus current smokers (i.e., daily or 
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occasional), and b) a three-category measure: nonsmokers, occasional smokers, and daily 
smokers. We also reported cigarette smoking intensity/quantity among current smokers. A five-
category measure was created to compare the two surveys: nonsmokers (former or never), <1 
cigarette/day or <30 cigarettes/month, 1-10 cigarettes/day, 11-19 cigarettes/day, and ≥20 
cigarettes/day.  
Alcohol consumption: Last-year alcohol consumption pattern was examined in both 
CHIWOS and CCHS. A four-category comparable measure was created in each survey: none 
(did not drink in the past 12 months), ≤1 time/week, 2-3 times/week, and ≥4 times/week. CCHS 
measured the monthly pattern of binge drinking as, “How often in the past 12 months have you 
had 4 or more drinks on one occasion?” with six response categories: never, less than once a 
month, once a month, 2 to 3 times a month, once a week, and more than once a week. The same 
question but in the last month was measured in CHIWOS, with an open-ended response option 
indicating the number of times. Binge drinking was compared between the two surveys under the 
assumption that past-year binge drinking patterns were consistent with past month. We created a 
measure with similar response categories: no alcohol consumed, alcohol consumed but no binge 
drinking, binge drinking less than once a week (i.e., equivalently, less than 3 times a month), and 
binge drinking at least once a week (i.e., equivalently, four times or more a month). In CHIWOS, 
33 women reported last-month binge drinking without specifying the number of times over the 
last month; therefore, instead of treating them as missing values, we categorized them into “less 
than once a week.” 
Drug use: We compared the use of the following drugs available in the two surveys in BC: 
cannabis, cocaine or crack, speed (amphetamine), and heroin. CCHS asked respondents, “Have 
you used [any of these drugs] in the past 12 months?”, affirmative responses were further 
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followed, “How often [did you use any of these drugs in the past 12 months]?” with the 
following response options: less than once/ month, 1 to 3 times/month, once/week, more than 
once/week, and every day. CHIWOS measured cannabis use as, “What is your cannabis use 
history?” with the following response categories: a) regularly in the last 30 days, b) occasionally 
in the last 30 days, c) used in the past year but not in the past 30 days, d) used in the past but not 
in the past year, e) never used or only ever used it once or twice. To be consistent with CCHS, 
CHIWOS’s response options ‘b’ and ‘c’ were considered as occasional cannabis use. CHIWOS 
participants with a positive history of cannabis use were also followed, “Have you used cannabis 
mainly for medicinal reasons or recreational reasons, or both?” We recoded medicinal 
(prescribed) use of cannabis use as non-recreational use, while any other recreational reasons 
(alone or in combination with medicinal use) were considered as non-prescribed cannabis use. 
This distinction was made as CCHS aimed to measure the use of illicit drugs, but not 
prescription drugs.  
CHIWOS assessed the use of crack or cocaine, speed, and heroin over the last 3 months. 
Positive responses were additionally followed to measure the frequency of use as, daily, at least 
once/week, and less than once/week. The same information was assessed in CCHS, but over the 
past year. Crack and cocaine use were measured in one single question in CCHS, while 
CHIWOS measured them separately. Therefore, daily use of any of these two drugs was 
considered as daily crack or cocaine use.  
For the purpose of comparison, we created a three-category measure for cannabis use and 
crack or cocaine use as: none (i.e., former or never), occasional (< once/week), and regular use 
(≥ once/week). As the absolute “n” for speed (amphetamine) and heroin use did not meet the 
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minimum CCHS vetting guideline, we combined regular and occasional use and then created a 
binary variable for each of these two drugs: none vs. occasional/regular use.  
3.2.3 Data analysis  
We reported the prevalence and the 95% confidence intervals (CI) of each substance from the 
CHIWOS sample. We then obtained the prevalence of the same substances from the CCHS 
sample, using sampling weights that Statistics Canada assigned each respondent to correspond to 
the number of Canadian residents they represent. The bootstrap variance estimation technique 
using a set of 500 replicates was used to obtain the 95% CI of the CCHS estimates.
30
 To address 
the imbalanced distribution of age and ethnoracial groups, we used a standardization method 
which combines stratum-specific prevalences into a single summary estimate through taking a 
weighted average.
31
 Standardization obtains these weights in averaging from a standard 
population. In the present study, these weights were obtained from the CHIWOS data set and 
applied to CCHS data. To do this, we created a 16-category variable representing CHIWOS’s 
age and ethnoracial group distribution (i.e., four age categories: 16-35, 36-45, 46-55, or >55; four 
ethnoracial categories: white, African, Caribbean, Black (ACB), Indigenous, or other/multi-
ethnicities). We then applied CHIWOS’s age and ethnoracial group distribution to CCHS to 
produce a second set of estimates in which CCHS and CHIWOS samples had a similar 
distribution with respect to these two variables. 
The standardized prevalence differences (SPD) were reported to quantify the differences 
between the two surveys for each substance use. The SPD is a commonly used measure for the 
purpose of population health assessment and provides information on the public health impact. 
The SPD was computed by subtracting the CCHS expected estimates standardized to age and 
ethnoracial groups from the CHIWOS observed estimates; with an SPD greater than zero (i.e., 
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the null) denoting a greater prevalence of the given substance in WLWH. The SPD’s 95% CI 
was provided using the methods of variance estimates recovery (MOVER),
32
 with 95% CI 
excluding 0 indicating statistical significance at p<0.05. The analyses were performed using 
Stata version 15. 
3.3. Results  
3.3.1 Demographics 
WLWH differed from the unstandardized general population data by age and ethnoracial groups 
as well as relationship status, education and yearly personal income levels (Table 3.1). Greater 
proportions of women in the unstandardized general population were older and belonged to 
white ethnoracial group than WLWH. Other characteristics of these two samples are presented in 
Table 3.1, along with the prevalences in the standardized CCHS data. After standardization, the 
CCHS estimates had identical age and ethnoracial group structure. All subsequent comparisons 
of substance use were conducted using standardized data.  
Overall 83% and 87% of WLWH reported taking HIV medication and having a suppressed 
viral load (i.e., <50 c/mL), respectively. The median time living with HIV since diagnosis was 11 
years (IQR: 7, 17) (data not shown). 
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Table 3.1: The Distribution of Age, Ethnoracial Groups, Relationship Status, Education Status, and Yearly Personal Income 
in the Cohort of Women with HIV Compared with the Assumed HIV-Negative Women of the General Population in Canada. 
 CHIWOS estimates  
(N=1,422) 
CCHS estimates 
(N=46,851)
*
 
 
N % (95% CI) N 
Unstandardized  
% (95% CI) 
Standardized
 
 
% (95% CI)
c
  
Ethnoracial and age groups       
 White  16-35 (years)  145 10.2 (8.7, 11.9) 8,749 21.1 (20.6, 21.7) 10.2
d
 
   36-45  162  11.4 (9.8, 13.2) 4,582 11.2 (10.6, 11.5) 11.4 
   46-55  178  12.5 (10.9, 14.3) 5,775 13.9 (13.4, 14.5) 12.5 
   > 55  99 7.0 (5.7, 8.4) 12,020 29.0 (28.5, 29.6) 7.0 
Black  16-35  107 7.5 (6.3, 9.0) 457 1.1 (0.9, 1.3) 7.5 
   36-45  163  11.5 (9.9, 13.2) 280 0.7 (0.5, 0.9) 11.5 
   46-55  111 7.8 (6.5, 9.3) 333 0.8 (0.6, 1.1) 7.8 
   > 55  37 2.6 (1.9, 3.6) 268 0.7 (0.5, 0.8) 2.6 
Indigenous  16-35  100 7.0 (5.8, 8.5) 424 1.0 (0.9, 1.2) 7.0 
  36-55  120 8.4 (7.1, 10.0) 161 0.4 (0.3, 0.5) 8.4 
  36-45  74 5.2 (4.2, 6.5) 176 0.4 (0.3, 0.5) 5.2 
  46-55  24 1.7 (1.1, 2.5) 255 0.6 (0.5, 0.7) 1.7 
Others 16-35  20 1.4 (0.9, 2.2) 3,286 7.9 (7.4, 8.4) 1.4 
  36-45  34 2.4 (1.7, 3.3) 1,837 4.4 (4.0, 4.9) 2.4 
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  46-55  37 2.6 (1.9, 3.6) 1,271 3.1 (2.7, 3.5) 2.6 
  > 55  11 0.8 (0.4, 1.4) 1,539 3.7 (3.4, 4.1) 0.8 
Relationship status       
Single  689 48.7 (46.1, 51.3) 10,438 24.3 (23.7, 24.8) 26.6 (24.6, 28.7) 
Married, common-law 545 32.1 (29.7, 34.6) 24,971 58.0 (57.3, 58.7) 55.3 (52.7, 57.9) 
Separated/divorced/widowed  271 19.2 (17.2, 21.3) 7,636 17.7 (17.2, 18.3) 18.1 (15.8, 20.4) 
Education status       
Less than high school  227 16.1 (14.2, 18.1) 6,568 15.4 (14.9, 16.0) 12.3 (11.0, 13.6) 
High school completed  532 37.6 (35.1, 40.2) 10,514 24.7 (24.0, 25.4) 23.9 (21.9, 25.9) 
Diploma/trade/college  456 32.2 (29.8, 34.7) 12,998 30.6 (29.8, 31.3) 35.9 (33.4, 38.4) 
University degree (≥Bachelor’s 
degree) 
200 14.1 (12.4, 16.1) 12,474 29.3 (28.6, 30.1) 27.9 (25.4, 30.4) 
Yearly personal income 
a
      
<20,000 CAD
b
  997 70.3 (67.8, 72.6) 12,263 29.1 (28.4, 29.9) 28.1 (26.1, 30.0) 
20,000 to <40,000 CAD 244 17.2 (15.3, 19.3) 10,425 24.8 (24.1, 25.5) 24.5 (22.4, 26.7) 
≥ 40,000 CAD 144 10.1 (8.7, 11.8) 12,620 30.0 (29.2, 30.8) 33.1 (30.4, 35.8) 
Not stated  34 2.4 (1.7, 3.3) 6,795 16.1 (15.5, 16.8) 14.3 (12.3, 16.3) 
Trans women  54 3.8 (2.9, 4.9) ---
 e
 ---
e
 ---
 e
 
* Out of 128,310 respondents, 46,851 (36.5%) were eligible for the current study: women aged 16+ residing in three provinces of BC, ON, QC; 
a
 aged > 17 years 
old; 
b
 Canadian dollar (CAD); 
c
 95% CIs were not estimated for standardization variables; 
d 
Standardization made the two study populations identical with regard 
to age and ethnoracial group structure; 
e
 Not available as CCHS does not contain data identifying trans status.
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3.3.2 Cigarette smoking 
A higher prevalence of cigarette smoking frequency and intensity was reported among WLWH 
compared with estimates expected based on the age-/ethnoracial-standardized women of the 
general population. Current cigarette smoking (i.e., daily/occasional) was reported by 43.7% of 
WLWH relative to 17.8% of the expected estimates of general population (SPD 25.9%), 
indicating that 25.9% (i.e., 259 per 1000) of WLWH reported current cigarette smoking, in 
excess of what would be expected of Canadian women of similar ages/ethnoracial backgrounds. 
Daily cigarette smoking was reported by 40.7% of WLWH versus 13.9% of expected estimates 
from general population women (SPD 26.8%). WLWH tended to smoke cigarette more intensely 
than the expected estimates of the general population (Table 3.2).  
Table 3.2: Comparison of Cigarette Smoking between Women with HIV (N=1,422) and 
Assumed HIV-Negative Women of the General Population (N=46,851). 
Cigarette smoking measures  CHIWOS 
 
(1) 
CCHS estimates  SPD
¥ 
 
(1) – (2) 
CCHS
£
 
AER Std.
† 
(2) 
Overall cigarette smoking     
Nonsmoker (i.e., former/never) 56.3 
(53.7, 58.9)
‡
 
84.3 
(83.7, 84.9) 
82.2 
(80.8, 83.7) 
-25.9 
(-28.9, -22.9) 
Current smokers (i.e., daily/occasional) 43.7 
(41.1, 46.3) 
15.7 
(15.1, 16.3) 
17.8 
(16.3, 19.2) 
25.9 
(22.9, 28.9) 
Current cigarette smoking status     
Nonsmoker (i.e., former/never) 57.0 
(54.4, 59.6) 
84.3 
(83.7, 84.9) 
82.2 
(80.8, 83.7) 
-25.2 
(-28.2, -22.2) 
Occasional smokers 
a
  2.3 
(1.6, 3.2) 
3.8 
(3.5, 4.2) 
3.9 
(3.2, 4.6) 
-1.6  
(-2.6, -0.5) 
Daily smokers
 b
 40.7 11.9 13.9 26.8  
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(38.1, 43.3) (11.3, 12.4) (12.5, 15.2) (23.9, 29.7) 
Intensity of cigarette smoking      
Nonsmoker (i.e., former/never)
c
 57.0  
(54.4, 59.6) 
84.4  
(83.8, 85.0) 
82.4 
(80.9, 83.9) 
-25.4 
(-28.4, -22.4) 
<1 cig/day or <30 cig/month 2.3 
(1.6, 3.2) 
2.5  
(2.3, 2.8) 
2.5 
(2.1, 2.9) 
-0.2 
(-1.0, 0.8) 
1 to 10 cig/day 20.4 
(18.3, 22.6) 
6.6  
(6.2, 7.0) 
7.8 
(6.7, 9.0) 
12.6 
(10.2, 15.1) 
>10 to <20 cig/day 5.4  
(4.4, 6.8) 
3.2  
(2.9, 3.4) 
4.0 
(3.2, 4.8) 
1.4 
(0.1, 3.0) 
≥ 20 cig/day 14.9  
(13.1, 16.9) 
3.3 
(3.0, 3.6) 
3.3 
(2.8, 3.8) 
11.6 
(9.8, 13.6) 
‡ 
Data are % (95% CI); 
£
 unstandardized weighted estimates are reported and the 95% CI was constructed using 
bootstrap method; 
†
 Age- and ethnoracial-standardized expected estimates based on women of the general 
population from CCHS; 
¥
 SPD: standardized prevalence difference (% (95% CI)); the 95% CI was constructed using 
MOVER algorithm; 
a 
Occasional smokers (<1 cigarette/day or <30 cigarettes/month); 
b
 Daily smokers (≥1 
cigarettes/day or ≥30 cigarettes/month); c Because of missing values in variable intensity of cigarette smoking, the 
proportion of the first and second categories if different from the same categories in variable current cigarette 
smoking status, while the absolute numbers is the same.  
 
3.3.3 Alcohol consumption 
WLWH more frequently reported no alcohol consumption compared with the expected estimates 
(40.7% vs. 28.0%). The proportion of alcohol consumption categories among WLWH than 
expected estimates from standardized general population data was: 46.8% vs. 52.2% consumed 
alcohol ≤1 time/week, 7.0% vs. 12.9% consumed alcohol 2-3 times/week, and 5.5% vs. 6.9% 
consumed alcohol 4+ times/week. The monthly pattern of binge drinking in WLWH was: 15.4% 
vs. 30.6% for less than once/week (SPD -15.2%), and 4.6% vs. 3.9% for at least once/week (SPD 
0.7%). The combination of these two categories showed that 20.0% of WLWH reported binge 
drinking at least once/month compared with 34.5% in women of the general population (Table 
3.3).  
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Table 3.3: Comparison of Alcohol Consumption between Women with HIV (N=1,422) and 
Assumed HIV-Negative Women of the General Population
 
(N=46,851) 
 CHIWOS 
 
(1) 
CCHS estimates  SPD
¥ 
 
(1) - (2) 
CCHS
£
 
AER Std.
† 
(2) 
Alcohol consumption frequency      
None (Never/none in specified time) 40.7 
(38.2, 43.3)
‡
 
24.5 
(23.7, 25.4) 
28.0 
(25.4, 30.5) 
12.7 
(9.1, 1.4) 
≤1 time a week 46.8 
(44.2, 49.4) 
51.3 
(50.4, 52.1) 
52.2 
(49.6, 54.8) 
-5.4 
(-9.1, -1.7) 
2-3 times a week 7.0 
(5.7, 8.4) 
15.1 
(14.5, 15.7) 
12.9 
(11.5, 14.1) 
-5.9 
(-7.7, -3.9) 
4+ times a week 5.5 
(4.4, 6.8) 
9.1 
(8.7, 9.5) 
6.9 
(5.8, 8.1) 
-1.4 
(-3.0, 0.4) 
Binge drinking categories 
a
     
No alcohol consumed  41.0 
(38.5, 43.7) 
24.6 
(23.8, 25.5) 
28.0 
(25.4, 30.6) 
13.0 
(9.4, 16.7) 
Alcohol consumed, not binge  39.0 
(36.4, 41.5) 
40.3 
(39.5, 41.1) 
37.5 
(34.9, 40.0) 
1.5 
(-2.1, 5.1) 
Binge drinking less than once a week 15.4 
(13.6, 17.4) 
30.9 
(30.1, 31.7) 
30.6 
(28.7, 32.4) 
-15.2 
(-17.8, -12.6) 
Binge drinking at least once a week 4.6 
(3.6, 5.9) 
4.2 
(3.9, 4.5) 
3.9 
(3.3, 4.4) 
0.7 
(-0.3, 2.1) 
‡ 
Data are % (95% CI); 
£
 unstandardized weighted estimates are reported and the 95% CI was constructed using 
bootstrap method; 
†
 Age- and ethnoracial-standardized expected estimates based on women od the general 
population from CCHS; 
¥
 SPD: standardized prevalence difference (% (95% CI)), and the 95% CI was constructed 
using MOVER algorithm; 
a
 CHIWOS measured the last-month pattern of binge drinking, while CCHS measured the 
last-year pattern of binge drinking.  
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3.3.4 Drug use 
Last-month non-prescribed cannabis use in WLWH from BC was almost two times greater than 
last-year use of this drug from women of the general population in BC: 14.6% vs. 6.6% reported 
regular use (SPD 8.0%), and 18.1% vs. 6.1% reported occasional use (SPD 12.0%). The results 
of last 3 months use of illicit drug use compared with last-year use of these drugs showed a 
higher proportion of WLWH in BC reported cocaine or crack use: 16.8% vs. 0.1% for regular 
use (SPD 16.7%), and 8.2% vs. 1.5% for occasional use (SPD 6.7%), regular/occasional speed 
use (2.5% vs. 0.1%; SPD 2.4%), and regular/occasional heroin use (11.3% vs. 0.1%; SPD 
11.2%) (Table 3.4).  
Table 3.4: Comparing Illicit Drug Use between Women Living with HIV and Assumed 
HIV-Negative Women of the General Population
*
. 
 
Drug use 
a
 
CHIWOS 
 
(1) 
CCHS estimates  SPD
¥ 
 
(1) – (2) 
CCHS
£
 
AER Std.
† 
(2) 
Non-prescribed cannabis 
use 
b
 
    
Regular use 
c
 14.6 
(11.3, 18.7)
 ‡
 
4.5 
(3.4, 5.2) 
6.6 
(4.7, 8.6) 
8.0 
(4.1, 8.6) 
Occasional use 
d
 18.1 
(14.4, 22.4) 
7.1 
(6.1, 8.1) 
6.1 
(4.9, 7.2) 
12.0 
(8.1, 16.5) 
None 
e
 67.3 
(62.2, 72.1) 
88.4 
(87.2, 89.6) 
87.3 
(83.5, 91.1) 
-20.0 
(-26.3, -13.9) 
Cocaine or crack use     
Regular use 
f
 16.8 
(13.2, 21.0) 
0.1 
(0.01, 0.2) 
0.1 
(0.00, 0.2) 
16.7 
(13.1, 20.9) 
Occasional use g 8.2 0.7 1.5 6.7 
113 
 
(5.78, 11.61) (0.4, 1.0) (0.2, 2.9) (3.9, 10.3) 
None (never or former) 75.0 
(70.2, 79.2) 
99.2 
(98.8, 99.5) 
98.4 
(95.0, 101.7) 
-23.4 
(-29.2, -17.9) 
Speed (amphetamine) use     
Regular/occasional use 
f,g,h
 2.5 
(1.3, 4.8) 
0.1 
(0.01, 0.2) 
0.1 
(0.00, 0.2) 
2.4 
(1.2, 4.7) 
None (never or former) 
97.5 
(95.2, 98.68) 
99.9 
(99.8, 100.0) 
99.9 
(96.8, 
100.0)
††
 
-2.4 
(-6.2, 0.9) 
Heroin use     
Regular/occasional use 
f,g,h
 11.3 
(8.4, 15.1) 
0.1 
(0.02, 0.2) 
0.1 
(0.01, 0.2) 
11.2 
(8.3, 15.0) 
None (never or former) 
88.7 
(84.9, 91.6) 
99.9 
(99.7, 100.0) 
99.9 
(96.8, 
100.0)
††
 
-11.2 
(-16.1, -7.0) 
*
 CHIWOS-BC (N=356) and CCHS-BC (N=7,698); 
‡ 
Data are % (95% CI); 
£
 unstandardized weighted estimates are 
reported and the 95% CI was constructed using bootstrap method; 
†
 Age- and ethnoracial-standardized expected 
estimates based on women of the general population from CCHS; 
¥
 SPD: standardized prevalence difference (% 
(95% CI)), and the 95% CI was constructed using MOVER algorithm; 
††
 the upper limit was 102.96% but we made 
is to the maximum proportion 100.0%; 
a
 CCHS collected data for the period of last 12 months for all drugs, while 
CHIWOS collected data on cannabis use for last month and other drugs in last three months; 
b
 Any non-prescribed 
use of cannabis (i.e., non-medicinal, non-prescribed, self-medicating, or both medicinal and non-medicinal use 
simultaneously); 
c
 CCHS: every day or at least once a week, while it was measured as using regularly in CHIWOS; 
d
 
CCHS: Occasional use (1-3 times a month or less than once a month), CHIWOS: occasional use (occasionally or 
used but not in the past 30 days); 
e
 No non-prescribed or medicinal cannabis use; f Regular use: at least once a week; 
g
 Occasional/episodic: less than once a week; 
h
 Regular and occasional use were merged in Amphetamine and 
Heroin use as the absolute “n” did not meet the minimum vetting guideline.  
 
3.4. Discussion 
We found that a considerable proportion of WLWH reported current cigarette smoking, were 
intensive cigarette smokers (i.e., ≥20 cigarettes/day), reported binge drinking, and reported 
regular/occasional use of non-prescribed cannabis, and other illicit drugs including crack or 
cocaine, speed, and heroin. We also provided evidence for an excess prevalence of cigarette 
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smoking and the use of non-prescribed cannabis, and other illicit drugs, but a lower to similar 
frequency of alcohol consumption, in WLWH compared to their age- and ethnoracial group-
similar general population counterparts. 
While a considerable difference was found between WLWH and their general population 
counterparts with regard to drug use and cigarette smoking, but not alcohol drinking, we 
acknowledge that these differences could in part be because of other uncontrolled population 
background characteristics. For example, prior studies have highlighted the contribution of 
socioeconomic factors (e.g., low income, unemployment) and mental health conditions to 
substance use among WLWH.
5
 Moreover, HIV-specific factors such as HIV-related stigma may 
play a role in substance use as a maladaptive or avoidant coping strategy.
33
 However, control of 
these in cross-sectional analysis can be problematic in ignoring potential mediation and creating 
artificially similar groups that obscure real differences that can result from age (or life stage) and 
from systemic discrimination and differential life options across ethnoracial groups.   
Our findings were consistent with findings of the few available studies comparing WLWH 
with HIV-negative women. A higher proportion of cigarette smoking was found among WLWH 
in a 2015 US study (34.6% vs. 18.0% were current cigarette smokers; with an age-ethnoracial-
education-poverty adjusted prevalence difference of 16.6%)
2
 and a 2014 French study (32% 
regular tobacco smokers, with an age-education adjusted prevalence rate ratio of 1.32).
3
 
Consistent with previous research,
1
 alcohol consumption was comparatively lower in WLWH 
than that in the general population; however, it was still one of the most prevalent substances 
reported by WLWH in the current study. The reason for the observed lower frequency of alcohol 
consumption among WLWH of the current study is unclear. Further research is needed to 
explore whether such lower frequency of alcohol use among WLWH is due to the higher use of 
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other drugs such as recreational cannabis use. Given the negative impacts of alcohol 
consumption on care and treatment outcomes,
34
 our findings in line with other studies of women 
with HIV
35
 suggest that there is a need for screening of alcohol drinking and targeted 
interventions within HIV care.  
The comparison of our findings on illicit drug use with extant literature is difficult because 
there are few such comparison analyses specifically for WLWH. However, identifying a higher 
prevalence of drug use in individuals with HIV than the general population is relevant to the HIV 
setting, and suggests the need to ensure that factors that affect substance use among WLWH are 
identified and addressed, and that adequate resources are provided for addressing drug use in the 
context of HIV care. Limited descriptive studies have also indicated high prevalences of 
substance use in WLWH; for example, current cigarette smoking (56%) and concomitant use of 
other drugs in smokers (24.4% vs. 4.0% in nonsmokers)
12
, past-year heavy/hazardous drinking 
over an 11-year follow-up period (ranged from 14% to 24%),
5
 current marijuana use (from 21% 
to 14% over the 16-year follow-up period) and daily marijuana use (from 3.3% to 6.1% in all 
studied women).
36
 Future research could examine which factors may contribute to WLWH using 
or avoiding substances, including discrimination, HIV-related stigma, intimate partner violence, 
and other factors that can lead to initiation or continuation of substance use. The identified 
substance use disparities, particularly smoking and illicit drug use, can help researchers explore 
pathways leading to greater vulnerability among WLWH.  
Given the contribution of substance use to suboptimal HIV outcomes, considering the 
mixed evidence for the role of cannabis,
37,38
 the high substance use prevalence identified in the 
current research has important implications for the clinical management of HIV.
12,39
 This is 
particularly important as substance use oftentimes co-presents with other health-related problems 
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such as psychiatric comorbidities and socio-structural barriers, that interactively impact HIV 
outcomes in individuals with HIV including WLWH.
40-42
 These findings highlight the need to 
make interventions available to women who use both drugs and antiretroviral therapy, 
particularly in cases where the substance use interferes with maintenance of effective HIV 
treatment.
34,43
 Integration of substance use treatment services into HIV primary care settings may 
contribute to enhancing the quality of HIV care and care delivery.
9,39,44
 Our findings also 
advocate for tailored, women-centred harm reduction strategies in which women’s unique needs 
are effectively recognized,
45
 and peer-driven interventions through which peers can also 
contribute to the care and treatment programs delivery.
46
 Having access to pharmacologic and 
psychotropic substance use and harm reduction services through this model of care is essential to 
reduce use and harms of substance use.
6,7,9
 To improve greater involvement and adherence to 
treatment, one recommendation is that such a model of care delivery also provides sustained 
follow-up with regular evaluations of HIV therapies to substance-using WLWH.
39,43,47
 
This study had some limitations. CHIWOS recruited WLWH through Peer Research 
Associates (PRAs) – a non-random sampling design. Additionally, self-report data on substance 
use, a potentially stigmatizing behaviour, is subject to social desirability bias. In particular, this is 
of concern for data from the general population. However, this potential bias might have been 
mitigated in CHIWOS by using the PRAs, who also shared the experience of living with HIV. 
This was an attempt to build trust with WLWH, to allow for them to better contribute to the 
research in sharing their sensitive information.
24
 Moreover, we compared the measure of 
substance use in WLWH with the assumed HIV-negative women of the general population. 
Because of small population estimates of WLWH in Canada – 97 per 100,000 females,26 the 
inclusion of WLWH in the assumed HIV-negative group would not substantially change our 
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estimates. Furthermore, while CHIWOS collected data on cisgender (non-trans) women and 
trans women with HIV, CCHS does not contain data identifying trans women; therefore, it is 
both likely that there are also trans women in CCHS and it is impossible to adjust for gender 
identity.  
In conclusion, substance use was prevalent among women living with HIV, with 
prevalences of cigarette smoking and illicit drug use in excess of what would be expected, but 
not of alcohol consumption and binge drinking. Due to their negative impacts on HIV outcomes, 
morbidity, and mortality, these results highlight the need for future research and programming to 
better understand factors that may contribute to substance use within the group of WLWH, and 
to intervene on these factors, or on health risk factors within HIV care settings. Future research 
may also be useful in identifying substance users through screening methods, in educating HIV 
care providers concerning screening for substance use problems, and in addressing specific 
causal pathways for use of substances and their impacts on HIV outcomes.  
118 
 
3.5. References 
1. Ikeda ML, Barcellos NT, Alencastro PR, et al. Alcohol Drinking Pattern: A Comparison 
between HIV-Infected Patients and Individuals from the General Population. PLoS One. 
2016;11(6):e0158535. 
2. Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with 
HIV compared with the general adult population in the United States: cross-sectional 
surveys. Ann. Intern. Med. 2015;162(5):335-344. 
3. Tron L, Lert F, Spire B, Dray-Spira R. Tobacco smoking in HIV-infected versus general 
population in france: heterogeneity across the various groups of people living with HIV. 
PLoS One. 2014;9(9):e107451. 
4. Cofrancesco J, Jr., Scherzer R, Tien PC, et al. Illicit drug use and HIV treatment outcomes 
in a US cohort. AIDS. 2008;22(3):357-365. 
5. Cook RL, Zhu F, Belnap BH, et al. Longitudinal trends in hazardous alcohol consumption 
among women with human immunodeficiency virus infection, 1995-2006. Am. J. 
Epidemiol. 2009;169(8):1025-1032. 
6. Durvasula R, Miller TR. Substance abuse treatment in persons with HIV/AIDS: challenges 
in managing triple diagnosis. Behav Med. 2014;40(2):43-52. 
7. Gonzalez A, Barinas J, O'Cleirigh C. Substance use: impact on adherence and HIV medical 
treatment. Curr. HIV/AIDS Rep. 2011;8(4):223-234. 
8. Hicks PL, Mulvey KP, Chander G, et al. The impact of illicit drug use and substance abuse 
treatment on adherence to HAART. AIDS Care. 2007;19(9):1134-1140. 
9. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for 
human immunodeficiency virus/acquired immune deficiency syndrome among drug users: 
a systematic review. Addiction. 2008;103(8):1242-1257. 
10. Life expectancy of individuals on combination antiretroviral therapy in high-income 
countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-299. 
11. Petoumenos K, Law MG. Smoking, alcohol and illicit drug use effects on survival in HIV-
positive persons. Curr. Opin. HIV AIDS. 2016;11(5):514-520. 
12. Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV 
prognosis among women in the HAART era: a report from the women's interagency HIV 
study. Am. J. Public Health. 2006;96(6):1060-1065. 
119 
 
13. Vagenas P, Azar MM, Copenhaver MM, Springer SA, Molina PE, Altice FL. The impact 
of alcohol use and related disorders on the HIV continuum of care: a systematic review: 
alcohol and the HIV continuum of care. Curr. HIV/AIDS Rep. 2015;12(4):421-436. 
14. Gonzalez-Serna A, Chan K, Yip B, et al. Temporal trends in the discontinuation of first-
line antiretroviral therapy. J. Antimicrob. Chemother. 2014;69(8):2202-2209. 
15. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of 
HIV-1 transmission. N. Engl. J. Med. 2016;375(9):830-839. 
16. Barve S, Kapoor R, Moghe A, et al. Focus on the liver: alcohol use, highly active 
antiretroviral therapy, and liver disease in HIV-infected patients. Alcohol Res. Health. 
2010;33(3):229-236. 
17. Kumar S, Rao PS, Earla R, Kumar A. Drug-drug interactions between anti-retroviral 
therapies and drugs of abuse in HIV systems. Expert Opin. Drug Metab. Toxicol. 
2015;11(3):343-355. 
18. Helleberg M, May MT, Ingle SM, et al. Smoking and life expectancy among HIV-infected 
individuals on antiretroviral therapy in Europe and North America. Aids. 2015;29(2):221-
229. 
19. Puskas CM, Kaida A, Miller CL, et al. The adherence gap: a longitudinal examination of 
men's and women's antiretroviral therapy adherence in British Columbia, 2000-2014. Aids. 
2017;31(6):827-833. 
20. Cescon A, Patterson S, Chan K, et al. Gender differences in clinical outcomes among HIV-
positive individuals on antiretroviral therapy in Canada: a multisite cohort study. PLoS 
One. 2013;8(12):e83649. 
21. Kuyper LM, Wood E, Montaner JS, Yip B, O'Connell J M, Hogg RS. Gender differences 
in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-
Infected patients in a population-based cohort. J. Acquir. Immune Defic. Syndr. 
2004;37(4):1470-1476. 
22. Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV 
treatment among injection drug users. AIDS. 2008;22(11):1247-1256. 
23. Loutfy MR, Sherr L, Sonnenberg-Schwan U, Walmsley SL, Johnson M, d'Arminio 
Monforte A. Caring for women living with HIV: gaps in the evidence. J. Int. AIDS Soc. 
2013;16:18509. 
120 
 
24. Webster K, Carter A, Proulx-Boucher K, et al. Strategies for recruiting women living with 
HIV in community-based research: Lessons from Canada. Prog. Community Health 
Partnersh. 2018;12(1):21-34. 
25. UNAIDS. The Gap Report 2014. [cited 2018 Jan 04]. Available from: 
http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidsp
ublication/2014/UNAIDS_Gap_report_en.pdf. 2014. 
26. Public Health Agency of Canada. HIV and AIDS in Canada: Surveillance Report to 
December 31, 2014. Ottawa: Minister of Public Works and Government Services Canada. 
2015. 
27. Loutfy M, de Pokomandy A, Kennedy VL, et al. Cohort profile: The Canadian HIV 
Women's Sexual and Reproductive Health Cohort Study (CHIWOS). PLoS One. 
2017;12(9):e0184708. 
28. UNAIDS. The Greater Involvement of People Living with HIV (GIPA). Geneva: UNAIDS 
Policy Brief, Joint United Nations Programme on HIV/AIDS. Available from (Last 
accessed: 25 April, 2018): 
http://data.unaids.org/pub/BriefingNote/2007/JC1299_Policy_Brief_GIPA.pdf. 2007. 
29. Canadian Community Health Survey. Annual component user files, 2013 microdata files. 
Statistics Canada [cited 25 Oct 2017]. 2013. 
30. Rust KF, Rao JN. Variance estimation for complex surveys using replication techniques. 
Stat. Methods Med. Res. 1996;5(3):283-310. 
31. Rothman K, Greenland S, Lash T. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott 
Williams & Wilkins; 2008. 
32. Zou GY, Donner A. Construction of confidence limits about effect measures: a general 
approach. Stat. Med. 2008 27(10):1693-1702. 
33. Turan B, Hatcher AM, Weiser SD, Johnson MO, Rice WS, Turan JM. Framing 
mechanisms linking HIV-related stigma, adherence to treatment, and health outcomes. Am. 
J. Public Health. 2017;107(6):863-869. 
34. Zhang Y, Wilson TE, Adedimeji A, et al. The impact of substance use on adherence to 
antiretroviral therapy among HIV-infected women in the United States. AIDS Behav. 
2018;22(3):896-908. 
121 
 
35. Jones AS, Lillie-Blanton M, Stone VE, et al. Multi-dimensional risk factor patterns 
associated with non-use of highly active antiretroviral therapy among human 
immunodeficiency virus-infected women. Womens Health Issues. 2010;20(5):335-342. 
36. D'Souza G, Matson PA, Grady CD, et al. Medicinal and recreational marijuana use among 
HIV-infected women in the Women's Interagency HIV Study (WIHS) cohort, 1994-2010. 
J. Acquir. Immune Defic. Syndr. 2012;61(5):618-626. 
37. Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral 
therapy adherence and HIV-related symptoms. J. Behav. Med. 2014;37(1):1-10. 
38. Okafor CN, Zhou Z, Burrell LE, 2nd, et al. Marijuana use and viral suppression in persons 
receiving medical care for HIV-infection. Am. J. Drug Alcohol Abuse. 2017;43(1):103-110. 
39. Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and 
mortality in a multicenter cohort of HIV-1 positive women. Aids. 2008;22(11):1355-1363. 
40. Nahvi S, Cooperman NA. Review: the need for smoking cessation among HIV-positive 
smokers. AIDS Educ. Prev. 2009;21(3 Suppl):14-27. 
41. Cook JA, Grey DD, Burke-Miller JK, et al. Illicit drug use, depression and their association 
with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend. 
2007;89(1):74-81. 
42. Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART 
access and adherence among injection drug users. Int. J. Drug Policy. 2010;21(1):4-9. 
43. Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and 
adherence to antiretroviral treatment among HIV-infected black women. J. Community 
Health. 2004;29(2):117-127. 
44. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, 
opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical 
care settings: results from a multisite study. J. Acquir. Immune Defic. Syndr. 2011;56 
(Suppl 1):S22-32. 
45. O'Brien N, Greene S, Carter A, et al. Envisioning Women-Centered HIV Care: 
Perspectives from Women Living with HIV in Canada. Womens Health Issues. 
2017;27(6):721-730. 
46. Simoni JM, Nelson KM, Franks JC, Yard SS, Lehavot K. Are peer interventions for HIV 
efficacious? A systematic review. AIDS Behav. 2011;15(8):1589-1595. 
122 
 
47. Cohen MH, Cook JA, Grey D, et al. Medically eligible women who do not use HAART: 
the importance of abuse, drug use, and race. Am. J. Public Health. 2004;94(7):1147-1151. 
 
 
123 
 
4. Chapter 4: Patterns of social determinants of health associated with drug 
use among women living with HIV in Canada: a latent class analysis
1
 
 
4.1. Introduction  
Illicit drug use, particularly opioids and stimulants, is common among people living with HIV 
(PLWH). For example, 10%, 24%, and 39% of PLWH in a US study reported heroin, 
amphetamines, and cocaine use, respectively, by any administration route.
1
 Although data on the 
prevalence of drug use among women living with HIV (WLWH) is limited, 28.6% of WLWH 
reported recent crack cocaine use, with 3.2% as persistent users.
2
 In Canada, available evidence 
showed that 25.0% and 11.3% of WLWH reported recent crack cocaine and heroin use (by any 
route), respectively.
3
  
Illicit drug use remains one of the most important factors influencing engagement in the 
HIV care cascade among individuals with HIV.
1,4-6
 Much evidence has documented poorer HIV 
treatment outcomes among people who use drugs, particularly among WLWH.
5-11
 For example, 
greater suboptimal combination antiretroviral therapy (cART) adherence was documented 
among WLWH who reported a history of drug use than among women who did not, or among 
men regardless of drug use.
7
 Drug use also predicts increased risk of disease progression, HIV 
transmission, and mortality,
1,2,10
 and continues to complicate HIV care and treatment efforts 
among PLWH.
12,13
 Although active drug use has been shown to complicate the clinical 
management of individuals with HIV and common comorbidities such as hepatitis C, increasing 
evidence documents how marginalization and criminalization of people who use/inject drugs 
                                                          
1
 A version of this chapter has been published: Shokoohi M, Bauer GR, Kaida A, et al. Patterns of social 
determinants of health associated with drug use among women living with HIV in Canada: a latent class analysis. 
Addiction. 2019 Jan 30. doi: 10.1111/add.14566. 
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interferes with access and adherence to HIV medications.
14
 Particular attention, therefore, needs 
to be given to such drug use practice throughout the course of HIV care and treatment among 
WLWH.  
Although some determinants of illicit drug use are well documented (e.g., demographics, 
cognitive, behavioural),
15
 few studies have explored the role of the social determinants of health 
(SDoH). The SDoH are the conditions (e.g., economic and social marginalization, and various 
forms of discrimination) in which people are born, work, live, and age, and the wider set of 
forces shaping the conditions of daily life that greatly contribute to health inequalities.
16
 Greater 
adversities regarding these living conditions can lead to high levels of physiological and 
psychological stresses arising from coping with stressors.
16
 For PLWH, HIV-related stigma in 
intersection with other social determinants (e.g., race and gender discrimination)
17
 can result in 
coping behaviours such as illicit drug use
18
 to help contend with worries and stresses,
19
 which 
can in turn increase vulnerabilities to HIV-related health outcomes.
18,20-22
 
Notably, multiple dimensions of SDoH tend to co-occur, and may cluster together into 
common combinations. Such concomitant determinants have been consistently treated as 
independent when studied in association with drug use. For example, previous studies have 
assessed the separate association of HIV stigma,
23
 food insecurity,
24
 unemployment,
25
 and low 
social support
26
 with drug use. However, there are limited data examining how clustering of 
these determinants is related to drug use. Such evidence is essential for developing HIV care and 
treatment programs to address potentially modifiable adversities and reduce their impacts on the 
lives of WLWH. Drawing on the Canadian HIV Women’s Sexual and Reproductive Health 
Cohort Study (CHIWOS),
27
 we conducted a latent class analysis (LCA) to uncover underlying 
clusters of SDoH. LCA as a data reduction strategy classifies individuals into mutually exclusive 
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and exhaustive latent classes using multiple categorical observed variables.
28
 LCA has been a 
useful technique for identifying population subgroups in different disciplines (e.g., substance 
using women at risk for HIV.
29
 We then applied inverse probability weighting to address 
confounding and selection bias in examining the association of the clusters of SDoH with drug 
use. 
4.2. Methods  
4.2.1 Study sample 
We used data from CHIWOS (www.chiwos.ca), a community-based cohort study. As previously 
described,
27
 CHIWOS is a large cohort of WLWH (≥16 years; trans inclusive) residing in the 
Canadian provinces of British Columbia (BC), Ontario, and Quebec. WLWH (n=1,422) were 
interviewed during 2013-2015 (time-point 1) and after ~18-months (time-point 2; n=1,252). We 
considered 170 participants (11.9%) lacking time-point 2 data as censored (i.e., lost to follow-
up). Participants were recruited through peers, HIV clinics, AIDS service or community-based 
organizations, word of mouth, and other methods.
30
 Trained Peer Research Associates (PRAs) 
administered the survey through in-person interviews at clinics, community sites, or participants’ 
homes, or via phone/Skype. Informed consent was obtained from all participants prior to the 
interview, consistent with the ethics protocol approved by Simon Fraser University, University 
of British Columbia/Providence Health, Women’s College Hospital, and McGill University 
Health Centre. 
4.2.2 Drug use 
Recent drug use was defined as last three months at the first time-point and last six months at the 
second time-point, and included use of opioids (heroin, speedballs, Dilaudid, non-prescribed 
methadone, OxyContin/Oxycodone, morphine, Talwin & Ritalin) or stimulants (cocaine, crack, 
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crystal methamphetamine, amphetamine, MDA). The regular (daily or at least once/week) or 
episodic (less than once/week) use of these drugs was ascertained among those who reported any 
use. Due to small proportions in the episodic use category (i.e., ~1%), a binary outcome at time-
point 2 was created: use of any vs. no drugs.  
4.2.3 SDoH indicators 
A set of potentially modifiable SDoH that have the potential to co-occur among WLWH were 
examined at time-point 1, including: racial discrimination, gender discrimination, enacted HIV 
stigma, perceived social support, barriers to access to care, food security, housing status, income 
level, employment status, education, recent sex work involvement, and recent incarceration. 
Included SDoH indicators: a) were measured at the first survey time-point, b) are potentially 
modifiable, c) were currently or recently experienced, and; d) align with the Canadian list of 
SDoH
19
 (HIV-related stigma being an exception specific to PLWH). Selection of SDoH was 
limited to current or recent conditions to avoid the potential for collider stratification bias
31
 that 
could be introduced in a selected (HIV-positive) sample by studying earlier social determinants 
that may have affected HIV status. 
Racial discrimination was measured with the 8-item Everyday Discrimination Scale 
(current study α=0.96)32. In line with operationalization used in the prior research,33 WLWH who 
reported discriminatory experiences due to their race (e.g., treated with less courtesy, respect) 
sometimes, frequently, or almost every day were considered as having experienced racial 
discrimination. The same scale (with the same definition) focusing on discriminatory 
mistreatments due to gender was used to measure gender discrimination (α=0.94). Enacted HIV 
stigma was measured using three items of Wright's abridged 10-item version of Berger's HIV 
Stigma Scale (α=0.85), measuring the extent to which WLWH experienced enacted/personalized 
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stigma toward PLWH.
34
 Experience of HIV-related stigma was defined if WLWH reported any 
HIV-related discriminatory events with strongly agree/agree response options (i.e., been hurt by 
people’s reaction, stopped socializing, or lost friends). Social support was examined by the 4-
item Medical Outcome Study: Social Support Survey, measuring emotional-informational, 
tangible, affectionate, and positive social interaction supports (α=0.85). The overall mean score 
ranged from 1 to 5, with > 2 indicating poor social support availability.
35
 Difficulties in access to 
care was assessed using the 12-item Barriers to Access to Care Scale, measuring barriers 
experienced due to geography/distance, medical and psychological service, community stigma, 
and personal resource (α=0.93). The overall mean severity scores ranged from 1 to 4, with ≥ 2 
signifying severe/significant barriers.
21
 Past-year experiences of food security were examined by 
three items: fears of running out of food; experiences of running out of food; and unaffordability 
of balanced meals, yielding an overall score ranging 1-6, with > 1 indicating food insecurity.
36
 
Income level was defined as low if participants reported having a yearly household income level 
< $20,000. Current employment status was categorized as unemployed (no income or income 
only from non-employment sources such as unemployment/welfare, dividends and interest, or 
pension) vs. employed (any paid job). Current education level was dichotomized as below high 
school vs. completed high school or more. Current housing status was also measured. 
Participants who reported residing in places such as a self-contained room, transition house, 
halfway house, safe house, or outdoors were considered as unstable housing. Past six months sex 
work involvement was also included, and defined as having been provided with money, drug, 
shelter, food, etc. in exchange for sex. Finally, any past year experience of incarceration was 
included as a structural-level determinant indicating social exclusion.  
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4.2.4 Covariates 
The following covariates were hypothesized to be associated with either both SDoH clusters and 
drug use or only drug use: age (continuous); ethnoracial groups (white/Caucasian, 
African/Caribbean/Black, Indigenous, others); province (BC, Ontario, Quebec); city size (large, 
others); sexual orientation (heterosexual, LGBQ); relationship status (married/common-
law/relationship, others); years living with HIV (<6 years, 6-14 years, > 14 years); cART status 
(optimal [≥ 95% adherence], suboptimal [< 95% adherence], not engaged in HIV treatment); 
ever diagnosed with a mental health condition; resilience (10-item Resilience Scale) ; any history 
of childhood sexual/physical violence; any experience of adulthood 
sexual/physical/verbal/action-limited violence; having been under the care of Child Protection 
Services or in foster care; and alcohol use (abstainers/low, moderate [1-7 drinks/week], heavy [> 
7 drinks/week]). Drug use history before or at time-point 1 was also included to account for 
confounding by outcome history.
37
 Missing values of covariates under the assumption of missing 
at random were singly imputed to reduce the loss of statistical power when computing inverse 
probability weights (IPW).
38
 
4.2.5 Latent class analysis (LCA) 
We used LCA to identify clusters of SDoH indicators. Under the assumption that all observed 
indicators are independent conditional on the latent variable, LCA aims to identify distinct 
groups of individuals with similar patterns within an unobserved categorical variable.
28
 LCA was 
started with a two-class model and systematically increased to more classes (S Table 4.1). LCA 
provides both class membership probabilities and item-response probabilities condition on class 
membership to help interpret the final identified class (Table 4.1). The expectation–
maximization (EM) algorithm with 5,000 iterations was employed to identify the best model 
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fit.
39
 The selection of the best LCA model was informed by using goodness-of-fit indices, 
supporting statistics, and interpretability of class memberships. The following fit statistics were 
reported: log-likelihood, Akaike’s information criterion (AIC), Bayesian information criterion 
(BIC), and sample-size-adjusted BIC (aBIC), and consistent AIC (CAIC).
40-42
 Lower values of 
these criteria indicate better fit and parsimony. Two supporting statistics were also reported: 
Entropy as  a measure of classification accuracy, with values approaching to 1 indicating better 
class separation,
43
 and the percentage of seeds associated with the fitting models, with values 
close to 100% indicating they were unlikely to have hit the local maxima. For each model, the 
log-likelihood was replicated with 1,000 random starting values to avoid local maxima. Under 
the assumption of missing at random, LCA accounted for missing values of the SDoH indicators 
using the full information maximum likelihood estimation. LCA was conducted using SAS 
PROC LCA procedure.
44
 
4.2.6 Models and estimations  
We used inverse probability weights (IPW)
45,46
 to account for confounding due to the presence of 
potentially imbalanced covariates across the SDoH clusters, and inverse probability censoring 
weights (IPCW) to account for prospective selection bias due to potentially non-random loss to 
follow-up/censoring (S Table 4.2). The product of these two weights yielded the final stabilized 
weights (S Table 4.3), producing a pseudo-population in which the independent variable and 
covariates are unassociated (S Table 4.4). In fitting models through IPW, we assumed correct 
specification of IPW models, conditional exchangeability, and positivity.
47
  
4.2.7 Control of confounding using IPW  
SDoH clusters were modeled using a multinomial logistic regression to estimate stabilized 
weights: the numerator was computed as the marginal probability of the SDoH clusters divided 
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by the denominator, which was computed as the probability that a participant was assigned to an 
SDoH cluster given the covariates and opioid/stimulant use history. These models were all 
performed among participants without censored information in time-point 2. 
4.2.8 Control of selection bias using IPCW  
Additionally, to account for any potential selection bias due to differential loss-to-follow-up at 
time-point 2, we estimated IPCW using logistic regression models: numerator was defined as the 
probability of not being censored given SDoH, and denominator was computed as the probability 
of not being censored given SDoH, covariates and opioid/stimulant use history.  
4.2.9 Association of SDoH clusters with drug use  
The association between SDoH clusters and any opioid/stimulant use was examined using 
generalized linear models with log link and Poisson distribution; crude and weighted risk ratios 
(RRs) and 95% confidence intervals (CIs) were reported. Further adjustment was made for 
imbalanced covariates after applying the IPW. These analyses were conducted using Stata 15.  
4.2.10 Sensitivity analysis 
We reported E-value to evaluate the extent to which residual (unmeasured) confounding might 
explain away the observed associations, and computed as: E = RR
*
 + sqrt{RR
* 
× RR
* – 1}, 
where RR
*
 = 1/RR for RR < 1.
48
 E-value is a representation of the minimum strength of 
association that an unmeasured confounder would need to have with SDoH clusters and drug use 
to nullify the observed associations.  
4.3. Results  
4.3.1 SDoH classes  
Prevalences for individual social determinants ranged from 6.3% (N = 82/1307) and 6.5% (N = 
92/1419) for recent sex work involvement and incarceration to 71.8% (N = 1004/1398) and 
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77.8% (N = 1098/1412) for enacted HIV stigma and unemployment, respectively (Table 4.1). 
After considering LCA fit statistics and model interpretability, the four-class model was 
determined as the optimal number of classes (S Table 4.1). These four classes included WLWH 
with either none/least SDoH adversities (class 1 labeled as no/least SDoH adversities: N = 94 
[6.6%]); WLWH who predominantly reported experiencing race and gender discrimination along 
with HIV-related stigma and barriers in access to care, but without economic hardship indicators 
(class 2 labelled as discrimination/stigma: N = 256 [18.0%]); WLWH who mainly reported food 
insecurity, low household income, and unemployment, accompanied with HIV-related stigma 
(class 3 labeled as economic hardship: N = 430 [30.2%]); and WLWH who experienced gender 
and race discrimination, HIV-related stigma, low social support, access to care difficulties, food 
insecurity, low income, and unemployment (class 4 labeled as most SDoH adversities: N = 642 
[45.2%]). 
Table 4.1: Class Membership Probabilities and Item-Response Probabilities of Social 
Determinants of Health (SDoH) from Latent Class Analysis among Women Living with 
HIV – CHIWOS (N=1,422). 
 
 
SDoH measures  
 None/least 
SDoH 
(N = 94; 
6.6%)
b
 
Discrimination 
and Stigma  
(N = 256; 
18.0%) 
Economic 
hardship 
(N = 430; 
30.2%) 
Most SDoH 
adversities  
(N = 642; 
45.2%) 
Race discrimination  
(708/1408; 50.3%)
a
 
No 0.00 0.40
c
 0.91 0.18 
Yes 0.00 0.60 0.09 0.82 
None
d
 1.00 0.00 0.00 0.00 
Gender discrimination  
(818/1415; 57.1%) 
No 0.00 0.33 0.91 0.04 
Yes 0.00 0.67 0.09 0.96 
None 1.00 0.00 0.00 0.00 
Enacted HIV stigma  No 0.00 0.22 0.40 0.17 
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(1004/1398; 71.8%) Yes 0.00 0.78 0.60 0.83 
None 1.00 0.00 0.00 0.00 
Low social support  
(722/1367; 52.8%) 
No 0.00 0.51 0.51 0.37 
Yes 0.00 0.49 0.49 0.63 
None 1.00 0.00 0.00 0.00 
High barriers to access to 
care  
(725/1371; 52.8%) 
No 0.00 0.43 0.55 0.36 
Yes 0.00 0.57 0.45 0.64 
None 1.00 0.00 0.00 0.00 
Food insecurity   
(907/1416; 64.1%) 
No 0.00 0.63 0.31 0.18 
Yes 0.00 0.37 0.69 0.82 
None 1.00 0.00 0.00 0.00 
Low income  
(901/1379; 65.3%) 
No 0.00 0.90 0.21 0.11 
Yes 0.00 0.10 0.79 0.89 
None 1.00 0.00 0.00 0.00 
Unemployment  
(1098/1412; 77.8%) 
No 0.00 0.67 0.09 0.02 
Yes 0.00 0.33 0.91 0.98 
None 1.00 0.00 0.00 0.00 
Low education  
(227/1415; 16.0%) 
No 0.00 1.00 0.83 0.75 
Yes 0.00 0.00 0.17 0.25 
None 1.00 0.00 0.00 0.00 
Unstably housed  
(152/1422; 10.7%) 
No 0.00 0.99 0.90 0.83 
Yes 0.00 0.01 0.10 0.17 
None 1.00 0.00 0.00 0.00 
Recent sex work practice  
(82/1307; 6.3%) 
No 0.00 0.99 0.95 0.90 
Yes 0.00 0.01 0.05 0.10 
None 1.00 0.00 0.00 0.00 
Recent incarceration  
(92/1419; 6.5%) 
No 0.00 1.00 0.96 0.88 
Yes 0.00 0.00 0.04 0.12 
None 1.00 0.00 0.00 0.00 
a 
(n/N; %) indicating the prevalence of the SDoH indicators under the study; 
b
 Class membership probabilities; 
c
 
Item-response probabilities, indicating the probability of experiencing a SDoH indicator for each identified latent 
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class; 
d 
We categorized each SDoH measure into three categories: No: indicating either did not have/experience this 
determinant, Yes: indicating either living/experiencing this determinant, None: indicating either did not experience 
any of these 12 determinants or experienced only one (i.e., least). Item response probabilities of “Yes” category ≥ 
0.50 are bolded, and item response probabilities of “None” category with 100% are underlined. The “None” 
category was added to produce a distinct class named “None/least SDoH adversities” to ease interpretation of the 
latent classes and reduce LCA model complexity. 
 
4.3.2 Participants’ characteristics  
WLWH were an average of 42.8 [SD 10.6] years of age, with 584 (41.1%) members of the white 
ethnoracial group, 1237 (87.3%) heterosexual, 689 (48.5%) single, 552 (40.2%) living with HIV 
for 6-14 years, 863 (70.0%) self-reporting optimal cART adherence; 819 (62.7%) and 1057 
(80.4%) reported exposure to violence as children and adults, respectively, 573 (40.7%) reported 
a mental health diagnosis, and 140 (10.1%) were heavy alcohol users. The distributions of these 
covariates across the SDoH clusters are presented in Table 4.2.  
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Table 4.2: Characteristics of Women Living with HIV (WLWH) across the Social Determinants of Health (SDoH) Classes – 
CHIWOS Time-point 1, 2013-2015 (N = 1,422). 
 
Variables 
Overall SDoH classes 
None/least 
adversities 
Discrimination/ 
stigma 
Economic 
hardship 
Most 
adversities 
P-value
b
 
Age, yr
d
 (mean [SD]) 42.8 [10.6] 39.2 [10.3]  43.5 [10.6] 42.9 [11.5] 43.1 [10.0] 0.007 
Ethno-racial group      <0.001 
White/Caucasian 584 (41.1)
a
 58 (61.7) 97 (37.9) 219 (50.9) 210 (32.7)  
African/Caribbean/Black 418 (29.4) 23 (24.5) 109 (42.6) 123 (28.6) 163 (25.4)  
Indigenous 318 (22.3) 7 (7.4) 29 (11.3) 60 (14.0) 222 (34.6)  
Other 102 (7.2) 6 (6.4) 21 (8.2) 28 (6.5) 47 (7.3)  
Province      <0.001 
Ontario  717 (50.4) 50 (53.2) 131 (51.2) 235 (54.6) 301 (46.9)  
British Columbia  356 (25.0) 13 (13.8) 49 (19.1) 65 (15.1) 229 (35.7)  
Quebec   349 (24.6) 31 (33.0) 76 (29.7) 130 (30.2) 112 (17.5)  
Living in large cities 1169 (82.2) 83 (88.3) 203 (79.3) 345 (80.2) 538 (83.8) 0.106 
Bing heterosexual 1237 (87.3) 85 (90.4) 237 (93.3) 395  (91.9) 520 (81.4) <0.001 
Relationship status      <0.001 
Single (non-married) 689 (48.5) 40 (42.6) 100 (39.1) 201 (46.7) 348 (54.4)  
Married/common-law  454 (32.0) 44 (46.8) 103 (40.2) 134 (31.1) 173 (27.0)  
Others  277 (19.5) 10 (10.6) 53 (20.7) 95 (22.1) 119 (18.6)  
Years living with HIV       0.001 
135 
 
< 6 years 345 (25.1) 23 (25.0) 40 (15.7) 128 (31.4) 154 (24.8)  
6-14 years  552 (40.2) 35 (38.0) 118 (46.7) 140 (34.3) 259 (41.8)  
> 14 years  477 (34.7) 34 (37.0) 96 (37.8) 140 (34.3) 207 (33.4)  
Taking HIV treatment      0.001 
Yes, optimal (≥ 95%) 863 (70.0) 65 (69.9) 163 (64.7) 279 (65.0) 356 (55.5)  
Yes, suboptimal (< 95%) 312 (22.0) 12 (12.9) 52 (21.4) 74 (17.2) 172 (26.8)  
Not engaged in treatment  240 (17.0) 16 (17.2) 35 (13.9) 76 (17.7) 113 (17.6)  
Mental health diagnosis 573 (40.7) 26 (28.0) 93 (36.6) 134 (31.6) 320 (50.3) <0.001 
Resiliency (below median)
c
 662 (47.1) 22 (23.66) 104 (40.9) 172 (40.6) 364 (57.4) <0.001 
Childhood violence 819 (62.7) 34 (38.6) 138 (56.8) 211 (53.8) 436 (74.7) <0.001 
Adulthood violence 1057 (80.4) 52 (59.1) 189 (77.5) 284 (71.9) 532 (90.5) <0.001 
Child development events 326 (23.0) 10 (10.6) 33 (13.0) 74 (17.3) 209 (32.7) <0.001 
Heavy alcohol use       0.132 
Abstainers/low (< 1 drink/week) 956 (69.1) 64 (68.8) 174 (68.5) 302 (71.1) 419 (68.1)  
Moderate (1-7 drinks/week) 288 (20.8) 22 (23.7) 60 (23.6) 88 (20.7) 118 (19.2)  
Heavy (> 7 drinks/week) 140 (10.1) 7 (7.5) 20 (7.9) 35 (8.2) 78 (12.7)  
Drug use history
d
        
Before study entry 234 (16.8) 3 (3.2) 10 (3.9) 48 (11.24) 173 (27.5) <0.001 
At entry (time-point 1) 244 (17.5) 2 (2.2) 11 (4.3) 50 (11.9) 181 (28.8) <0.001 
a 
Data are presented as N(%) unless specified; 
b 
P-values are for the chi-square test for categorical covariates and one-way ANOVA for continuous covariates; 
c
 
Scores ranged 10-70, with higher scores indicating increased resilience (median=64); 
d
 Opioid/stimulant use histories before and at time-point 1.
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4.3.3 SDoH clusters and drug use  
Overall, opioid/ stimulant use at time-points 1 and 2 were respectively reported by 244 (17.5%) 
and 212 (17.2%.). Drug use at time-point 2 was reported by 143 (26.4%) among WLWH with 
most SDoH adversities, with 53 (14.1%), 13 (5.6%) and 3 (3.5%) for economic hardship, 
discrimination/stigma, and no/least SDoH classes, respectively (Figure 4.1). The crude 
regression analysis demonstrated that WLWH in the no/least SDoH adversities, 
discrimination/stigma, and economic hardship classes had significantly lower likelihood of 
opioid/stimulant use than WLWH in the most SDoH adversities class. Compared with the most 
SDoH adversities class, weighted analysis showed that WLWH in no/least SDoH class were at 
87% decreased risk of drug use (RR 0.13, 95% CI: 0.03, 0.58), while an association was not 
observed for other classes. Additionally, WLWH in the no/least SDoH class were at decreased 
risk of drug use compared to WLWH in the economic hardship class (RR 0.13, 95% CI: 0.03, 
0.63) and discrimination/stigma class (RR 0.15; 95% CI: 0.03, 0.78) (Table 4.3). 
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Figure 4.1: Prevalence of Drug Use According to the Social Determinants of Health (SDoH) 
Classes Obtained from Latent Class Analysis (LCA) – CHIWOS. 
 
Illicit drugs included a) Stimulants: cocaine, crack (crack cocaine), crystal, speed (amphetamine) and MDA; and b) 
Opioids: heroin, speedballs (heroin+ cocaine), Dilaudid (hydromorphone), non-prescription use of methadone, 
OxyContin/Oxycodone, morphine, Talwins & Ritalin. These drugs were measured at baseline (time-point 1, 2013-
15) and in ~18 month follow up (time-point 2; 2015-17). Analytic sample size for these prevalences was 1,395 at 
time-point1 and 1,236 at time-point 2.   
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Table 4.3: Inverse Probability Weighted Estimates of the Association of the Social Determinants of Health (SDoH) Classes 
with Drug Use among Women Living with HIV (WLWH) – CHIWOSa 
 
 
 
SDoH classes
c
 
Observed estimates  E-value for the observed 
estimates 
c
 
Crude RR
b
 
(95% CI) 
P-value Weighted RR 
(95% CI) 
P-value Weighted RR  Upper CI  
Economic hardship class vs.   
 Most SDoH adversities 
0.53  
(0.40, 0.71) 
<0.001  0.95  
(0.67, 1.34) 
0.760 
--- --- 
Discrimination/stigma class vs.  
 Most SDoH adversities 
0.21  
(0.12, 0.37) 
<0.001 0.82  
(0.44, 1.52) 
0.539 
--- --- 
None/least adversities class vs.  
 Most SDoH adversities  
0.13 (0.04, 
0.40) 
<0.001 0.13  
(0.03, 0.58)   
0.008 
14.86 2.84 
Discrimination/stigma class vs.  
 Economic hardship  
0.40  
(0.22, 0.71) 
0.002 0.87  
(0.44, 1.68)  
0.678 
--- --- 
None/least adversities class vs.  
 Economic hardship  
0.24  
(0.07, 0.76) 
0.015 0.13  
(0.03, 0.63) 
0.011 
14.86 2.55 
None/least adversities class vs.  
 Discrimination/stigma  
0.61  
(0.18, 2.1) 
0.440 0.15  
(0.03, 0.78) 
0.024 
11.81 1.88 
a 
N = 1,236 in crude analysis and N= 1,225 in weighted analysis; 
b 
RR: risk ratio (95% confidence intervals: CI); 
c
 This is a sensitivity analysis evaluating the 
extant to which an unmeasured confounder would explain away the exposure-outcome estimates observed for the association between the SDoH classes and drug 
use. E-value was check for the observed point estimate and the upper 95% CI that is close to the null RR = 1.  
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The sensitivity analysis suggested that these associations were relatively robust to potential 
unmeasured confounding. For instance, for the observed RR: 0.13 for drug use among those with 
no/least SDoH adversities versus those with most adversities, an unmeasured confounder 
correlated with both exposure and outcome by RRs of ~14.86-fold each, above and beyond the 
measured confounders, would explain away the observed association, but weaker confounding 
would not. Such an E-value for the upper 95% limit of the same association was 2.84-fold 
(Table 4.3).  
4.4. Discussion  
In our study of data from a large prospective cohort of WLWH in Canada, we observed that most 
WLWH reported experiencing multiple forms of a set of mutually reinforcing SDoH. We 
identified two partially overlapped SDoH clusters of discrimination/stigma and economic 
hardship as well as one cluster containing most of the SDoH adversities. Most notably, we found 
that the prevalence of self-reported opioid/stimulant use was approximately seven times higher in 
WLWH who experienced the most SDoH adversities than those experiencing no/least adversity 
(26.4% vs. 3.5%). WLWH with no/least adversity were substantially less likely to report drug 
use at ~18 months follow up compared with WLWH experiencing an accumulation of social 
disadvantages. 
Overall, the high prevalence of socio-structural adversities among WLWH is consistent 
with existing knowledge that women experience substantial SDoH vulnerabilities and multiple 
forms of these adversities.
49,50
 The majority of the SDoH indicators were well-distinguished 
across the SDoH classes using LCA analysis, except for low education, unstable housing, sex 
work involvement, and incarceration. That these four determinants were less distinctive may be 
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due to their relatively low proportions, likely resulted in a low overall impact on drug use in the 
current sample of WLWH. 
We documented that the clustered classes of multiple SDoH adversities were associated 
with drug use. Notably, no difference was observed in the risk of drug use for the two classes of 
discriminations/stigma and economic hardship compared with the class with most SDoH 
adversities and also the same risk of drug use was estimated when WLWH in the no/least class 
were compared with WLWH in these two classes. Such findings may help shed light on the 
processes that generate and reinforce well-documented syndemics of HIV and substance use, by 
showing the role that each specific cluster of SDoH may play in initiation/continuation of drug 
use. Our results suggest that improving modifiable social determinants may be crucial to 
addressing this syndemic.
51
 Harm reduction and treatment interventions need to seriously 
consider the important role of multiple SDoH – regardless of their types. Drug treatment 
programs that mainly focus on behaviour change interventions may result in limited impact if no 
additional efforts are made to change the social environments of drug users.
52
 
Our findings may also have implications for HIV care and treatment programs by 
illuminating the association of current social determinants with illicit drug use, which has been 
shown to create challenges within the HIV care cascade. Prior evidence has demonstrated how 
income level,
53
 HIV stigma,
22
 and food insecurity  increase vulnerabilities to suboptimal cART 
adherence by limiting access to HIV care and treatment services, and affecting individuals’ 
health seeking behaviours. Illicit drug use, e.g., crack cocaine, also impacts HIV clinical care 
through the same mechanism of HIV treatment interruptions.
2,10,11,54
 Individually or combined, 
these factors can threaten the benefits accompanied with early HIV treatment initiation and the 
commitments toward eliminating the HIV pandemic. Paying particular attention to these 
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interlinked social and drug use determinants should be a key priority in efforts to improve HIV 
medical care for WLWH, and merits continued and thorough investigation. Given the impacts of 
these SDoH adversities and risk practices on HIV care and treatment outcomes, these findings 
indicate a need for regular assessment of these factors and targeted support for women with 
greater needs within routine HIV care,
55
 which if addressed holistically, may reduce the 
likelihood of suboptimal HIV clinical outcomes. 
While this study took advantage of CHIWOS as the largest community-based research 
cohort of WLWH in Canada, it had some limitations. First, non-random sampling of the 
participants may limit the generalizability and interpretation of our findings. Second, we relied 
on self-reported drug use, which may be subject to social desirability bias; however, participants 
were interviewed by PRAs who also experienced living with HIV (and in some cases, using 
drugs), and this may have limited such bias. Third, although unmeasured confounding is a source 
of bias in observational research, our sensitivity analysis showed that relatively strong 
unmeasured confounding would be required to nullify the observed associations.  
The current research has several strengths despite these limitations: First, we used data 
from a nationwide large sample of WLWH. Second, our research extends the relatively limited 
extant knowledge on drug use among women with HIV. Third, our research contributes to 
theoretical development through examining the inclusion of detailed individual-level data of 
current and modifiable social determinants as leading stressors in the target population’s daily 
life. Fourth, we demonstrated how these determinants cluster together using LCA, a probability-
based technique that provides a better insight into the underlying clusters of the individual SDoH 
indicators given the concurrent occurrence of these determinants. Fifth, IPW was used to account 
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for both confounding and selection bias. Finally, the survey had a high retention rate (88%) after 
18 months of follow-up.  
Despite a growing body of evidence on the independent associations between social 
determinants and drug use, less focus has been put on ways these determinants overlap, or on 
their clustering impacts on drug use. The complex relationships between the SDoH indicators, 
the documented (individual) associations with barriers to care, and stigma that surrounds both 
drug use and many aspects of social adversity suggest that HIV care programs will need to make 
intentional efforts to ensure that patients have full access to optimal care across the HIV care 
cascade. Our findings support the targeted assessment of multiple social determinant and drug 
use vulnerabilities; HIV-specific and women-centered care models have good potential to create 
the kind of low-stigma environment that would allow for these issues to be both assessed and 
addressed.
56
 Developing evidence-based treatment for drug dependence, including harm 
reduction strategies, requires a recognition of the role of social determinants of health. 
Individuals with these socio-structural adversities in intersection with drug use may continue to 
experience greater challenges with regard to HIV treatment adherence and HIV outcomes; 
therefore, the continued support for individuals with greater vulnerabilities is required.  
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4.5. Supplementary Tables  
S Table 4.1: Comparison of Goodness-of-fit Measures for Different Class Models (N=1,422) 
Model  LL
a 
AIC
b
 BIC
c
 CAIC
d
 Entropy % seeds
e
 
1-class  -12363.0 10080.9 10207.2 10231.2 1.000 100% 
2-class  -8582.2 2569.1 2826.9 2875.9 1.000 100% 
3-class  -8271.3 1997.4 2386.7 2460.7 0.843 98.4% 
4-class
f
 -8030.0 1564.9 2085.6 2184.6 0.831 93.5% 
5-class  -7966.5 1487.8 2140.0 2264.0 0.819 35.0% 
6-class  -7922.1 1449.0 2232.7 2381.7 0.814 15.0% 
7-class  -7889.8 1434.5 2349.7 2523.7 0.745 32.4% 
a
 Log-Likelihood (LL); 
b
 Akaike information criterion (AIC); 
c
 Bayesian information criterion (BIC); 
d
 Consistent 
AIC (CAIC), 
e 
Percentage of seeds associated with best fitted model (% seeds); 
f
 4-class model had the lowest BIC 
and CAIC. Moving forward to model with more classes, entropy suggested lower classification accuracy (e.g., 
~10% reduction from 4-class to 7-class). In addition, the 4-class model had a higher percentage of seeds associated 
with best fitted model (i.e., increased confidence that the best solution was achieved even though it is not a fit 
criterion). Fit indices/statistics align with model interpretability suggested the 4-class model provided a better fit 
with plausible distribution of the sample within each class. 
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S Table 4.2: Characteristics of Women Living with HIV (WLWH) who were Lost to 
Follow-up (i.e., Censored), CHIWOS, 2013-2017  
 
Variables  
Not Lost to follow up 
(N = 1252) 
Lost to follow up 
(N = 170) 
P-value 
SDoH classes    0.057 
Class 1: No/least SDoH adversities  88 (7.03) 6 (3.53)  
Class 2: Discrimination/Stigma  232 (18.53) 24 (14.12)  
Class 3: Economic adversities   381 (30.43) 49 (28.82)  
Class 4: Most SDoH adversities  551 (44.01) 91 (53.53)  
Age, yr
d
 (mean [SD]) 42.9 [10.61] 42.2 [10.34] 0.430 
Ethno-racial group   0.062 
White/Caucasian 515 (41.13) 69 (40.59)  
African/Caribbean/Black 380 (30.35) 38 (22.35)  
Indigenous 272 (21.73) 46 (27.06)  
Other 85 (6.79) 17 (10.00)  
Province   0.018 
Ontario  637 (50.88) 80 (47.06)  
British Columbia  299 (23.88) 57 (33.53)  
Quebec   316 (25.24) 33 (19.41)  
Living in large cities 1029 (82.19) 140 (82.35) 0.958 
heterosexual 1095 (87.81) 142 (83.53) 0.116 
Relationship status   0.596 
Single (non-married) 612 (48.92) 77 (45.56)  
Married/common-law  394 (31.49) 60 (35.50)  
Others  245 (19.58) 32 (18.93)  
Years living with HIV    0.648 
< 6 years 310 (25.49) 35 (22.15)  
6-14 years  487 (40.05) 65 (41.14)  
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> 14 years  419 (34.46) 58 (36.71)  
Taking HIV treatment   0.012 
Yes, optimal (≥ 95%) 759 (60.91) 104 (61.54)  
Yes, suboptimal (< 95%) 264 (21.19) 48 (28.40)  
Not engaged in treatment  223 (17.90) 17 (10.06)  
Mental health diagnosis 499 (40.21) 74 (44.58) 0.282 
Resiliency (below median) 568 (45.81) 94 (56.97) 0.007 
Childhood violence 708 (61.51) 111 (71.15) 0.019 
Adulthood violence 918 (79.07) 139 (90.26) 0.001 
Child development events 269 (21.55) 57 (33.73) <0.001 
Heavy alcohol use    0.011 
Abstainers/low (< 1 drink/week) 865 (70.44) 94 (59.12)  
Moderate (1-7 drinks/week) 242 (19.71) 46 (28.93)  
Heavy (> 7 drinks/week) 121 (9.85) 19 (11.95)  
Stimulant/opioid use     
Before study entry 187 (15.19) 47 (28.31) <0.001 
At entry (time-point 1) 193 (15.70) 51 (30.72) <0.001 
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S Table 4.3: Distributions of the Estimated Weights for the Classes of the Social 
Determinants of Health (SDoH), Censoring, and both, CHIWOS, Time-point 1, 2013-2015 
 Mean (SD) Percentiles 
5
th
 25
th
 50
th
 75
th
 95
th
 
Stabilized weights for 
SDoH weights  
      
 Class 1 0.90 (1.30) 0.16 0.26 0.46 0.95 3.21 
 Class 2 0.96 (0.82) 0.39 0.54 0.74 1.04 2.20 
 Class 3 1.00 (0.67) 0.50 0.63 0.80 1.12 2.26 
 Class 4 0.99 (0.60) 0.48 0.60 0.81 1.18 2.01 
 Overall  0.98 (0.73) 0.43 0.58 0.78 1.13 2.18 
Stabilized weights for  
censoring weights  
      
 Overall  0.99 (0.08) 0.91 0.94 0.98 1.02 1.14 
Stabilized weights for 
final weights  
      
 Class 1 0.89 (1.38) 0.15 0.26 0.45 0.93 3.18 
 Class 2 0.97 (0.86) 0.39 0.53 0.73 1.02 2.30 
 Class 3 1.02 (0.75) 0.47 0.62 0.78 1.13 2.35 
 Class 4 0.97 (0.55) 0.50 0.62 0.81 1.15 1.89 
 Overall  0.98 (0.76) 0.43 0.58 0.77 1.12 2.12 
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S Table 4.4: Inverse-Probability Weighted Estimates of the Parameters of a Marginal 
Structural Model for the Association of the Classes of the Social Determinants of Health 
(SDoH) on Drug Use among Women Living with HIV (WLWH), CHIWOS, Canada, 2013-
2017  
 SDoH classes
a
  
Variables  No/least SDoH 
adversities  
Discrimination/ 
stigma 
Economic 
adversities   
Age, yr (mean) 0.99 (0.95, 1.02)  0.99 (0.97, 1.01) 1.00 (0.98, 1.01) 
Ethno-racial groups    
White/Caucasian 1 1 1 
Indigenous 1.01 (0.29, 3.46) 0.91 (0.5, 1.66) 0.88 (0.56, 1.38) 
African/Caribbean/Black 0.75 (0.36, 1.56) 0.87 (0.57, 1.32) 0.96 (0.67, 1.38) 
Other 0.58 (0.18, 1.85) 0.98 (0.48, 1.99) 0.99 (0.53, 1.86) 
Study province    
Ontario  1 1 1 
British Columbia  0.61 (0.21, 1.78) 0.63 (0.39, 1.02) 1.05 (0.69, 1.59) 
Quebec  0.77 (0.35, 1.67) 0.90 (0.56, 1.45) 1.00 (0.69, 1.43) 
Living large size cities 1.08 (0.42, 2.74) 1.11 (0.70, 1.76) 0.96 (0.63, 1.48) 
Heterosexual 0.60 (0.14, 2.56) 1.65 (0.86, 3.14) 1.22 (0.76, 1.95) 
Relationship status    
Single (non-married) 1 1 1 
Married 0.84 (0.38, 1.85) 0.81 (0.53, 1.25) 1.07 (0.74, 1.56) 
Others  0.89 (0.31, 2.55) 0.78 (0.49, 1.26) 1.02 (0.68, 1.53) 
Years living with HIV    
< 6 years 1 1 1 
6-14 years  1.22 (0.49, 3.05) 0.88 (0.52, 1.49) 0.91 (0.62, 1.34) 
> 14 years  1.53 (0.68, 3.48) 0.89 (0.52, 1.52) 0.95 (0.63, 1.41) 
Taking HIV treatment    
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Yes, optimal 1 1 1 
Yes, suboptimal 0.57 (0.23, 1.42) 1.11 (0.66, 1.87) 1.02 (0.67, 1.55) 
Not in treatment  0.75 (0.32, 1.78) 0.97 (0.55, 1.70) 0.89 (0.59, 1.36) 
Mental health diagnosis 1.44 (0.66, 3.18) 0.82 (0.55, 1.23) 0.94 (0.68, 1.31) 
Resiliency (below median) 0.48 (0.22, 1.03) 0.90 (0.6, 1.34) 0.97 (0.71, 1.34) 
Childhood violence 1.02 (0.51, 2.03) 0.89 (0.59, 1.34) 0.95 (0.69, 1.32) 
Adulthood violence 0.71 (0.33, 1.53) 0.90 (0.55, 1.45) 0.92 (0.62, 1.37) 
Childhood development events 0.67 (0.22, 2.02) 0.98 (0.56, 1.70) 0.96 (0.63, 1.45) 
Heavy alcohol use     
Abstainers/low (< 1 drink/week) 1 1 1 
Moderate (1-7 drinks/week) 1.55 (0.55, 4.34) 0.98 (0.62, 1.57) 0.87 (0.58, 1.30) 
Heavy (> 7 drinks/week) 0.30 (0.12, 0.79)
b
 1.68 (0.79, 3.55) 0.97 (0.57, 1.67) 
Stimulant/opioid use     
Before study entry 0.95 (0.17, 5.38) 0.84 (0.37, 1.90) 0.88 (0.55, 1.41) 
At entry (time-point 1)
 
 0.89 (0.16, 5.06) 0.72 (0.32, 1.58) 0.95 (0.61, 1.50) 
a
 Base class in multinomial logistic regression was most SDoH adversities; 
b
 Further adjustment for this imbalanced 
covariate resulted in no changes in the regression estimates presented in Table 3.  
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5. Chapter 5: A Latent Class Analysis of the Social Determinants of Health 
Impacting Heavy Alcohol Consumption among Women Living with HIV 
in Canada: The Canadian HIV Women’s Sexual and Reproductive 
Health Cohort Study
1
 
 
5.1. Introduction  
Heavy alcohol consumption is prevalent among individuals living with HIV, including women.
1-
3
 For example, a study conducted in the United States (US) over an 11-year follow-up period 
found that almost half of women living with HIV (WLWH) reported any past-year alcohol 
consumption, with 14% to 24% reporting heavy/hazardous drinking,
1
 defined as ≥ 4 drinks per 
occasion or > 7 drinks/week.
4
 Research in Canada has documented that 20% (i.e., 15.4% less 
than once a week and 4.6% weekly) of WLWH reported any past-month binge drinking, defined 
as ≥ 4 drinks per occasion,5 compared to 34.5% (i.e., 30.6% less once a week and 3.9% weekly) 
from general population women of similar ages/ethnoracial backgrounds.
3
 
While less frequent in WLWH than the general population,
3
 heavy alcohol use has been 
shown to be negatively associated with outcomes along the HIV treatment cascade. For example, 
Monroe et al. in a US longitudinal study found that heavy drinkers and frequent binge drinkers 
were respectively associated with inferior retention in HIV care and lower visit adherence.
6
 
Research on WLWH has also documented the impact of heavy drinking and poor HIV outcomes; 
for example, Barai et al. in a secondary analysis of data collected in a US randomized control 
                                                          
1
 A version of this chapter has been published: Shokoohi M, Bauer GR, Kaida A, et al. A Latent Class Analysis of 
the Social Determinants of Health Impacting Heavy Alcohol Consumption among Women Living with HIV in 
Canada: The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study. AIDS and Behavior. 2019; 
doi: 10.1007/s10461-019-02454-3. 
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trial found heavy drinking as a barrier to achieving viral suppression,
7
 appearing through 
alteration of virus infectivity, immune response, tissue injury and inflammatory markers.
8-10
 In 
addition, heavy drinking accounts for considerable mortality among WLWH; e.g., Neblett et al. 
in a US longitudinal cohort of WLWH found that heavy drinking independently increased the 
risk of earlier death by 40% (aHR = 1.40).
11
 Indeed, a better recognition of heavy drinking has 
implications for HIV care and treatment. Further, the identification of such prevalent but 
modifiable risk-taking practices is essential to improve the health and wellbeing of WLWH, who 
now represent almost one-quarter of all new HIV diagnoses in Canada.
12
 
While extant research has shown the association of increased heavy drinking with 
sociodemographic factors (e.g., age and race/ethnicity) as well as psychological, and treatment or 
clinical factors (e.g., viral load and CD4 indictors),
1,11,13-16
 less has been explored through a 
social determinants of health (SDoH) framework. SDoH are living conditions in which people 
are born, live, work, and age,
17
 and represent structural causes of health problems.
17,18 SDoH are 
particularly important among WLWH as an array of socio-structural adversities such as low 
income, food insecurity, low social support, stigma and discrimination have been reported.
19,20
 
Approaches informed by an SDoH framework may examine such daily living stressors that 
contribute to WLWH’s likelihood of initiating or continuing heavy/hazardous drinking as a 
coping behaviour. This framework underscores the complex dynamic of social, economic and 
structural factors that have the potential to cluster together; a key feature of these determinants 
that has been methodologically less taken into account. 
In the present study, we explored the association between SDoH and heavy alcohol use 
among WLWH in Canada. As SDoH tend to co-occur in particular combinations,
20
 we examined 
the concomitant patterns of these determinants using latent class analysis (LCA). We then 
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explored the association of the clustered SDoH with heavy drinking. This research is informed 
by an SDoH framework contending that upstream socio-structural determinants share or 
influence individuals’ health,17 as well as a syndemics framework referring to disease-social 
condition interactions that synergistically influence the health of a population within the context 
of persistent social inequalities.
21
 Understanding the unique (distinct) clusters of social 
determinants through which heavy drinking may be impacted and/or intervened on can help 
address alcohol use among WLWH.  
5.2. Methods  
5.2.1 Study sample 
We used data from the community-based Canadian HIV Women’s Sexual and Reproductive 
Health Cohort Study (CHIWOS). As previously described,
22,23
 CHIWOS enrolled WLWH aged 
≥16 years, including transgender women, residing in the provinces of British Columbia (BC), 
Ontario, or Quebec. A total sample of 1,422 were interviewed during 2013-2015 (time-point 1), 
and 1,252 after ~18-months (2016-17, time-point 2). Participants who had died or did not 
participate in time-point 2 were considered as censored (i.e., lost to follow-up; N = 170; 11.9%). 
Participants were recruited from HIV clinics, community-based organizations, peers, and online 
networks. The survey was administered via trained peer research associates (PRAs) through 
face-to-face interviews at clinics, community sites, participants’ homes, or via phone/Skype.23 
CHIWOS was approved by the Research Ethics Boards of Simon Fraser University, University 
of British Columbia/Providence Health, Women’s College Hospital and McGill University 
Health Centre. 
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5.2.2 Alcohol use measures  
Alcohol use measures at time-point 2 were considered as the study outcomes when investigating 
its association with SDoH measured at time-point 1. A standard drink was defined as having a 
341 ml (12 oz.) bottle of 5% alcohol beer, cider or cooler, or a 142 ml (5 oz.) glass of 12% 
alcohol wine, or a 43 ml (1.5 oz.) (single shot) serving of liquor or spirits. Two measures of 
alcohol consumption were defined according to the definitions from the available 
recommendation:
4,5
 
Weekly alcohol use: The average quantity of drinks per week was computed by multiplying 
last-year frequency of alcohol use (with five response options: never, monthly or less, 2-4 times 
a month, 2-3 times a week, 4 or more times a week) by quantity of alcohol consumed on a 
typical drinking day (with five response categories: 1-2, 3-4, 5-6, 7-9, 10 or more). We used the 
midpoint for response options. We then created a three-category measure: nondrinking or low 
drinking (< 1 drink/week), moderate drinking (1-7 drinks/week), and heavy drinking (> 7 
drinks/week).  
Binge drinking: Past-month heavy binge drinking (i.e., ≥ 6 drinks on one single occasion) 
at least once/month was measured and categorized into three categories: non-drinking or non-
binge drinking, infrequent binge drinking (< 1/month), or frequent binge drinking (≥ 1/month). 
The typical threshold for binge drinking among women is 4 or more drinks;
5
 however, having a 
more conservative measure of two more drinks over the typical binge drinking threshold has 
been found to be of value in capturing adequately the nature of problem drinking practice in 
other studies.
24
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5.2.3 SDoH indicators 
The following 12 potentially modifiable current or recent SDoH indicators measured at time-
point 1 were examined: race discrimination, gender discrimination, enacted HIV stigma, social 
support, barriers to access to care, food security, housing status, employment status, education, 
income level, recent sex work involvement, and recent incarceration. In this study, we only 
included the current/recent SDoH indicators to avoid the potential for spurious correlation and 
biased estimation known as collider stratification bias.
25
 Such bias can be introduced in studies 
of selected populations (here, WLWH) if they investigate earlier exposures (here earlier social 
determinants such as childhood events) that may have affected study inclusion/exclusion criteria 
(here HIV status).  
We separately measured racial discrimination and gender discrimination, defined as any 
discriminatory mistreatments due to race and gender, using the 8-item Everyday Discrimination 
Scale.
26
 Consistent with its operationalized definition,
27
 WLWH who reported (sometimes, 
frequently, or almost everyday) having discriminatory experiences due to their race and gender 
were considered as having experienced race discrimination and gender discrimination, 
respectively. Three items of Wright's shortened version of Berger's HIV Stigma Scale were used 
to measure enacted HIV stigma (i.e., been hurt by people’s reaction, stopped socializing, or lost 
friends), indicating the extent to which participants faced mistreatment due to their HIV status.
28
 
Participants who reported any HIV-related discriminatory events with strongly agree/agree 
response options were considered as having experienced HIV-related stigma. A 4-item Medical 
Outcome Study: Social Support Survey
29
 was used to gauge perceived social support, measuring 
emotional-informational, tangible, affectionate, and positive social interaction supports. The 
overall possible mean score ranged from 1-5, with scores > 2 indicating poor social support 
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availability.
30
 Barriers to Access to Care was measured using a 12-item scale.
31
 Overall possible 
mean severity scores ranged from 1-4, with scores ≥ 2 indicating severe/significant barriers.32 
Food insecurity over the past 12 months was assessed using three items: fears of running out of 
food; experiences of running out of food; and unaffordability of balanced meals. The sum of 
these items yielded an overall score ranged 1-6, with scores > 1 indicating food insecure.
33
 Other 
SDoH indicators included yearly household income level (less than $20,000 vs. $20,000 or 
more), current employment status (unemployed [e.g., no income or income from non-
employment sources such as employment insurance/compensation/welfare, dividends and 
interest, or pension plan] vs. employed [i.e., having any paid jobs]), current education level 
(below high school vs. completed high school), current housing status (unstable [e.g., residing in 
a self-contained room, transition house, halfway house, safe house, or outdoors] vs. stable 
housing), any sex work involvement in the last six months (Yes, No), and any history of 
incarceration in the last year (Yes, No). 
5.2.4 Covariates 
Covariates with potential association with either both SDoH classes and alcohol consumption 
measures or only alcohol consumption measures were considered, including: age (continuous; 
with its linear and quadratic forms in the model); ethnoracial groups (white, 
African/Caribbean/Black, Indigenous, other); city size (large, others); study province (Ontario, 
BC, Quebec); sexual orientation (heterosexual, LGBQ); relationship status (single (non-married), 
married/common-law, others); years living with HIV (<6 years, 6-14 years, > 14 years); 
antiretroviral therapy status (optimal [≥ 95% treatment adherence], suboptimal [< 95% treatment 
adherence], not engaged in treatment); ever being diagnosed with a mental health condition by a 
care provider (Yes, No); resilience measured using the 10-item version of the Resilience Scale,
34
 
160 
 
ranging 10-70, with higher scores implying increased resilience, dichotomized at its median; any 
history of childhood sexual/physical violence (Yes, No); any experience of adulthood 
sexual/physical/verbal/action-limited violence (Yes, No); having been under the care of Child 
Protection Services or in foster care (Yes, No); last-year cigarette smoking history (never/former, 
occasional/regular); last-month non-prescribed cannabis use (never/former, occasional/regular), 
last three months any non-prescribed/illicit opioid and/or stimulant use (Yes, No), ever used 
alcohol counseling services (Yes, No). 
5.2.5 Latent class analysis (LCA)  
We conducted LCA to identify the clusters of SDoH assessed at time-point 1. LCA as a data 
reduction strategy is a probabilistic model-based clustering technique to detect unobserved but 
homogenous patterns of the observed indicators within an unobserved categorical measure. LCA 
identifies such latent variable under the assumption that all observed indicators are independent 
given the latent variable (i.e., the latent variable is the reason that observed indicators are 
correlated).
35
 The expectation–maximization (EM) algorithm with 5,000 iterations was used to 
find the best model fit.
36
 We started LCA with a 2-class model and progressively increased (S 
Table 5.1), for each the log-likelihood was replicated with 1,000 random starting values to 
increase the confidence that the best identified model solution is the true maximum likelihood 
solution. Therefore, we reported the percentage of seeds associated with best fitting model, with 
higher values indicating being unlikely to hit the local maxima. While we predominantly relied 
on the interpretability of class memberships, the following fit statistics were also reported to help 
obtain the best model: log-likelihood, Akaike’s information criteria (AIC), Bayesian information 
criteria (BIC), and sample-size-adjusted BIC (aBIC), and consistent AIC (CAIC),
37-39
 with their 
lower values implying better goodness-of-fit and parsimony. Entropy as a measure of 
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classification accuracy was also reported (varied from 0 to 1), with higher values suggesting 
clearer separation/distinction among the latent classes.
35
 
As shown in (S Table 5.1), we proposed the 4-class model as the best fitting model of the 
SDoH classes among WLWH. The observed prevalence of each item as well as item-response 
probabilities (Yes category only) condition on class membership of the 4-class model are 
illustrated in Supplementary Figure 1. These four classes included: WLWH who experienced 
none or only one SDoH adversity (class 1, labeled as none/least SDoH adversities; 6.6%); 
WLWH who predominantly reported experiencing racial discrimination, gender discrimination 
and HIV-related stigma, accompanied by experiencing barriers in access to care without 
economic hardship experiences (class 2, labeled as discrimination/stigma group; 17.9%); 
WLWH who mainly reported food insecurity, low household income, and unemployment 
without stigma/discrimination (class 3, labeled as economic hardship group; 31.6%); and 
WLWH who experienced gender and racial discrimination, HIV-related stigma, low social 
support, greater difficulties access to care, food insecurity, low income, and unemployment 
(class 4, labeled as most SDoH adversities; 43.9%). After identification of the fitting model, each 
participant was assigned to the SDoH latent classes in which they had the greater posterior 
probability. LCA accounted for missing values using the full information maximum likelihood 
estimation under the assumption of missing at random. We conduced LCA using the SAS PROC 
LCA procedure.
35
 
5.2.6 Models and estimations  
Inverse probability weights (IPW) was used to account for confounding bias due to the 
potentially imbalanced covariates across the SDoH classes. We also used inverse probability 
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censoring weights (IPCW) to account for prospective selection bias due to potentially non-
random loss to follow-up (S Table 5.2).  
Covariate selection: Consistent with recommendations,
40
 measured covariates that were 
potentially associated with the study outcomes were considered. To account for confounding by 
outcome history, we also included alcohol use measures at time-point 1.
41
 Missing values of 
covariates considered for generating the weights were singly imputed under the assumption of 
missing at random to reduce the loss of statistical power.
42
 
Control of confounding using IPW: We generated stabilized weights using multinomial 
logistic regression models: the numerator was computed as the marginal probability of the SDoH 
classes (accounting for imbalanced proportions of the SDoH classes) divided by the denominator 
which was computed as the probability that a participant assigned to a SDoH class conditioning 
on the measured covariates. These models were performed among WLWH without censored 
information in time-point 2.  
Control of selection bias using IPCW: We first created a binary measure indicating 
censored individuals at time-point 2. Then, IPCW using binary logistic regression model was 
obtained: the numerator was defined as the probability of not being censored given SDoH 
classes, and the denominator was calculated as the probability of not being censored given SDoH 
and the study covariates.
43
 
Final stabilized weight: We created the final stabilized weight using the product of IPW 
and IPCW. The distribution of the weights across the SDoH classes is presented in (S Table 5.3). 
Under the following assumptions: correct specification of IPW models, conditional 
exchangeability, and positivity,
44
 the final weight removes the association between SDoH 
classes, as the main independent variable, and the study covariates
43
 (S Table 5.4). 
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Association of SDoH classes with alcohol use measures: The association between SDoH 
classes and alcohol use measures was examined using multinomial logistic regression models as 
the alcohol use outcomes had more than two categories. We then estimated crude and weighted 
relative-risk ratios (RRR) and 95% confidence intervals (CI). Further adjustment was made for 
history of the study outcomes. Additionally, a sensitivity analysis was conducted to evaluate the 
extent to which unmeasured confounding would explain away the observed associations. To do 
this, we computed the E-values as: E = RRR + sqrt{RRR
 
× RRR
 – 1}, where RRR referred to the 
significant observed estimates. We replaced RRR with RRR
*
 = 1/RRR for those estimates less 
than the null (RRR = 1).
45
 E-value for RRR provides values below, equal to or above the null, 
representing the minimum strength of the association between unmeasured confounders with 
SDoH clusters and/or alcohol use to nullify the observed associations. These analyses were done 
using Stata 15. 
5.3. Results 
5.3.1 Participants’ characteristics  
Characteristics of study participants enrolled in time-point 1 can be seen in Table 5.1. The mean 
age was 42.8 [SD 10.6] years old. The largest category identified as white (41.1%), while 29.4% 
identified as African/Caribbean/Black, 22.3% as Indigenous, and 7.2% as other. The majority 
reported their sexual orientation as heterosexual (87.3%). About one-third (32%) reported being 
in a relationship, married, or common-law; 40.2% reported living with HIV for 6-14 years; and 
70.0% reported optimal HIV treatment adherence. Childhood and adulthood violence were 
reported by 62.7% and 80.4%, respectively. Ever having a mental health diagnosis was reported 
by 40.7%. The distribution of these covariates across the SDoH classes is also presented in 
Table 5.1.  
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Table 5.1: Characteristics of Women Living with HIV Overall and Stratified by Social Determinants of Health (SDoH) 
Classes, CHIWOS Survey – Time-point 1  
 
 
Variables at time-point 1 
Overall SDoH classes at time-point 1 
None/least 
adversities 
Discrimination/ 
stigma 
Economic 
hardship 
Most 
adversities 
P-value
b
 
N  1,422 (100) 94 (6.6) 256 (18.0) 430 (30.2) 642 (45.2) ---  
Age, yr (mean [SD]) 42.8 [10.6] 39.2 [10.3]  43.5 [10.6] 42.9 [11.5] 43.1 [10.0] 0.007 
Ethno-racial identity       <0.001 
White 584 (41.1)
a
 58 (61.7) 97 (37.9) 219 (50.9) 210 (32.7)  
African/Caribbean/Black 418 (29.4) 23 (24.5) 109 (42.6) 123 (28.6) 163 (25.4)  
Indigenous 318 (22.3) 7 (7.4) 29 (11.3) 60 (14.0) 222 (34.6)  
Other 102 (7.2) 6 (6.4) 21 (8.2) 28 (6.5) 47 (7.3)  
Province      <0.001 
Ontario  717 (50.4) 50 (53.2) 131 (51.2) 235 (54.6) 301 (46.9)  
British Columbia  356 (25.0) 13 (13.8) 49 (19.1) 65 (15.1) 229 (35.7)  
Quebec   349 (24.6) 31 (33.0) 76 (29.7) 130 (30.2) 112 (17.5)  
Living in large cities 1169 (82.2) 83 (88.3) 203 (79.3) 345 (80.2) 538 (83.8) 0.106 
Being heterosexual 1237 (87.3) 85 (90.4) 237 (93.3) 395  (91.9) 520 (81.4) <0.001 
Relationship status      <0.001 
Single (non-married) 689 (48.5) 40 (42.6) 100 (39.1) 201 (46.7) 348 (54.4)  
Married/common-law  454 (32.0) 44 (46.8) 103 (40.2) 134 (31.1) 173 (27.0)  
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Others  277 (19.5) 10 (10.6) 53 (20.7) 95 (22.1) 119 (18.6)  
Years living with HIV       0.001 
< 6 years 345 (25.1) 23 (25.0) 40 (15.7) 128 (31.4) 154 (24.8)  
6-14 years  552 (40.2) 35 (38.0) 118 (46.7) 140 (34.3) 259 (41.8)  
> 14 years  477 (34.7) 34 (37.0) 96 (37.8) 140 (34.3) 207 (33.4)  
Taking treatment      0.001 
Yes, optimal adherence (≥ 95%) 863 (70.0) 65 (69.9) 163 (64.7) 279 (65.0) 356 (55.5)  
Yes, suboptimal adherence (< 95%) 312 (22.0) 12 (12.9) 52 (21.4) 74 (17.2) 172 (26.8)  
Not engaged in treatment  240 (17.0) 16 (17.2) 35 (13.9) 76 (17.7) 113 (17.6)  
Mental health diagnosis 573 (40.7) 26 (28.0) 93 (36.6) 134 (31.6) 320 (50.3) <0.001 
Low resiliency (below median)
c
 662 (47.1) 22 (23.66) 104 (40.9) 172 (40.6) 364 (57.4) <0.001 
Childhood violence 819 (62.7) 34 (38.6) 138 (56.8) 211 (53.8) 436 (74.7) <0.001 
Adulthood violence 1057 (80.4) 52 (59.1) 189 (77.5) 284 (71.9) 532 (90.5) <0.001 
Child development events 326 (23.0) 10 (10.6) 33 (13.0) 74 (17.3) 209 (32.7) <0.001 
Cigarette smoking 
(regular/occasional) 
616 (43.7) 15 (16.1) 65 (25.5) 176 (41.1) 360 (56.7) <0.001 
Non-prescribed cannabis use 
(regular/occasional) 
264 (18.9) 7 (7.7) 34 (13.4) 75 (17.7) 148 (23.6) <0.001 
Drug use
d
  244 (17.5) 2 (2.2) 11 (4.3) 50 (11.9) 181 (28.8) <0.001 
Received alcohol counseling  3 (3.2) 24 (9.4) 60 (14) 201 (31.3) 3 (3.2) <0.001 
Weekly alcohol use       0.132 
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Abstainers to low (<1 drink) 956 (69.1) 64 (68.8) 174 (68.5) 302 (71.1) 419 (68.1)  
Moderate (1 to 7 drinks) 288 (20.8) 22 (23.7) 60 (23.6) 88 (20.7) 118 (19.2)  
Heavy (>7 drinks) 140 (10.1) 7 (7.5) 20 (7.9) 35 (8.2) 78 (12.7)  
Binge drinking       0.037 
Non-drinkers/no binge drinking  1107 (81.9) 73 (79.4) 214 (85.3) 348 (85.5) 472 (78.5)  
Infrequent (< 1 per month) 14 (1.0) 1 (1.1) 4 (1.6) 1 (0.3) 8 (1.3)  
Frequent (≥ 1 per month) 230 (17.0) 18 (19.6) 33 (13.2) 58 (14.3) 121 (20.1)  
a 
Data are presented as N (%) unless specified; 
b
 P-values are for the chi-square test for categorical covariates and one-way ANOVA for continuous covariates; 
c
 
Scores ranged 10-70, with higher scores indicating increased resilience (median = 64); 
d
 Last three months any non-prescribed/illicit opioid and/or stimulant use 
measured.  
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5.3.2 Weekly alcohol use  
Overall, moderate (1-7 drinks/week) and heavy (>7 drinks/week) alcohol use at time-point 2 
were reported by 20.1% and 10.5%, respectively. Heavy alcohol use at time-point 2 was reported 
by 6.8% among WLWH in no/least SDoH adversities, 10.2% among WLWH in 
discrimination/stigma class, 8.8% among economic hardship class, and 12.6% among WLWH in 
the most SDoH adversities class (Table 5.2). 
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Table 5.2: Alcohol Consumption Measures (Study Outcomes) Overall and Across the Social Determinants of Health (SDoH) 
Classes among Women Living with HIV, CHIWOS Survey 
 
 
Alcohol use measures at time-
point 2 
Overall  SDoH classes at time point 1 
None/least 
adversities 
Discrimination/ 
stigma 
Economic 
hardship 
Most 
adversities 
P-value  
N  1237 88 231 378 540 --- 
Weekly alcohol use
*      0.006 
Abstainers to low (<1 drink)
 
858 (69.4) 55 (62.5) 156 (67.5) 282 (74.6) 365 (67.6)  
Moderate (1 to 7 drinks) 249 (20.1) 27 (30.7) 54 (23.4) 65 (17.2) 103 (19.1)  
Heavy (>7 drinks) 130 (10.5) 6 (6.8) 21 (9.1) 31 (8.2) 72 (13.3)  
Binge drinking
b,*
      0.001 
Non-drinkers/no binge drinking  952 (77.5) 70 (79.6) 183 (79.2) 309 (82.4) 390 (72.9)  
Infrequent (< 1 per month) 155 (12.6) 15 (17.1) 33 (14.3) 32 (8.5) 75 (14)  
Frequent (≥ 1 per month) 122 (9.9) 3 (3.4) 15 (6.5) 34 (9.1) 70 (13.1)  
a
 Data are presented as N (%); 
b
 Heavy binge drinking at time-point 2 was defined as having 6 or more drinks in one single occasion; * P-value < 0.05, indicating 
that the distribution of both alcohol consumption measures is significantly different across the SDoH classes.  
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Our results showed no crude associations between SDoH classes and heavy weekly alcohol 
consumption. However, the weighted regression analysis demonstrated that WLWH in no/least 
SDoH adversities had lower likelihood of weekly heavy alcohol use than WLWH in 
discrimination/stigma class (RRR = 0.10; 95% CI: 0.02, 0.68), economic hardship class (RRR = 
0.18; 95% CI: 0.03, 1.04; not significant), and most SDoH adversities class (RRR = 0.11; 0.02, 
0.62). While crude associations showed an increased likelihood of moderate weekly alcohol 
consumption among WLWH in the no/least SDoH adversity in comparison with other three 
classes, no significant association was observed in the weighted analyses (Table 5.3). 
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Table 5.3: The Association of Social Determinants of Health (SDoH) Classes on Weekly Alcohol Use using Inverse-Probability 
Weighting Analysis among Women Living with HIV in Canada, CHIWOS Survey 
 
 
 
SDoH classes at time-point 1 
Moderate use (1-7 drinks per week)
a
 Heavy use (> 7 drinks per week)
a
 
Crude estimates 
RRR (95% CI)
b
 
IPW estimates 
RRR (95% CI) 
Crude estimates 
RRR (95% CI) 
IPW estimates 
RRR (95% CI) 
Economic hardship vs. most adversities 0.82 (0.58 ,1.16) 0.66 (0.43, 1.01) 0.56 (0.36 ,0.87) 0.61 (0.32, 1.13) 
 P-value  0.253 0.060 0.011 0.120 
Discrimination/stigma vs. most adversities 1.23 (0.84 ,1.79) 1.04 (0.59, 1.84) 0.68 (0.41 ,1.15) 1.09 (0.39. 3.03) 
 P-value 0.291 0.866 0.151 0.863 
No/least adversities vs. most adversities 1.74 (1.04 ,2.9) 0.39 (0.09, 1.62) 0.55 (0.23 ,1.33) 0.11 (0.02, 0.62) 
 P-value 0.033 0.200 0.187 0.013 
Discrimination/stigma vs. economic hardship 1.50 (1.00 ,2.26) 1.56 (0.87, 2.83) 1.22 (0.68 ,2.20) 1.79 (0.64, 4.95) 
 P-value 0.052 0.135 0.499 0.262 
No/least adversities vs. economic hardship 2.13 (1.25 ,3.63) 0.59 (0.14, 2.45) 0.99 (0.40 ,2.49) 0.18 (0.03, 1.04) 
 P-value 0.005 0.473 0.987 0.056 
No/least adversities vs. discrimination/stigma 1.42 (0.81 ,2.47) 0.38 (0.08, 1.64) 0.81 (0.31 ,2.11) 0.10 (0.02, 0.68) 
 P-value 0.217 0.196 0.667 0.019 
a
 Base Group in Multinomial Logistic Regression: Abstainers to Low [<1 drink/week]); 
b
 RRR: relative-risk ratio (95% confidence intervals: CI); 
c
 Italicized 
estimates indicate having a p-value less than 0.10; 
d
 Bold estimates indicate having a p-value less than 0.05.  
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5.3.3 Binge drinking  
Overall, infrequent (<1/month) and frequent (≥1/month) binge drinking at time-point 2 were 
reported by 12.6% and 9.9%, respectively. Frequent binge drinking was reported by 3.4% among 
WLWH in no/least SDoH adversities, 7.2% among WLWH in discrimination/stigma class, 9.6% 
among economic hardship class, and 12.3% among WLWH in the most SDoH adversities class 
(Table 5.2). WLWH in no/least SDoH adversities class were shown to have a lower likelihood 
of frequent binge drinking than WLWH in discrimination/stigma class (RRR 0.02; 95% CI: 
0.002, 0.21), economic hardship class (RRR = 0.03; 95% CI: 0.01, 0.24), and most SDoH 
adversities class (RRR = 0.02; 95% CI: 0.002, 0.13). Furthermore, the likelihood of infrequent 
binge drinking was lower among WLWH in no/least SDoH adversities class than those in 
discrimination/stigma and the most SDoH adversities classes (Table 5.4).  
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Table 5.4: The Association of the Classes of Social Determinants of Health (SDoH) on Binge Drinking using Inverse-
Probability Weighting Analysis among Women Living with HIV in Canada, CHIWOS Survey  
 
 
SDoH classes at time-point 1 
Binge drinking < 1 per month
a
 Binge drinking ≥ 1 per montha 
Crude estimates 
RRR (95% CI)
b
 
IPW estimates 
RRR (95% CI) 
Crude estimates 
RRR (95% CI) 
IPW estimates 
RRR (95% CI) 
Economic hardship vs. most adversities 0.53 (0.34, 0.83) 0.75 (0.35, 1.59) 0.61 (0.39, 0.94) 0.56 (0.29, 1.10) 
 P-value 0.006 0.456 0.028 0.097 
Discrimination/stigma vs. most adversities 0.93 (0.60, 1.46) 1.57 (0.76, 3.22) 0.45 (0.25, 0.82) 0.70 (0.28, 1.70) 
 P-value 0.777 0.217 0.009 0.432 
No/least adversities vs. most adversities 1.11 (0.60, 2.05) 0.20 (0.04, 0.99) 0.23 (0.07, 0.77) 0.02 (0.002, 0.13) 
 P-value 0.728 0.050 0.018 < 0.001 
Discrimination/stigma vs. economic hardship 1.74 (1.03, 2.92) 2.09 (0.81, 5.39) 0.74 (0.39, 1.40) 1.23 (0.46, 3.26) 
 P-value 0.036 0.126 0.363 0.671 
No/least adversities vs. economic hardship 2.06 (1.06, 4.02) 0.26 (0.04, 1.44) 0.38 (0.11, 1.30) 0.03 (0.01, 0.24) 
 P-value 0.032 0.127 0.126 0.001 
No/least adversities vs. discrimination/stigma 1.18 (0.60, 2.32) 0.12 (0.02, 0.69) 0.52 (0.14, 1.86) 0.02 (0.002, 0.21) 
 P-value 0.614 0.017 0.317 0.001 
a
 Base Group in Multinomial Logistic Regression: Non-Drinkers/No Binge Drinking; 
b
 RRR: relative-risk ratio (95% confidence intervals: CI); 
c
 Italicized 
estimates indicate having a p-value less than 0.10; 
d
 Bold estimates indicate having a p-value less than <0.05. 
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5.3.4 Sensitivity analysis 
The sensitivity analysis reflected that our observed associations were relatively robust to 
potential unmeasured confounding. For example, for the observed RRR: 0.11 for heavy weekly 
alcohol consumption among WLWH in the no/least SDoH adversities class versus the most 
SDoH adversities class, an unmeasured confounder correlated with both exposure and outcome 
by RRRs of ~17.6-fold each, above and beyond the measured confounders, would explain away 
the observed association, but weaker confounding would not. Such an E-value for the upper 95% 
limit of the same comparison (Upper CI = 0.62) was 2.6-fold. The E-values for the significant 
observed associations were reported in (S Table 5.5). 
5.4. Discussion  
We explored the pattern of alcohol consumption measures and their association with four SDoH 
classes in a diverse cohort of WLWH in Canada. We found that 10.5% of WLWH reported 
heavy weekly alcohol use at enrollment and 9.9% reported frequent binge drinking at ~18 
months follow up, with greater proportion among WLWH who experienced multiple forms of 
SDoH adversities than those with no/least SDoH adversity. We also documented that WLWH 
with no/least SDoH adversity were less likely to report heavy alcohol consumption relative to 
WLWH experiencing either discrimination/stigma or economic hardship or suffering from the 
most SDoH adversities. These findings can inform intervention strategies to advance health 
among WLWH. 
Our research contributes to the literature in several ways. Firstly, we found that a large 
proportion of WLWH reported experiencing specific forms of socio-structural adversities 
including economic hardship and stigma/discrimination, or multiple types of disadvantages. 
Secondly, this study adds to the current understanding of how social determinants clustered 
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together and such clustering increased the likelihood of heavy drinking among WLWH. Thirdly, 
we documented that the risk of alcohol use did not change much (vs. no/least SDoH class) 
whether a women reported experiencing primarily stigma/discrimination, primarily economic 
hardship, or the most SDoH adversities. These findings may indicate that in addressing heavy 
drinking, it is important to consider the role that any form of SDoH inequities play in shaping 
such risk-taking practice. This is particularly important as heavy drinking has been shown to be a 
significant predictor of mortality among WLWH of the same cohort in Canada.
22
 Overall, our 
findings suggest that WLWH continue to experience a high level of stress as a result of social 
and structural inequalities, contributing to elevated risk of alcohol consumption.
46,47
 
While it is difficult for us to compare our findings directly with prior research, these 
findings are in line with the extant literature, implying that a greater level of social adversity is 
associated with increased likelihood of heavy drinking among WLWH.
1,13,14
 Previous studies 
have mostly reported the independent impact of individual social factors (either modifiable or 
non-modifiable ones) on alcohol use. For example, Cook et al. in a longitudinal study identified 
unemployment and low education as the independent predictors of heavy alcohol consumption 
among WLWH.
1
 They also found the independent effect of low education (but not employment 
or race/ethnicity) on higher odds of heavy drinking in a trajectory analysis.
13
 In 2018, Kelso-
Chichetto et al. found an association between alcohol consumption trajectories and 
race/ethnicity, but not with annual income levels among WLWH.
14
 Concentrating on modifiable 
social factors, we found a significant association of the clustered SDoH on heavy drinking 
among WLWH. While our estimates relied on a set of SDoH indicators gathered on only one 
time-period, future research could conduct a trajectory analysis to assess the stability of these 
social determinants over time in association with behavioural and HIV treatment outcomes.  
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Our study had some limitations. First, CHIWOS used a purposive, nonrandom sampling 
approach that may have oversampled WLWH receiving care, who may have different 
characteristics such as sociodemographic or socio-structural vulnerabilities than other WLWH. 
In turn, CHIWOS also oversampled WLWH experiencing intersecting forms of marginalization 
such as sex work and substance use to mitigate sampling bias.
22
 Second, data on both alcohol use 
and social determinants were gathered via self-report, and are subject to social desirability and 
recall biases (particularly the past-year frequency and quantity of alcohol use). However, the 
survey was administered by PRAs who are also WLWH,
22
 to build trust with participants in 
sharing their information.
23
  
Despite these limitations, this study has several notable strengths. We included a large 
sample of WLWH with diverse ethno-racial identities and social-economic experiences, which 
may provide a better picture of the target population beyond only those in clinical settings. 
Second, this research enhances understanding of the clustered SDoH and their association with 
heavy alcohol use. Third, a large proportion of the study sample remained in the follow-up 
survey, allowing for assessment of study outcomes which makes temporality between SDoH 
classes and alcohol use measures clear. Fourth, use of LCA including 12 SDoH indicators 
allowed for data reduction and a clearer presentation of the impact of the clustered SDoH on the 
study outcomes. This underscores the interdependent nature of the SDoH beyond their 
independent impacts.  
5.4.1 Conclusion 
Approximately one out of ten WLWH from the CHIWOS cohort met criteria for heavy drinking 
and frequent binge drinking, with higher likelihood among those experiencing overlapping forms 
of SDoH adversities. Our findings suggest that multiple forms of SDoH adversities – regardless 
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of their types – can substantially impact the initiation/continuation of heavy drinking. In the 
current era where viral suppression is achieved and an improved survival is expected among 
individuals who have access to HIV medications and are on treatment and in care,
48,49
 adversities 
regarding socioeconomic and structural determinants as well as behavioural factors (heavy 
drinking) may undermine the efforts of the management of HIV. Effective interventions aiming 
to target WLWH who drink at heavy levels should also consider the substantial contribution of 
socio-structural barriers that WLWH inequitably experience in their daily life. While integration 
of harm reduction approach into HIV care through the women-centered care model may be 
considered as an approach in addressing heavy drinking and social barriers,
50
 more evidence-
based research is needed to determine the effectiveness of such interventions. Our findings 
highlight the urgency to address SDoH for interventions to be fully beneficial for WLWH who 
involve in heavy drinking.  
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5.5. Supplementary Tables and Figures  
S Table 5.1: Comparison of Goodness-of-fit Measures for Different Class Models (N=1,422) 
Model  LL
a 
AIC
b
 BIC
c
 CAIC
d
 Entropy % seeds
e
 
1-class  -12363.0 10080.9 10207.2 10231.2 1.000 100% 
2-class  -8582.2 2569.1 2826.9 2875.9 1.000 100% 
3-class  -8271.3 1997.4 2386.7 2460.7 0.843 98.4% 
4-class
f
 -8030.0 1564.9 2085.6 2184.6 0.831 93.5% 
5-class  -7966.5 1487.8 2140.0 2264.0 0.819 35.0% 
6-class  -7922.1 1449.0 2232.7 2381.7 0.814 15.0% 
7-class  -7889.8 1434.5 2349.7 2523.7 0.745 32.4% 
a
 Log-Likelihood (LL); 
b
 Akaike information criterion (AIC); 
c
 Bayesian information criterion (BIC); 
d
 Consistent 
AIC (CAIC), 
e 
Percentage of seeds associated with best fitted model (% seeds); 
f
 4-class model had the lowest BIC 
and CAIC. Moving forward to model with more classes, entropy suggested lower classification accuracy (e.g., 
~10% reduction from 4-class to 7-class). In addition, the 4-class model had a higher percentage of seeds associated 
with best fitted model (i.e., increased confidence that the best solution was achieved even though it is not a fit 
criterion). Fit indices/statistics align with model interpretability suggested the 4-class model provided a better fit 
with plausible distribution of the sample within each class. 
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S Table 5.2: Characteristics of Women Living with HIV who were Lost to Follow-up (i.e., 
Censored), CHIWOS, 2013-2017  
 
Variables at time-point 1 
Not Lost to follow up 
(N = 1252) 
Lost to follow up 
(N = 170) 
P-value
b
 
SDoH classes    0.057 
Class 1: No/least SDoH adversities  88 (7.03)
a
 6 (3.53)  
Class 2: Discrimination/Stigma  232 (18.53) 24 (14.12)  
Class 3: Economic adversities   381 (30.43) 49 (28.82)  
Class 4: Most SDoH adversities  551 (44.01) 91 (53.53)  
Age, yr (mean [SD]) 42.9 [10.61] 42.2 [10.34] 0.430 
Ethno-racial group   0.062 
White 515 (41.13) 69 (40.59)  
African/Caribbean/Black 380 (30.35) 38 (22.35)  
Indigenous 272 (21.73) 46 (27.06)  
Other 85 (6.79) 17 (10.00)  
Province   0.018 
Ontario  637 (50.88) 80 (47.06)  
British Columbia  299 (23.88) 57 (33.53)  
Quebec   316 (25.24) 33 (19.41)  
Living in large cities 1029 (82.19) 140 (82.35) 0.958 
Heterosexual 1095 (87.81) 142 (83.53) 0.116 
Relationship status   0.596 
Single (non-married) 612 (48.92) 77 (45.56)  
Married/common-law  394 (31.49) 60 (35.50)  
Others  245 (19.58) 32 (18.93)  
Years living with HIV    0.648 
< 6 years 310 (25.49) 35 (22.15)  
6-14 years  487 (40.05) 65 (41.14)  
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> 14 years  419 (34.46) 58 (36.71)  
Taking treatment   0.012 
Yes, optimal adherence (≥ 95%) 759 (60.91) 104 (61.54)  
Yes, suboptimal adherence (< 95%) 264 (21.19) 48 (28.40)  
Not engaged in treatment  223 (17.90) 17 (10.06)  
Mental health diagnosis 499 (40.21) 74 (44.58) 0.282 
Low resiliency
c
 (below median) 568 (45.81) 94 (56.97) 0.007 
Childhood violence 708 (61.51) 111 (71.15) 0.019 
Adulthood violence 918 (79.07) 139 (90.26) 0.001 
Child development events 269 (21.55) 57 (33.73) <0.001 
Cigarette smoking 
(regular/occasional) 
516 (41.4) 100 (60.2) <0.001 
Non-prescribed cannabis use 
(regular/occasional) 
226 (18.4) 38 (23.0) 0.150 
Drug use
d
  193 (15.7) 51 (30.7) <0.001 
Received alcohol counseling  234 (18.7) 54 (31.8) <0.001 
Weekly alcohol use    0.011 
Abstainers to low (<1 drink) 865 (70.4) 94 (59.1)  
Moderate (1 to 7 drinks) 242 (19.7) 46 (28.9)  
Heavy (>7 drinks) 121 (9.8) 19 (11.9)  
Binge drinking    <0.001 
Non-drinkers/no binge drinking  997 (83.6) 110 (69.2)  
Infrequent (< 1 per month) 12 (1.0) 2 (1.3)  
Frequent (≥ 1 per month) 183 (15.3) 47 (29.6)  
a 
Data are presented as N (%) unless specified; 
b
 P-values are for the chi-square test for categorical covariates and 
one-way ANOVA for continuous covariates; 
c
 Scores ranged 10-70, with higher scores indicating increased 
resilience (median = 64); 
d
 Last three months any non-prescribed/illicit opioid and/or stimulant use measured.  
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S Table 5.3: Distributions of the Estimated Weights for the Classes of the Social 
Determinants of Health (SDoH), Censoring, and both, CHIWOS, Time-point 1, 2013-2015 
 Mean (SD) Percentiles 
5
th
 25
th
 50
th
 75
th
 95
th
 
Stabilized weights for 
SDoH weights  
      
 Class 1
a
 0.97 (2.50) 0.12 0.20 0.43 1.00 2.26 
 Class 2 1.01 (1.04) 0.39 0.51 0.72 0.98 3.19 
 Class 3 0.99 (0.67) 0.48  0.61 0.79 1.11 2.16 
 Class 4 0.99 (0.61) 0.48 0.58 0.80 1.16 2.19 
 Overall  0.99 (0.97) 0.41 0.57 0.78 1.12 2.25 
Stabilized weights for  
censoring weights  
      
 Overall  1.00 (0.08) 0.91 0.94 0.98 1.02 1.15 
Stabilized weights for 
final weights  
      
 Class 1 1.01 (2.90) 0.12 0.21 0.43 0.99 2.17 
 Class 2 1.04 (1.16) 0.38 0.51 0.71 1.03 3.3 
 Class 3 1.00 (0.75) 0.45 0.62 0.78 1.13 2.24 
 Class 4 0.97 (0.55) 0.51 0.61 0.78 1.12 2.01 
 Overall  0.99 (1.06) 0.40 0.58 0.76 1.09 2.17 
a 
Class 1: No/least SDoH adversities; Class 2: Discrimination/Stigma; Class 3: Economic adversities; Class 4: Most 
SDoH adversities  
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S Table 5.4: Inverse-Probability Weighted Estimates of the Parameters of a Marginal 
Structural Model for the Association of the Social Determinants of Health (SDoH) Classes 
on Alcohol Use Measures among Women Living with HIV, CHIWOS, Canada, 2013-2017  
 SDoH classes
a
 
Variables  No/least SDoH 
adversities  
Discrimination/ 
stigma 
Most SDoH 
adversities  
Age, yr (mean) 0.97 (0.93, 1.01)
b
 0.99 (0.97, 1.01) 1 (0.99, 1.02) 
Ethno-racial groups  
(Ref: White) 
   
Indigenous 2.07 (0.45, 9.6) 1.08 (0.58, 2.03) 0.88 (0.56, 1.39) 
African/Caribbean/Black 0.94 (0.43, 2.03) 0.86 (0.56, 1.32) 0.95 (0.66, 1.37) 
Other 0.63 (0.18, 2.21) 1.04 (0.43, 2.53) 0.96 (0.52, 1.78) 
Study province  
(Ref: Ontario) 
   
British Columbia  0.35 (0.1, 1.23) 0.62 (0.36, 1.07) 0.99 (0.65, 1.52) 
Quebec  0.53 (0.19, 1.47) 0.91 (0.54, 1.52) 0.99 (0.69, 1.42) 
Living large size cities 1.79 (0.62, 5.14) 1.18 (0.73, 1.92) 0.97 (0.63, 1.47) 
Heterosexual 0.27 (0.05, 1.55) 1.37 (0.62, 3.02) 1.19 (0.74, 1.89) 
Relationship status  
(Ref: Single) 
   
Married 0.74 (0.23, 2.37) 0.76 (0.48, 1.2) 1.03 (0.71, 1.49) 
Others  0.67 (0.17, 2.62) 0.64 (0.39, 1.04) 1.05 (0.71, 1.58) 
Years living with HIV  
(Ref: < 6 yrs) 
   
6-14 years  2.23 (0.64, 7.72) 0.85 (0.48, 1.51) 0.9 (0.62, 1.32) 
> 14 years  1.76 (0.78, 3.97) 0.81 (0.46, 1.44) 1.01 (0.68, 1.52) 
Taking treatment  
(Ref: Yes, optimal) 
   
Yes, suboptimal 0.45 (0.12, 1.64) 1.28 (0.74, 2.21) 1.05 (0.68, 1.6) 
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Not in treatment  0.6 (0.2, 1.77) 1 (0.53, 1.89) 0.87 (0.57, 1.31) 
Mental health diagnosis 1.62 (0.49, 5.4) 0.82 (0.53, 1.28) 0.96 (0.69, 1.33) 
Low resiliency
c
 (below median) 0.32 (0.11, 0.91) 1.01 (0.66, 1.55) 0.96 (0.7, 1.32) 
Childhood violence 1.15 (0.42, 3.14) 1.08 (0.71, 1.63) 0.97 (0.7, 1.33) 
Adulthood violence 0.73 (0.26, 2.06) 0.99 (0.6, 1.62) 0.91 (0.61, 1.36) 
Childhood development events 0.42 (0.11, 1.57) 1.22 (0.68, 2.17) 0.96 (0.64, 1.45) 
Cigarette smoking 
(regular/occasional) 1.11 (0.29, 4.22) 1.2 (0.77, 1.84) 0.97 (0.71, 1.34) 
Non-prescribed cannabis use 
(regular/occasional) 0.44 (0.12, 1.63) 1.19 (0.66, 2.14) 0.8 (0.54, 1.18) 
Drug use
d
  2.12 (0.32, 13.91) 0.77 (0.34, 1.73) 0.9 (0.57, 1.4) 
Received alcohol counseling  2.16 (0.39, 11.9) 1.53 (0.84, 2.78) 0.79 (0.5, 1.25) 
Heavy alcohol use  
(Ref: Abstainers/low)    
Moderate (1-7 drinks/week) 2.39 (0.53, 10.74) 1.23 (0.71, 2.11) 0.84 (0.56, 1.27) 
Heavy (> 7 drinks/week) 0.3 (0.09, 0.93) 1.66 (0.76, 3.67) 1.09 (0.63, 1.89) 
Binge drinking (Ref: Non-
drinkers/no binge drinking)    
Less than once per month 9.36 (1.18, 74.31) 0.46 (0.17, 1.22) 0.54 (0.23, 1.26) 
At least once per month  0.59 (0.26, 1.34) 1.41 (0.76, 2.63) 0.93 (0.59, 1.46) 
a Base group in multinomial logistic regression was “the most SDoH adversities”; b Data are presented as relative-risk ratio 
(RRR) and 95% confidence intervals (CI); c Scores ranged 10-70, with higher scores indicating increased resilience (median = 
64); d Last three months any non-prescribed/illicit opioid and/or stimulant use measured.  
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S Table 5.5: Sensitivity Analysis of the Magnitude of Potential Unmeasured Confounding 
that Would Totally Explain Away the Observed [Significant] Association from the Inverse 
Probability Weighting Analysis between the Classes of the Social Determinants of Health 
(SDoH) and Alcohol Use Measures  
 
SDoH Clusters 
E-value 
for point 
estimate  
E-value for 
CI close to 
the null  
E-value 
for point 
estimate  
E-value for 
CI close to 
the null  
Moderate weekly alcohol 
use
a
 
Heavy weekly alcohol 
use
a
 
No/least adversities vs. most 
adversities 
---
c
 --- 17.6 2.6 
No/least adversities vs. 
discrimination/stigma 
--- --- 19.5 2.3 
 Infrequent binging  
(< 1/month)
b
 
Frequent binging  
(≥ 1/month)b 
No/least adversities vs. most 
adversities 
9.5 1.1 99.5 14.9 
No/least adversities vs. economic 
hardship 
--- --- 66.1 7.8 
No/least adversities vs. 
discrimination/stigma 
16.1 2.3 99.5 9.0 
a
 Base group: nondrinking or low (< 1 drink per week); 
b
 Base group: Non-drinkers/no binge drinking; 
c
 
The sensitivity analysis was not done for these estimates as the 95% CIs of their observed point estimate 
crossed the null RRR = 1. 
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S Figure 5.1: Prevalence and Item-Response Probabilities (= Yes) for each Social Determinant of Health (SDoH) Obtained 
from Latent Class Analysis with four Classes among Women Living with HIV– CHIWOS (n=1,422) 
 
RD: Racial Discrimination, GD: Gender Discrimination, ST: HIV-related Stigma, SS: Perceived Social Support, BR: Barriers to Access to Care, FI: Food 
Insecurity, LI: Low Household Income, UE: Unemployment, ED: Low Education, HS: Unstable Housing; SW: Recent Sex Work Involvement, IN: Recent 
Incarceration; 
 
Class 1 (6.6%): none/least SDoH adversities (the assigned probability for this class was 0), Class 2 (17.9%): a group who mainly experienced 
discrimination/stigma, Class 3 (31.6%): a group who mainly experienced economic hardship, Class 4 (43.9%): a group of WLWH who experienced most SDoH 
adversities.
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6. Chapter 6: Integrated Discussion 
This last chapter reviews key findings of this research derived from the four peer-reviewed 
published papers (Chapters 2-5), the implications of these findings for the HIV care and 
treatment and health outcomes of women living with HIV, and highlight future research. 
6.1. Summary of key findings 
Drawing on the cross-sectional data from the largest cohort study of women with HIV in Canada 
(CHIWOS, time-point 1, 2013-2015), we found that a high proportion of women with HIV 
reported experiencing social and structural adversities and low quality of life (Chapter 2) as well 
as substance use (Chapter 3). In comparison with Canadian women of similar ages/ethnoracial 
backgrounds (CCHS, 2013-14), a higher proportion of women with HIV reported living with 
poverty (measured by annual personal income) and food insecurity, experienced social exclusion 
(measured by poor perceived social support, and racial and gender discriminations), recorded 
lower quality of life (measured using a single-item self-assessment of overall health status) (all in 
Chapter 2), as well as reported substance use including intensive cigarette smoking, non-
prescribed cannabis use, crack-cocaine, speed ,and heroin use (but not alcohol use) (Chapter 3).  
Analysis of the longitudinal data of women with HIV (CHIWOS, time-point 1 and 2, 2013-
17) also showed that a substantial proportion of women with HIV reported experiencing multiple 
forms of a set of potentially modifiable social determinants of health (SDoH). Latent class 
analysis (LCA) identified four distinct SDoH subgroups, consisting of one small cluster of 
women with HIV who reported no or least SDoH adversities, two unique clusters including 
discrimination/stigma and economic hardship, and one single cluster containing multiple forms 
of social adversities (Chapters 4 and 5). Additional analyses also showed that self-reported 
opioid/stimulant use (Chapter 4) and heavy alcohol drinking (Chapter 5) were significantly less 
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likely to be reported among women living with HIV who reported none/least SDoH than among 
women in other three SDoH clusters, regardless of the type of SDoH adversities. These findings 
suggested the substantial contribution of the clusters of SDoH adversities to illicit drug use and 
heavy drinking among women with HIV. 
6.2. Socio-structural adversities  
As described, women with HIV were found to experience a high prevalence of individual SDoH 
adversities (Chapter 2). They also reported experiencing these adversities in excess of what 
would be expected from the assumed HIV-negative general population of women. While direct 
comparison of these determinants between individuals with HIV, including women, and the 
general population is challenging due to limited comparability of population-based data on the 
indicators of SDoH owing to differences in equity measurements as well as general data quality 
and availability,
1
 the current research documented that women with HIV inequitably experienced 
greater barriers or difficulties in their daily life in excess of what would be expected. These 
findings underscore the importance of the recognition of the social, economic and structural 
barriers accounting for health inequities among women, which not only exacerbate the 
vulnerability of them to an elevated risk of HIV infection,
2
 but also, in turn, among women who 
are living with HIV, have the potential to negatively impact their ability to optimally navigate the 
HIV care and treatment programs.  
These findings suggest that to improve the health and well-being of women with HIV, 
programs should focus on interventions addressing inequalities that women frequently face. To 
do this, the ongoing collection and quality measurement of SDoH indicators across either 
surveillance systems or care and treatment programs is necessary.
1
 Having more comprehensive 
data on all aspects of health indicators, with the addition of SDoH measures, would enable health 
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care providers to identify the burden of SDoH adversities, gain a broader and more complete 
picture of HIV epidemiology, and then address (i.e., through developing structural interventions) 
these underlying causes of HIV and health conditions. The CDC emphasizes that without the 
collection of all relevant SDoH indicators, a large proportion of HIV data is incomplete in the 
context of broader population health, and adds that the increased understanding of SDoH data 
“may lend more credibility to the science of SDH, and prevention efforts will be able to use and 
execute more contextually appropriate initiatives to reduce health disparities and promote health 
equity.”1 Furthermore, identifying such underlying causes is required to be also considered as 
one of the main priorities of the extant HIV programs. In this regard, future research should pay 
additional attention to how such underlying determinants can be better integrated into the current 
priorities of HIV programs.
3
 In addition to the current focus on the provision of better HIV care 
and treatment services, practitioners and public health experts should also strive to ameliorate the 
socio-structural adversities that individually (e.g., stigma alone) or in combination (e.g., stigma 
and discrimination) continue to result in poor health outcomes among affected people. Improved 
data collection on the SDoH indicators may help healthcare providers recognize the leading role 
of these barriers and reduce some of these adversities, such as stigma,
1,4-6
 that these individuals 
may frequently encounter in their life.  
Addressing SDoH inequalities among women is particularly important as women face 
greater vulnerability to discriminatory social, economic, and political processes,
7-9
 resulting in 
greater health inequalities.
1
 Our findings in support of the current evidence suggest that 
experiencing a high degree of SDoH adversities may explain the potential pathways by which 
women with HIV experience inequalities in their health outcomes, and support possible 
interventions to address the gaps in such health inequalities.
10
 In addition to their elevated 
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vulnerability to HIV infection, women experience socioeconomic inequalities that pose 
additional challenges to their HIV care and treatment programs.
11
 It is believed that a better 
understanding of these adversities, for example, stigma, is of paramount public health 
importance and the foundation for the development of programs in addressing these adversities 
and their resultant health inequalities.
11
 Consistent with extant evidence, our findings support 
structural interventions, referring to public health interventions that improve health through 
changing the structural factors – which are aspects of the social, economic, and physical 
environment – within which health or health outcomes are produced and reproduced.12 Frieden 
believes that interventions focusing on socio-structural levels (e.g., socioeconomic factors) tend 
to be more effective as  these interventions cover a broader portion of society and require less 
individual effort, and can help obtain optimal public health benefits.
13
 
The SDoH adversities are largely the result of the unjust distribution of power and 
resources, indicating the important role of policy in addressing these adversities.
5,14,15
 Therefore, 
understanding these leading adversities (i.e., barriers) can help inform healthcare providers 
where women interrupt their HIV care along the cascade.
16
 Our findings also suggest that, in 
addition to approaches to prevent, control and manage HIV on the individual (e.g., behavioural) 
level factors, it is important to seek strategies to address the underlying social and structural 
contributors of health inequalities, such as food insecurity, lack of or low education, HIV stigma, 
and discrimination, which have negative impacts on HIV outcomes.
4
 
A growing body of evidence has shown that the SDoH adversities (e.g., food insecurity,
17
 
under-housing,
18
 gender-related factors,
19
 and stigma
20,21
) have been substantially associated 
with poor HIV outcomes (e.g., low treatment adherence). This may indicate that the SDoH that 
are sensitive indicators of women’s capacity have the potential to impede them prioritizing their 
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health care needs over such survival needs. Therefore, if the goal in the current era of effective 
HIV treatment is to help individuals with HIV achieve optimum cART outcomes,
10,22,23
 
addressing these key social and structural barriers should be considered as one of the main 
priorities of HIV programs. Evidence has supported that reducing the burden of these daily life 
challenges or hardships can also help improve HIV outcomes. For example, Martinez et al. in a 
12-month prospective clinical trial showed that household food assistance and nutrition 
education programs positively improved HIV treatment adherence (defined as on-time 
prescription refills).
24
 With regard to HIV stigma and discrimination, additional research is 
required to better understand other pathways through which these barriers can influence 
subsequent behaviours, health and well-being. Evidence suggests that interventions such as skill 
building through peer coaching, education programs to provide a better understanding of the 
diseases/infection, and connecting them with community resources and peers, may help affected 
individuals overcome stigma and discrimination and improve their engagement in healthcare 
process.
25-28
 Economic hardship, particularly low annual personal and household income and 
food insecurity, were significantly higher among women with HIV versus HIV-free women of 
the general population, indicating the need for economic strengthening for women with HIV to 
promote utilization of HIV care services. 
6.3. Clustered social determinants  
A key feature of the social determinants is that they tend to co-occur.
29
 Therefore, studying 
social determinants individually may miss the co-occurring patterns of these determinants. For 
example, those living with income insecurity are more likely to be exposed to food insecurity, or 
those experiencing racial discrimination and/or HIV-related stigma might be at a higher 
likelihood of having lower social support. There has been a growing interest in this phenomenon 
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to identify opportunities for impactful strategies dealing with health-related behaviours.
ex.30,31
 
Some studies have analyzed the co-occurrence of these determinants through the count of the 
total number or types of social determinants.
32
 While such additive methods can help provide 
information on the burden of the social determinants, they strongly rely on the assumption of 
homogeneity in the co-presence of these determinants in a population.
30
 However, the use of 
model-based complex analytical approaches, such as latent class analysis (LCA), can help 
provide valuable insights into the complexity of these determinants. In addition, such approaches 
can help researchers determine individual indicators of these determinants within the identified 
clusters. Further, instead of analyzing these determinants separately in association with a health 
outcome, LCA helps explore the impact of clustering of these determinants. 
In the current study, our analyses and findings showed that women reported experiencing 
complex adversities characterized by social, economic, and structural determinants of health. 
LCA analyses demonstrated that social determinants are clustered together and create unique 
classes/groups of adversities. Of the four identified SDoH classes, three classes exhibited a 
combination of two or more SDoH adversities. While the majority of the study sample reported 
experiencing multiple forms of adversities (i.e., class 4), we were able to identify two more 
clear/distinct classes of SDoH adversities including stigma/discrimination and economic 
hardship that have been the key barriers to prevention as well as care and treatment of HIV 
infection from the beginning of its epidemic. In particular, our findings indicated that multiple 
forms of discriminatory behaviours had the potential to cluster together (i.e., racial 
discrimination, gender discrimination, and HIV-related stigma). Findings also showed that 
multiple indicators of economic difficulties were clustered in one unique group. Further, these 
two unique classes together tended to cluster and created a more complex class of SDoH (i.e., 
196 
 
class 4), which might indicate that the unique clusters of stigma/discrimination and economic 
hardship can both independently in their unique clusters and jointly together account for the 
majority of health inequalities. These findings also suggest the need to consider multiple social, 
economic and structural adversities when analyzing and reporting the severity (e.g., prevalence) 
of these determinants and recognizing their detrimental impacts on health outcomes. Examining 
one single indicator may not properly characterize the daily living experiences of underserved 
individuals such as women with HIV, who typically report experiencing multiple adversities. 
ex.33
 
Identifying the patterns of these determinants and examining their grouped/clustered 
impact not in separation but in combination has implications for health inequalities reduction and 
health promotion programs. The use of such analytic approaches aiming at the identification of 
the latent patterns of social determinants can help in the contextualization of the clustered 
determinants, as their co-occurrence as well as synergistic impacts may contribute to more 
intense adverse health outcomes than if they were experienced (or treated in the analysis) alone. 
Moreover, programs targeting multiple determinants (i.e., addressing multiple social, economic, 
and structural adversities) would have the potential for a greater impact on public health relative 
to the strategies that only address one single adversity. For example, in addressing housing 
instability among vulnerable populations, considering other vulnerabilities such as food 
insecurity and/or economic pressure is critical. Assessing the pattern of these determinants can 
also help prioritize most vulnerable individuals for better support.  
6.4. Substance use among women with HIV 
Significant efforts have been made over time to reduce adverse clinical and health outcomes 
among individuals with HIV in Canada.
34
 Evidence has suggested that people with HIV, 
particularly those in resource-rich nations such as Canada,
35-37
 have or are approaching a normal 
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life expectancy (i.e., that is almost equivalent to that of HIV-uninfected individuals) if they 
receive appropriate cART treatment.
34,37-41
 Such considerable change in the profile of HIV may 
give rise to the greater experience of chronic health conditions among these individuals.
42
 
Evidence has also supported such elevated burden of chronic conditions among people receiving 
HIV treatment versus their HIV-free counterparts.
35,43,44
 Aside from the intersection of aging and 
HIV infection itself that negatively impact the overall health of these individuals, identifying and 
addressing other potential challenges that these individuals continue to experience in gaining a 
healthy state remains essential.
35
 Substance use is one such potential barrier contributing to a 
lower survival or quality of life of individuals with HIV compared with individuals without HIV 
and it needs to be carefully studied and addressed among these individuals,
37,45
 particularly 
among women, a population with limited resources available on their social and behavioural 
factors.
46
  
As described in the Introduction Chapter, the detrimental contribution of substance use to 
the elevated poor HIV treatment outcomes and mortality among individuals with HIV has been 
well documented.
34,42,46-64
 Prior research documented that individuals who were involved in 
substance use were at elevated risk for suboptimal linkage to and retention in HIV care, HIV 
treatment adherence, AIDS-related illness and mortality.
42,46,63-66
 Substance use is of paramount 
importance in ongoing concentration for the management of HIV infection. Literature suggests 
that a considerable proportion of non-AIDS-related causes are now the prevailing cause of 
mortality among these individuals, yet many of these causes have a strong link with substance 
use.
42
  
Our findings suggesting a high prevalence of substance use in the study population have 
implications for HIV care and treatment programs in the current era of Treatment as Prevention 
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(TasP). These findings may indicate that behavioural barriers yet remain as one of the main 
challenges in the management of HIV among women with HIV. These risk-taking practices may 
also explain the variations/gaps in the elevated non-AIDS comorbidities and mortality of 
individuals with HIV, women in particular, over their counterparts in the general population. As 
substance use has the potential to interrupt every step along the cascade, our findings emphasize 
that the effectiveness of HIV care and treatment services may rely on how these risk-taking 
barriers are effectively addressed.  
Evidence has extensively highlighted the need for developing care models where, in 
addition to addressing HIV-related care and treatment, substance use is routinely assessed. 
Raposeiras-Roubín et al. (2017) believe that the awareness within the health system with respect 
to the elevated risks posed by substance use on causes of mortality among individuals with HIV 
is suboptimal.
67
 Dawson-Rose et al. (2017) noted that while primary care clinics are the best 
setting to offer screening and interventions for substance use, few HIV clinics routinely assess 
substance use. These authors added that implementation of standard practice for screening 
substance use in HIV primary care clinics is necessary.
68
 Nijhawan et al. (2008) believe that 
substance use should be discussed without alienating substance users in the context of a trusting 
provider-patient relationship.
69
 It has been emphasized that healthcare providers should ensure 
that the overarching goal of substance use interventions is to maintain individuals in HIV 
care,
69,70
 and better manage the HIV/AIDS complications.
42
 Interventions, either behavioural 
(e.g., counselling for tobacco use cessation,
71
 or a case management intervention model for 
alcohol and illicit drug use
72
), pharmacological (e.g., nicotine patches
71
 and Vaporised nicotine 
products
73
 for cigarette smoking cessation, lamotrigine for crack cocaine users,
74
 buprenorphine 
and methadone maintenance therapy for illicit drug users
75-77
), or psychosocial (e.g., contingency 
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management treatment for opioids and cocaine
78
) interventions/supports for individuals with 
HIV involving in substance use should become a priority in routine HIV care services. The 
integration of these interventions warrants further investigation for the management of the use of 
various substances.  
Existing research proposed multiple models for integration of HIV care and substance use 
interventions, such as
69,77
 i) a primary care model, through which the HIV treatment provider 
prescribes the substitution therapy; ii) an on-site specialist model, through which a substance use 
specialist prescribes the substance use interventions; iii) a hybrid model, through which an on-
site specialist prescribes the initial induction therapy of the substance use intervention and the 
HIV care provider prescribes its maintenance phase; iv) a drug treatment model, through which 
both HIV care and substance use services are provided in a substance use clinic setting, v) 
directly administered antiretroviral therapy (DAART), is another integrated care that through 
which substance using individuals with HIV receive supervised doses of HIV treatment in a 
substance use clinic setting,
69,79-81
 and vi) patient-centered model of care, in which individuals 
with HIV receive diverse health-related services, including harm reduction programs, in a 
friendly environment setting
28,42,67
 are offered for maintaining individuals with HIV optimally 
engaged in care, and for meeting national and global goals of HIV treatment.
82
 Similar to the 
latter form of model of HIV care, gender-matched-centered model of care has also been 
proposed. For example, a women-centered model of HIV care
83,84
 and a women-centered harm 
reduction approach
85,86
 have been identified as promising models for addressing women’s 
comprehensive care needs.
84,87-90
 Consistent with extant research,
28,42,67,84
 our findings advocate 
for developing women-centered models of care where, in addition to providing multiple 
healthcare services, women with HIV can also have access to harm reduction and substance use 
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intervention programs. In the Canadian context, O'Brien et al. (2017) underlined that a women-
centered approach to HIV care is essential for guiding policy and practice to promote the health 
and clinical outcomes for women with HIV.
84
 These researchers additionally pointed out that 
given gaps in care and inequalities in health, models/approaches that address the care priorities 
of women living with HIV “must be incorporated into care delivery to ensure that women's 
comprehensive care needs are met and to enable diverse populations to benefit equally from 
health care advances.” 
6.5. Social determinates give rise to elevated risk of substance use  
Our research added to the literature demonstrating high prevalences of substance use among 
women with HIV. While the prevalences of all studied substances were high, the prevalence of 
illicit drug use and cigarette smoking, in particular, were in excess of what would be expected 
from the background HIV-negative women (Chapter 2). Our additional analyses using latent 
class analysis (LCA) identified distinct subgroups (clusters) of women with HIV characterized 
by a set of potentially modifiable social and structural determinants. These analyses showed that 
a substantial proportion (93.4%) of study participants reported experiencing two or more types of 
SDoH adversities (classes 2-4). Furthermore, our findings demonstrated that illicit drug use and 
drinking patterns among women with HIV were socio-structurally distributed, such that women 
who experienced less social adversities were less likely to report using these substances than 
those in other three classes who experienced distinct levels of SDoH adversities. Future research 
should identify and explore interventions addressing social determinants among women with 
HIV.  
Several theoretical frameworks can help guide our understanding of potential pathways 
through which the SDoH clusters increase the risk of substance use. Our research is also 
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centrally informed by a social determinants of health (SDoH) framework, highlighting that 
political, economic and cultural drivers impact socioeconomic status/position, which in turn 
shapes SDoH impacting health and well-being,
4,5,91
 and influencing health inequities. This 
framework mostly focuses on the upstream determinants of health such as education, occupation, 
income, housing status, social support, stigma and discrimination. In the context of HIV and 
substance use, this framework has been used to emphasize that socio-structural determinants play 
a pivotal role in risk-taking behaviours
2,92,93
 and poor HIV outcomes,
94-96
 resulting in health 
inequalities. Informed by these theoretical frameworks, our findings imply that the 
overlapping/clustering social determinants have the potential to severely constrain the ability of 
women with HIV to effectively respond to behaviour change strategies. A syndemics theory can 
also support these findings. This model links multiple social and structural adversities to co-
occurring and synergistic health epidemics that disproportionately affect vulnerable populations, 
and magnify the negative impact of disease interaction.
97-99
 This model highlights the 
contribution of the excess burden of “entwined and mutually enhancing health problems” to the 
health inequalities,
97
 fueled by social, economic and structural inequities.
98,99
 Applications of this 
theory to HIV studies have mostly concentrated on factors that synergistically contribute to HIV 
risk among vulnerable populations.
100,101
 A special form of this theory is known as the SAVA 
syndemic, referring to the clustering of substance use, violence and HIV/AIDS among 
marginalized populations such as women of color living with HIV.
102
 This model explicitly 
advocates for socio-structural interventions that more effectively address the intersecting issues 
of substance use, structural adversities such as violence, and poor outcomes which necessitate 
systemic work to target the underlying conditions perpetuating health inequities among 
marginalized populations.
101,102
 In accordance with a self-medication model,
103
 our findings may 
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also indicate that women with HIV initiate or continue substance use (e.g., alcohol use) as a 
coping strategy to alleviate their daily stressors. This model underscores behavioural coping as a 
potentially relevant mediator for the association between multiple social adversities and 
substance use.
63,104
 Consistent with this model, Wardell et al. (2018) in a longitudinal analysis in 
Canada showed that greater HIV-related stigma, as a key and relevant SDoH in the context of 
HIV, predicted increased maladaptive strategies for coping (e.g., self-blame, denial), and that 
maladaptive coping mediated the prospective associations between HIV-related stigma and 
alcohol use severity.
92
  
HIV research has extensively accentuated the contribution of social determinants to both 
the distribution of HIV infection (i.e., as the drivers of HIV infection) and poor HIV outcomes 
(i.e., among those who are living with HIV). Research has also highlighted interventions 
addressing social determinants of HIV infection and substance use among affected individuals as 
the most effective interventions in addressing poor outcomes and then reducing health 
inequalities.
69,105-107
 For example, Wolitski et al. (2010) in a randomized controlled trial assessed 
the longitudinal effects of a structural intervention (i.e., rental assistance on the housing status) 
on the health and risk behaviours of homeless and unstably housed people with HIV, and showed 
that the receipt of stable housing significantly reduced risk-taking behaviours, improved access 
to care, increased adherence to treatment, and improved self-reported physical and mental health 
(e.g., depression and perceived stress).
108
 These studies indicate that if HIV care programs 
viewed the patients as a whole, including their social determinants,
109
 improved outcomes would 
be achieved.
84
 This is particularly of the essence among women with HIV who are unjustly 
occupied in the socioeconomically disadvantaged position.
84,110-112
 Research in Canada, in line 
with international research, has noted that these leading determinants, even though essential to 
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addressing barriers of HIV care, are challenging to properly address in health care settings since 
many of these determinants (e.g., housing, poverty) lie beyond the purview of the health care 
system.
84,113,114
 O'Brien et al. (2017), however, believe that strategies such as interdisciplinary 
teams and revised prescription financing policies that address socioeconomic hardship may help 
bring greater attention to socio-structural barriers that have negative impacts on women’s care-
seeking behaviours, HIV outcomes, and overall health.
84
 In this regard, it is imperative to 
continue to educate and advocate for all healthcare professionals to acknowledge socio-structural 
factors giving rise to poor health.
84,113,115
 
Our findings indicate that, in addition to the efforts in increasing the number of individuals 
receiving cART treatment, the successful management of HIV requires making greater efforts in 
addressing the social barriers as well as substance use through the integration of health care 
services. Undoubtedly, substantial advances have been achieved in HIV care and treatment 
programs, and subsequently substantial reductions have been made in HIV morbidity and 
mortality; however, treatment alone does not appear to help end the HIV epidemic. Such 
prevalent clustering co-occurring conditions and/or adversities pose a “complex problem” for 
patients as well as healthcare providers and health systems that seek to provide coordinated care 
to them.
116,117
 The complexity in care has been referred to individuals with multiple co-morbid 
medical and behavioural health conditions whose care is complicated by social factors (e.g., 
poverty) and health system factors (e.g., segregated medical and behavioural healthcare 
programs).
116
  Grembowski et al. (2014) developed a conceptual model and defined complexity 
in care as the misalignment between patient needs and the services available for them (i.e., need-
service gap), highlighting the need for care systems to address dynamic or complex conditions 
and incorporating social, economic, and physical conditions as contextual factors that influence 
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patient needs and services delivery.
117
 In the face of such multiple co-occurring health, 
behavioural, and socio-structural adversities that have also been identified in the present study 
among women with HIV, research supports that the integration of services that address multiple 
services such as substance use treatment, psychosocial support, counselling, and HIV care might 
bring about improved health outcomes.
69,118
 While addressing each service can help improve 
care when applied individually, a multidisciplinary strategy such as a gender-focused HIV care 
strategy, where various health care needs are considered may better address the comprehensive 
needs of women with HIV.
69,84,119,120
 Women-centred interventions have become an emerging 
model for the provision of the comprehensive health care needs of women.
83-85,88,118
 For 
example, Carter et al. (2013) in a comprehensive review explored the concept of women-specific 
HIV/AIDS services, as a complex and multidimensional model, and identified the key 
dimensions of such model. According to this review, this approach to care is conceptualized to, 
for example, create an atmosphere of safety, respect and acceptance; facilitate interaction among 
peers; facilitate meaningful access to care through the provision of social and supportive 
services; provide gender-, culture- and HIV-sensitive training to health and social care providers; 
provide women's social economic needs/supports such as transportation assistance, and food; 
conduct gendered HIV/AIDS research.
83
 Ellsberg et al. (2015) in a review study recommended 
women-centered programs as one key intervention to reduce women’s risk of further 
victimization and promote their health and wellbeing through providing a combination of 
strategies such as psychosocial support, advocacy and counselling, and home visitation.
118
 These 
interventions are closely consistent with the principle of the Greater Involvement of People 
Living with HIV/AIDS (GIPA), a critical principle to halting and reversing the HIV epidemic, 
which has been formalized to support a greater involvement of individuals with HIV at all levels 
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(e.g., policy, programming, care, research) and advocate for their rights.
121
 Due to the particular 
social environment where women with HIV face these adversities (i.e., gendered nature of these 
adversities), our findings advocate for further research to identify more culturally tolerated, 
women-focused interventions and assess their effectiveness if the care programs are to better 
address health inequalities among women, particularly women in greater needs such as substance 
users.
83,119,120,122
 
This part of our analysis and findings also adds to the body of evidence supporting that 
social determinants are highly inter-correlated,
29
 a key feature of these determinants that has not 
been well taken into account in the analyses of the social determinants with health outcomes. 
Extant research has commonly treated these determinants as independent factors in the 
assessment of their impacts on the subsequent health outcomes. While this approach has 
implications for HIV care and treatment strategies on how to overcome the adversities with each 
determinant, future research should take the co-occurrence nature of these determinants into 
account. Such analysis has implications for HIV care in a way that any care models should 
address multiple adversities of women with HIV.  
6.6. Future research and directions 
Further research should 1) focus on the reproducibility of the identified latent classes in 
populations with different sociodemographic backgrounds and HIV-related clinical 
characteristics to see whether similar classes are found and how they contribute to substance use 
as well as other health outcomes, 2) identify the predictors of the SDoH latent classes, 3) explore 
the SDoH latent classes over time using other mixture models such as latent transition analysis 
(LTA),
123
 4) longitudinally investigate the association of the SDoH latent classes with health 
outcomes (e.g., substance use, HIV outcomes) among women with HIV, and 5) develop 
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conceptual and analytic strategies to explore how modifiable and non-modifiable SDoH can be 
modelled together to capture a detailed picture of the indicators of SDoH among individuals with 
HIV. In such models, it is important to assess how non-modifiable SDoH (such as gender, 
ethnoracial status) can modify the impact of modifiable SDoH on health outcomes, or how these 
modifiable factors may explain (i.e., transmit the impact) the relationship between non-
modifiable SDoH and health outcomes; 6) seek and identify culturally tailored, women-specific 
interventions in addressing multiple forms of women’s needs, particularly social adversities and 
substance use; and 7) promote linkages between substance use treatment programs and HIV care, 
that can be evaluated in the women-centered model of care.  
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7. Appendices  
Appendix A: A brief description of latent class analysis and procedures  
We used latent class analysis (LCA) to determine latent classes/subgroups of women with HIV 
with distinct profiles with regard to the social determinants of health (SDoH) based on 12 
observed categorical indicators including racial discrimination, gender discrimination, enacted 
HIV stigma, perceived social support, barriers to access to care, food security, housing status, 
income level, employment status, education, recent sex work involvement, and recent 
incarceration. LCA is a data-driven probabilistic model commonly used to identify the levels of 
the categorical latent variables representing classes (groups) with similar profiles based upon 
conditional probabilities. LCA uses the expectation-maximization (EM) algorithm
1
 – an iterative, 
maximum-likelihood estimation approach, to estimate the unknown parameters.
2
 The maximum 
number of iterations was set to 5000 (the default number in SAS LCA procedure) in the EM 
estimation procedure for the replication of the log-likelihood value to ensure that a best-fit 
solution is obtained. As an iterative approach, EM algorithm begins with a set of starting values 
and proceeds with a series of steps of parameter estimation and re-estimation iterations until 
[some] designated criterion is reached. As an attempt to avoid suboptimal estimates produced by 
local maxima of the likelihood function, multiple random sets of starting values (i.e., in the 
present study, 1000 random starting values) was used.  
We started LCA with a 2-class model and systematically increased to an 8-LCA model to 
examine the LCA solutions. Model interpretability along with the following goodness-of-fit 
indices or/and information criteria were considered to choose the best number of latent classes: 
Log-Likelihood, Akaike information criterion (AIC), Schwarz Bayesian information criterion 
(BIC), Consistent AIC (CAIC), and [relative] Entropy. Lower values for the AIC, BIC and CAIC 
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imply better model fit, while higher entropy reflects better classification or class distinction, with 
approaching 100% indicating clear delineation or better separation of latent classes (varied 
between 0 to 1).
3,4
 In addition, we reported the percentage of seeds associated with best fitting 
model as a diagnostic information on the random starting value process; higher percentages 
indicate that the model appears to be well-identified (i.e., highly unlikely to have hit local 
maxima). 
Missing data 
In LCA, where the latent class membership is always missing, manifest indicators used to 
estimate the latent classes may also come with missing values. Under the assumption of missing 
at random (MAR) – even though this assumption is sometimes ignored,5 LCA computes LCA 
parameters accounting for missing values of observed indicators (here, SDoH indicators) 
typically by maximum-likelihood estimation using the EM algorithm so that all available 
information are used to estimate the best model,
2
 except for those participants with full missing 
data for all observed indicators (Note: participants with missing values for the study outcomes in 
Chapter 4 and 5 were excluded from the associational analyses between clustering SDoH and 
substance use.  
EM algorithm  
As explained above, LCA estimates unknown parameters using the expectation-maximization 
(EM) algorithm
1
 which is maximum-likelihood estimation approach with iteration when some 
parts of the data is missing; e.g., the hidden classes,
2
 in each iteration two steps of the E-step and 
M-step is followed. The iterative process between the E-step and M-step aims to generate a 
sequence of parameter estimates that converges reliably to a local or global maximum of the 
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likelihood function.
5
 The first step is computed using the expected value of the log of the 
likelihood function, given the observed data and the initial parameter estimates (i.e., sometimes 
called starting values)
6
 which can be specified either by the researchers (if there is enough 
evidence knowing the distribution of these parameters – called user-specified starting values)7 or 
randomly. In the current research, random starting values (referring to any positive integer value) 
were specified. SAS program starts with the default starting value of 1/NCLASS for Gamma [γ] 
parameters, where NCLASS refers to the number of classes specified to estimate the class 
membership probabilities – unknown or hidden classes. One issue with the specification of the 
random starting values is that some starting values may bring about local solutions that are not 
reflecting the global maximum of the likelihood. In such case and to avoid this happen, multiple 
sets of starting values were specified and the solution with the best likelihood was chosen.
7
 The 
second step, the M-step, the algorithm maximizes the function to give new values of the 
parameter estimates, replaces the initial estimates of the starting values by the updated/new 
estimates of the parameters, and then returns to the first step (E step). This process (algorithm) 
iteratively continues until changes in either the parameter estimates or log-likelihood function 
reach some predefined level of precision (convergence criterion default set to 0.000001) in which 
the iteration halts.  
Parameters 
LCA estimates two sets of parameters:
7
 1) class membership probabilities (i.e., called as Gamma 
[γ] parameters), representing the probabilities that each participant falls into each class. For each 
participant, the sum of these probabilities across estimated classes equals one (i.e., 100%); and 2) 
class-specific item-response probabilities (i.e., called as Rho [𝜌]), representing the probabilities 
of each indicator predicting the class memberships. The Rho (𝜌) parameters express the 
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correspondence between the observed items and the latent classes. We did not include covariates 
predicting class membership probabilities into the model. Instead, we adjusted for covariates in a 
separate regression model after identifying the best fitting model in this step. This is called a 
three-step approach through which investigators examine the association between the best-fitted 
latent categorical variable and a distal outcome variable after class membership has already been 
determined.
8,9
 In comparison with the approach in which LCA process and regression models are 
combined in a joint model, the multi-step approach (i.e., conducing LCA and regression analyses 
separately) may attenuate associations; however, the multi-step approach allows the researchers 
to run multivariable regression analysis adjusted for a large set of covariates. In the presence of 
having numerous covariates required to be adjusted for the association of the latent classes and 
the distal outcomes, adjustment process may affect the CLA structure in the one-step approach, 
while it is unlikely to occur in the multi-step approach.
9,10
 
LCA models use distributional assumptions to estimate classes, by which the measure of 
distance in LCA is provided. For example, with binary items – which will be treated as outcomes 
in the process of LCA, such distributional assumptions must follow a binary-outcome 
distribution: a) items are assumed to be independent within each class, b) items are assumed to 
be distributed marginally as Bernoulli. This distribution has two possible outcomes: a) Y=1 
("success") occurs with probability 𝜌 and Y=0 ("failure") occurs with probability 1 minus 𝜌, 
where 0 < 𝜌 <1. In the present study, success meant experiencing an SDoH adversity and failure 
meant not experiencing that SDoH adversity. We also added another category to the SDoH 
indicators indicting that individuals either experienced none of the 12 SDoH indicators or only 
one of these indicators. This additional step helped create a better reference group representing 
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those who wither experienced none of the 12 SDoH adversities or only one of them, labeled as 
those who none/least SDoH adversity. Each indicator has a probability function as follows:  
𝑓(𝑦) = {
1 − 𝜌         𝑓𝑜𝑟 𝑦 =  0
𝜌                 𝑓𝑜𝑟 𝑦 = 1,
} 
alternatively as,  
𝑓(𝑦) =  (𝜌𝑖)
𝑦(1 − 𝜌𝑖)
(1−𝑦𝑖) 
For example, if we assume that Y = 1 representing that a women experienced food insecurity, 
and Y = 0 indicating no experience of food insecurity. Our sample tells us that the probability of 
women with HIV with food insecurity is approximately 64%. So, 𝜌 is 64%; therefore, P (Y=1) = 
0.64 and P(Y=0) = 0.36. The same likelihood function will be obtained as follow:  
If Y=1, the likelihood is: 𝑝(𝑦𝑖 = 1) =  (0.64)
1(1 − 0.64)(1−1) = 0.64, 𝑜𝑟 64% 
and, if Y=0, the likelihood is: 𝑝(𝑦𝑖 = 0) =  (0.64)
0(1 − 0.64)(1−0) = 0.36, 𝑜𝑟 36% 
These illustrations show that the likelihood function of the statistical distribution provided the 
likelihood of an event occurring (i.e., SDoH indicator as an outcome variable). Put differently, in 
the case of discrete-outcome variables, the likelihood of an event is the same as the probability of 
the event occurring. 
As mentioned above, one of the assumptions is independence between items/outcomes 
within each class. To make this simple, let’s think about another item, experiencing enacted 
HIV-related stigma. If we take a sample, the probability of having experienced stigma is 
approximately 72% (𝜌2=72%). Under assumption of independence of these two items 
(outcomes), the probability of occurring both food insecurity and experiencing HIV stigma is the 
product of the probability of the occurrence of each adversity separately:  
𝑃(𝑌1 = 1, 𝑌2 = 1) = (𝜌1 × 𝜌2) = 0.64 × 0.72 = 0.46 
224 
 
Generally, the likelihood of any set of outcomes when no predictors included can be expressed 
as:  
𝑃(𝑌𝐽 = 𝑦𝐽) = ∏ 𝜌𝑗
𝑦𝑗(1 − 𝜌𝑗)
(1−𝑦𝑗)
𝐽
𝑗=1
 
LCA models are special cases of more general models called Finite Mixture Models.
11,12
 A finite 
mixture model expresses the distribution of a set of outcome variables, Y, as a function of the 
sum of weighted distribution likelihoods. More generally, a finite mixture model can be 
expressed as:  
𝑓(𝑌) =  ∑ 𝛾𝑐𝑓(𝑌|𝑐)
𝐶
𝑐=1
 
This is the conditional distribution of Y given c which is a sequence of independent Bernoulli 
variables. For example, for two observed indicators (Y1 and Y2), we can express the LCA model 
as:  
𝑓(𝑌) =  ∑ 𝛾𝑐𝑓(𝑌1|𝑐)𝑓(𝑌2|𝑐)
𝐶
𝑐=1
 
where, 𝛾𝑐 is the probability of class c, (𝑌1|𝑐)is the probability of occurring Y1 in class c (which is 
a conditional probability), and (𝑌2|𝑐) is the probability of occurring Y2 in class c (a conditional 
probability). More generally, an LCA for the response vector of J variables (j = 1, . . . , J) with C 
classes (c = 1, . . . ,C) when no predictors of class membership included can be expressed as: 
𝑓(𝑦𝑖) = ∑ 𝛾𝑐 ∏ 𝜌𝑗𝑐
𝑦𝑖𝑗(1 − 𝜌𝑗𝑐)
1−𝑦𝑖𝑗
𝐽
𝑗=1
𝐶
𝑐=1
 
where, i refers to observations, 𝛾𝑐 (Gamma) is the probability that an individual is a member of 
SDoH class/group c, 𝑦𝑖𝑗 is the observed response of individual i to the item j, 𝜌𝑗𝑐 is the 
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probability of a positive response to item j (i.e., experiencing an SDoH indicator) from an 
individual from class c.  
LCA assumes that all observed indicators are independent given a class, called as local 
independence. By this, any association between observed variables/items is accounted for only 
by the presence of the latent class. Put differently, the latent class is the reason that variables are 
correlated; this is why indicators within classes are assumed to be independent (local 
independence). SAS tests this assumption using a chi-square test when the indicators as included 
in the models as binary; however, in the present study, we used three-category SDoH measures 
and then skipped this test and assumed that the estimated latent classes were locally independent.  
Software 
We used PROC LCA (https://methodology.psu.edu),
13
 a SAS procedure for latent class analysis, 
using using % macro alc. We also used a user-defined macro code named %macro it to produce 
the summary statistics of all requested models. In addition, %itemresponseplot and 
%identificationplot macros were used to produce plots assisting in the evaluation of models. 
Details of these macros are described by Berglund.
14
 Parameters were estimated by maximum 
likelihood using the expectation maximization (EM) algorithm. LCA used a baseline-category 
multinomial logistic regression (as we included three-category SDoH indicators) to predict latent 
class membership. 
Model evaluation 
To select the best fitting model, in addition to the interpretability of the classes, we relied on 
information criteria obtained from parsimony indices: 1) log-likelihood = -2ln(L), where ln(L) is 
the log-likelihood of the model; 2) Akaike information criterion (AIC) = -2ln(L) + 2p, where p is 
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the number of estimated model parameters; 3) Schwarz Bayesian information criterion (BIC) = -
2ln(L) + p*ln(N), where N is the total number of observations; 4) consistent AIC (CAIC) with 
CAIC = -2ln(L) + p * (1 + ln(N)). The convergence method was set to the maximum absolute 
deviation (convergence criterion default set to 0.000001). 
 
SAS procedure for LCA analysis  
/* Import csv into SAS */ 
libname sdh "F:\Statistical analysis - Objective 2\Wave 2 and 1 - Merged - 
 SDH analysis\SAS\LCA 12";  
proc import out=sdh.SdhfromCSV12 
 datafile = "F:\Statistical analysis - Objective 2\Wave 2 and 1 - Merged 
 - SDH analysis\SDH variables12.csv" dbms=csv replace; getnames=yes; 
 dataraw=2;  
run;  
 
/* Creating three-category indicators from the binary SDoH indicators */ 
data Sdh.LCAanalysis12; 
 set Sdh.SdhfromCSV12;  
 array zzz stigma bacs edu food house income racism sexism socsup   
  unemploy sexwork prison;  
  do over zzz;  
  zzz = zzz +1;  
 end; 
run;  
 
 
/* Contents and frequencies */ 
proc contents;  
run; 
proc freq data = Sdh.LCAanalysis12;  
 tables stigma bacs edu food house income racism sexism socsup unemploy  
 sexwork prison; 
run;  
 
 
/* LCA analysis from starting with one LCA-model, increased to eight */ 
/*Step A: Use %macro alc to run several LCA models (i.e., 1 to 8)*/ 
%macro alc (nc);  
proc lca data=Sdh.LCAanalysis12 outest=Sdh.outests1&nc 
outpost=Sdh.outposts1&nc;  
 id part_id; 
 title2 "LCA analysis with 12 SDH indicators";  
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 nstarts 1000;  
 nclass &nc; 
 items stigma bacs edu food house income racism sexism socsup unemploy  
  sexwork prison; 
 categories 3 3 3 3 3 3 3 3 3 3 3 3; 
 seed 100000000;  
 rho prior=1; 
 cores 1;  
run; 
%mend alc;  
%alc(1); %alc(2); %alc(3); %alc(4); %alc(5); %alc(6); %alc(7); %alc(8); 
 
 
/* Step 2: Use %macro it to summarize Model Fit Comparisons of 8 models */ 
%macro it (nc);  
 data Sdh.outests1&nc;  
 set Sdh.outests1&nc;  
 nclass=&nc;  
run;  
%mend;  
%it(1); %it(2); %it(3); %it(4); %it(5); %it(6); %it(7); %it(8); 
/*Then concatenating the output datasets of 8 models to produce a summary 
data set called allfit_alc using PROC PRINT */ 
data Sdh.allfit_alc;  
 set Sdh.outests11 - Sdh.outests18;  
run;  
proc print;  
run;  
proc print data=Sdh.allfit_alc noobs label;  
 title "Model fits for variables";  
 label nclass="# classes" log_likelihood="LL" degrees_of_freedom="DF"; 
 var nclass LOG_LIKELIHOOD DEGREES_OF_FREEDOM G_SQUARED AIC BIC CAIC  
  ABIC ENTROPY;  
run;  
/* The above code creates a table with all model fit statistics of the 8 LCA 
models.*/ 
/* The best (optimal) LCA fitted model was obtained in this step. */  
 
 
/* Model with 4 classes was chosen as the best LCA model */  
/* Two evaluation tools are used to assist in model selection*/ 
/* The “item response” and “model identification” plots are produced using 
the %itemresponseplot and %identificationplot macros */ 
%INCLUDE "C:\Users\Mostafa\Desktop\Proc LCA\SAS Graphics 
Macros\LcaGraphicsV2\LcaGraphicsV2 (1).sas"; 
proc lca data=Sdh.LCAanalysis12 
  outpost=Sdh.posts1_4c_alc  
  outseeds=Sdh.outseeds_4c_alc  
  outparam=Sdh.outparm_4c_alc  
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  outstderr=Sdh.outstderr_4c_alc; 
  id part_id;  
  title2 "LCA analysis test data with 4 classes";  
  nclass 4; 
  nstarts 1000; 
  items stigma bacs edu food house income racism sexism socsup 
unemploy sexwork prison; 
  categories 3 3 3 3 3 3 3 3 3 3 3 3; 
  seed 262169154; 
  rho prior=1; 
  cores 1;  
run; 
%itemresponsePlot(ParamDataset=Sdh.outparm_4c_alc); 
%IdentificationPlot(SeedsDataset=Sdh.outseeds_4c_alc); 
 
proc freq data=Sdh.outposts14;  
tables best / plots=freqplot(type=barchart scale=percent);  
run; 
 
proc format;  
value bestf 1='Most SDH adversities' 2='none/least SDH' 3='Economic hardship' 
4='Stigma/discrimination' ; 
run; 
/* This order was changed in the process of analysis with */ 
proc freq data=Sdh.outposts14;  
tables best / plots=freqplot(type=barchart scale=percent);  
format best bestf.;  
run; 
* Export into Stata;  
proc export data=Sdh.outposts14 outfile= "F:\Statistical analysis - Objective 
2\Wave 2 and 1 - Merged - SDH analysis\SAS\LCA 12\SAStoSTATA12.dta"; 
run; 
 
SAS Output for a 4-LCA model  
The SAS System        12:53 Tuesday, August 7, 2018  10 
LCA analysis SDH data 
 
Data Summary, Model Information, and Fit Statistics (EM Algorithm) 
 
 
 
Number of subjects in dataset:        1422 
Number of subjects in analysis:       1422 
Number of measurement items:            12 
Response categories per item:            3 3 3 3 3 3 3 3 3 3 3 3 
Number of groups in the data:            1 
Number of latent classes:                4 
 
NOTE: A data-derived prior was applied to the rho parameters to help 
      avoid parameter estimates on boundary values of zero and one. 
 
Rho starting values were randomly generated (seed = 100000000). 
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No parameter restrictions were specified (freely estimated). 
 
Seed selected for best fitted model:    1165345913 
Percentage of seeds associated with best fitted model:   93.70% 
 
The model converged in 78 iterations. 
 
Maximum number of iterations: 5000 
Convergence method: maximum absolute deviation (MAD) 
Convergence criterion:  0.000001000 
 
============================================= 
Fit statistics: 
============================================= 
 
Log-likelihood:     -8030.01 
G-squared:           1366.87 
AIC:                 1564.87 
BIC:                 2085.59 
CAIC:                2184.59 
Adjusted BIC:        1771.10 
Entropy:                0.83 
Degrees of freedom:   531341 
 
Test for MCAR 
      Log-likelihood:     -7346.58 
      G-squared:           1283.90 
      Degrees of freedom:  2921792 
 
Class membership probabilities: Gamma estimates (standard errors) 
Class:                     1          2          3          4 
                      0.4345     0.0661     0.3083     0.1911 
                     (0.0214)   (0.0066)   (0.0225)   (0.0170) 
Item response probabilities: Rho estimates (standard errors) 
  Response category  1: (this section was omitted by the authors) 
. 
. 
  Response category  2  
Class:                     1          2          3          4 
  stigma      :       0.8317     0.0018     0.6048     0.7800 
                     (0.0170)   (0.0044)   (0.0263)   (0.0293) 
  bacs        :       0.6384     0.0014     0.4509     0.5696 
                     (0.0219)   (0.0038)   (0.0268)   (0.0346) 
  edu         :       0.2477     0.0004     0.1683     0.0059 
                     (0.0187)   (0.0021)   (0.0199)   (0.0099) 
  food        :       0.8185     0.0017     0.6880     0.3707 
                     (0.0184)   (0.0042)   (0.0259)   (0.0365) 
  house       :       0.1701     0.0003     0.0980     0.0146 
                     (0.0160)   (0.0017)   (0.0154)   (0.0085) 
  income      :       0.8893     0.0017     0.7943     0.1004 
                     (0.0178)   (0.0043)   (0.0254)   (0.0370) 
  racism      :       0.8234     0.0013     0.0948     0.5967 
                     (0.0248)   (0.0038)   (0.0278)   (0.0375) 
  sexism      :       0.9604     0.0015     0.0864     0.6734 
                     (0.0198)   (0.0040)   (0.0393)   (0.0366) 
  socsup      :       0.6265     0.0014     0.4909     0.4996 
                     (0.0217)   (0.0038)   (0.0268)   (0.0354) 
  unemploy    :       0.9814     0.0020     0.9132     0.3264 
                     (0.0101)   (0.0047)   (0.0170)   (0.0441) 
  sexwork     :       0.1068     0.0002     0.0464     0.0091 
                     (0.0137)   (0.0013)   (0.0119)   (0.0078) 
  prison      :       0.1204     0.0002     0.0398     0.0013 
                     (0.0138)   (0.0014)   (0.0106)   (0.0070) 
 
  Response category  3 (this section was omitted by the authors) 
. 
. 
  
230 
 
References for appendix A:  
1. Muthen B, Shedden K. Finite mixture modeling with mixture outcomes using the EM 
algorithm. Biometrics. 1999;55(2):463-469. 
2. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via EM 
algorithm (with discussion). Journal of the Royal Statistical Society (Series B). 1977;39:1–
38. 
3. Celeux G, Soromenho G. An entropy criterion for assessing the number of clusters  in a 
mixture model. Journal of Classification. 1996;13:195-212. 
4. Asparouhov T, Muthen B. Variable-Specific Entropy Contributon. June 19, 2018. 
https://www.statmodel.com/download/UnivariateEntropy.pdf [Accessed March 10, 2019]. 
5. Harel O, Chung H, Miglioretti D. Latent class regression: inference and estimation with 
two-stage multiple imputation. Biom J. 2013;55(4):541-553. 
6. No authors listed. Perturbation of Starting Values June 16, 2003 
http://www.statmodel.com/download/Starts.pdf [Accessed March 10, 2019]. 
7. Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: A SAS Procedure for 
Latent Class Analysis. Struct Equ Modeling. 2007;14(4):671-694. 
8. Bolck A, Croon M, Hagenaars J. Estimating latent structure models with categorical 
variables: One-step versus three-step estimators. Political Analysis. 2004;12:3–27. 
9. Bray BC, Lanza ST, Tan X. Eliminating Bias in Classify-Analyze Approaches for Latent 
Class Analysis. Struct Equ Modeling. 2015;22(1):1-11. 
10. Vermunt JK. Latent class modeling with covariates: two improved three-step approaches. 
Polit Anal. 2010;18(4):450–469. 
11. McLachlan GJ, Peel D. Finite mixture models. New York, NY: John Wiley and Sons, Inc; 
2000. 
12. Muthén BO, Sheddon K. Finite mixture modeling with mitxure outcomes using the EM 
algorith. Biometrics. 1999;55:463–469. 
13. Lanza ST, Dziak JJ, Huang L, Xu S, Collins LM. PROC LCA & PROC LTA user’s guide. 
University Park: The Methodology Center, Pennsylvania State University;2015. 
14. Berglund PA. Latent Class Analysis Using PROC LCA (Paper 5500). 2016. University of 
Michigan https://support.sas.com/resources/papers/proceedings16/5500-2016.pdf 
[Accessed Feb10, 2018].  
231 
 
Appendix B: CHIWOS’s Data Sharing Agreement  
 
 
232 
 
 
 
  
233 
 
Appendix C: CCHS’s Microdata Research Contract  
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Appendix E: CHIWOS and CCHS surveys   
A. CHIWOS  
A1) Detailed CHIWOS Wave 1 Survey, English format, can be found here:  
http://www.chiwos.ca/wp-content/uploads/2014/08/CHIWOS-May-13-2014-En.pdf  
A2) Detailed CHIWOS Wave 2 Survey, English format, can be found here:  
http://www.chiwos.ca/wp-content/uploads/2012/04/CHIWOS-Wave-2-Survey-
2016.02.12-EN_clean.pdf  
B. CCHS 
Detailed Canadian Community Health Survey (CCHS; 2013) is accessible here:  
http://www23.statcan.gc.ca/imdb/p3Instr.pl?Function=getInstrumentList&Item_Id=1525
67&UL=1V&  
 
Selected list of variables in both CHIWOS and CCHS used in objectives 1a and 1b 
 CCHS 2013-2014 CHIWOS study, 2013-2015 Comparisons/categories  
Demographic 
variables 
   
Sex (SEX) SEX_Q01, DHH_SEX  
If necessary, ask: (Is 
[respondent name] male 
or female?) 
1 Male [will be excluded] 
2 Female 
(DK, RF are not allowed) 
S1-Q2b. What gender do 
you currently live as in your 
day-to-day life? 
Select one. 
Man [if only selection, end 
interview] 
Woman 
Sometimes man, sometimes 
woman 
Third gender, or something 
other than male or female 
Don't know 
Prefer not to answer 
This will be used for 
limiting the study on 
only females/women 
including trans women. 
We exclude the estimates 
for men in the CCHS 
data.  
 
Age  ANC_Q03  
What is ^YOUR1 age? 
|_|_|_| Age in years 
ANC_Q03 , ANC_03  
What is 
^SPECRESPNAME’s age?  
|_|_|_| Age in years  
 
Age will be a categorical 
variable and will be used for 
the adjustments  
This will be used to 
standardize the 
prevalences  
 
Limit the study to only 
those people aged ≥16.  
 
Age categories:  
16-25  
26-35  
36-45  
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 CCHS 2013-2014 CHIWOS study, 2013-2015 Comparisons/categories  
46-55 
56+  
Ethnic – race  SDC_Q4A  
To which ethnic or cultural 
groups did ^YOUR2 
ancestors belong? (For 
example: French, Scottish, 
Chinese, East Indian) 
SDC_4B  
 01 Canadian 
SDC_4B  
 02 French 
SDC_4C  
 03 English 
SDC_4D  
 04 German 
SDC_4E  
 05 Scottish 
SDC_4F  
 06 Irish 
SDC_4G  
 07 Italian 
SDC_4H  
 08 Ukrainian 
SDC_4I  
 09 Dutch 
(Netherlands) 
SDC_4J  
 10 Chinese 
SDC_4K  
 11 Jewish 
SDC_4L  
 12 Polish 
SDC_4M  
 13 Portuguese 
SDC_4N  
 14 South Asian 
(e.g. East Indian, Pakistani, 
Sri Lankan) 
SDC_4T  
 15 Norwegian 
SDC_4U  
 16 Welsh 
SDC_4V  
 17 Swedish 
SDC_4P  
 18 First Nations 
(North American Indian) 
SDC_4Q  
 19 Métis 
SDC_4R  
 20 Inuit 
SDC_4S  
 21 Other - Specify  
S1-Q7. What do you consider 
to be your racial and/or ethnic 
background? 
Select all that apply. 
Aboriginal person living in 
Canada (e.g., First Nations, 
Métis, and Inuit)  
Indigenous Person from a 
country outside of Canada 
Black African (e.g., Nigerian, 
Somali) 
Black Caribbean (e.g., 
Haitian) 
Black Other (e.g., Black 
Canadian) 
Caucasian/White 
Chinese or Taiwanese 
Filipino 
Japanese 
Korean 
Latin American (e.g., Chilean, 
Costa Rican, Mexican) 
South Asian (e.g., Indian, 
Bangladeshi, Pakistani, 
Punjabi, and Sri Lankan) 
Southeast Asian 
(e.g.,Cambodian, Laotian, 
Malaysian, Vietnamese) 
Arab (e.g., Egyptian, Kuwaiti, 
and Libyan) 
West Asian (e.g. Iraqi, Isreali, 
Lebanese, Afghani, Iranian) 
Central Asian (e.g., 
Kazakhstan, Kyrgyzstan, 
Tajikistan, Turkmenistan) 
Multiple races / Multiracial / 
“Mixed” 
Other, please specify: 
_________________ 
Don’t know  
Prefer not to answer  
This will be used to 
standardize the 
prevalences  
 
 
Ethnoracial groups:  
Indigenous 
White  
African, Caribbean, 
Black (ACB),  
Other ethnicities  
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 CCHS 2013-2014 CHIWOS study, 2013-2015 Comparisons/categories  
DK, RF 
Go to SDC_C04B 
And  
 
 
SDC_Q4B_1, SDC_41 
^ARE_C ^YOU1 an 
Aboriginal person, that is, 
First nations, Métis or Inuk 
(Inuit)? First Nations 
includes Status and Non-
Status Indians. 
1 Yes 
2 No  
DK, RF 
 
SDC_N4B_2 
(^ARE_C ^YOU1 First 
Nations, Métis or Inuk 
(Inuit)?) 
SDC_42A  1 First 
Nations (North American 
Indian) 
SDC_42B  2 Métis 
SDC_42C  3 Inuk 
(Inuit) 
DK, RF 
 
 
SDC_Q4C  
you may belong to one or 
more racial or cultural 
groups on the following 
list. Are you? 
SDC_43A  01 White 
SDC_43C  02 South 
Asian (e.g., East Indian, 
Pakistani, Sri Lankan, etc.) 
SDC_43B  03 
Chinese 
SDC_43D  04 Black 
SDC_43E  05 
Filipino 
SDC_43F  06 Latin 
American 
SDC_43H  07 Arab 
SDC_43G  08 
Southeast Asian (e.g., 
Vietnamese, Cambodian, 
Malaysian, Laotian, etc.) 
SDC_43I  09 West 
Asian (e.g., Iranian, 
Afghan, etc.) 
SDC_43K  10 
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 CCHS 2013-2014 CHIWOS study, 2013-2015 Comparisons/categories  
Korean 
SDC_43J  11 
Japanese 
SDC_43M  12 Other 
- Specify  
DK, RF 
Province  ADM_D3A 
Ontario  
British Columbia  
Québec  
Provinces: 
Ontario  
British Columbia 
Québec 
This will be used to limit 
the study to only the 
people of these three 
provinces  
Ontario  
British Columbia 
Québec 
 
Participants with on-
reserve status will be 
excluded from the 
analytic sample.  
Behavioural 
variables  
   
Alcohol use (ALC)    
Definition of a 
standard drink 
Now, some questions about 
^YOUR2 alcohol 
consumption. 
When we use the word 
‘drink’ it means: 
- one bottle or can of beer 
or a glass of draft 
- one glass of wine or a 
wine cooler 
- one drink or cocktail with 
one and a half ounces of 
liquor. 
A standard drink was 
considered to be contained 
13.45 grams of pure alcohol or 
the equivalent of 0.6 ounces 
(oz) of 100% alcohol and was 
defined as: 341 ml (12-oz) 
bottle of 5% alcohol "beer, 
cider or cooler", 142 ml (5-oz) 
glass of 12% alcohol "wine", 
and 43 ml (1.5-oz) serving of 
"liquor or spirits". 
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Alcohol frequency  Question identifier: 
ALC_Q1, ALC_1 
During the past 12 months, 
that is, from one year ago 
to 
yesterday, have you had a 
drink of beer, wine, liquor 
or any other alcoholic 
beverage? 
1 Yes  
2 No 
DK, RF 
 
Question identifier: 
ALC_Q2, ALC_2 
During the past 12 months, 
how often did you drink 
alcoholic 
beverages?  
1 Less than once a month 
2 Once a month 
3 2 to 3 times a month 
4 Once a week 
5 2 to 3 times a week 
6 4 to 6 times a week 
7 Every day 
DK, RF 
 
Variable: more than 3 
times a week, 2-3 times a 
week, once a week, once a 
month and others (less than 
once a month or never)  
S6-Q1 
How often in the last year 
have you had a drink 
containing alcohol? 
Never  
Monthly or less  
2-4 times a month  
2-3 times a week  
4 or more times a week 
DK 
PNTA 
a) Alcohol use in last 
year:  
Yes  
No  
 
b) alcohol drinking 
frequency  
4 or more times a week  
2-3 times a week  
2-4 times a months  
Monthly or less  
None  
Binge drinking  ALC_Q3, ALC_3 
How often in the past 12 
months have you had 
BINGE DRINK (=4 for 
women) or more drinks on 
one occasion? 
1 Never 
2 Less than once a month 
3 Once a month 
4 2 to 3 times a month 
5 Once a week 
6 More than once a week 
DK, RF 
S6Q3. Considering all types of 
alcoholic beverages (e.g., 
wine, beer, etc), have you had 
4 or more drinks on any one 
single occasion in the past 
month?   
• Yes 
• No  
 
S6Q4. How many times in the 
past month have you had 4 or 
more drinks on any one single 
occasion?  
 Indicate number of times: 
__________ 
0 = 0 
1 = 1 
2 - 9 = 2 
10  - 19 = 3 
Non-binge drinkers 
(monthly): those who 
responded NO to S6Q3 
(in CHIWOS) AND 
those who responded 
Never to ALC-Q3 (in 
CCHS); 
  
Light binge drinkers 
(monthly): those who 
responded Yes to S6Q3 
but reported 0 to S6Q4 or 
reported 1 to S6Q4 
(CHIWOS) AND those 
who responded once a 
month or less than once a 
month to ALC-Q3 (in 
CCHS).  
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20 or more = 4 Moderate binge drinkers 
(monthly): those who 
reported 2-3 times per 
month to S6Q4 
(CHIWOS) AND those 
who reported 2 to 3 times 
a month to ALC-Q3 (in 
CCHS). 
 
Heavy binge drinkers 
(monthly): those who 
reported 4 or more times 
per month to S6Q4 
(CHIWOS) AND those 
who reported once a 
week or more than once a 
week to ALC-Q3 (in 
CCHS). 
Smoking (SMK)    
Current status of 
cigarette smoking  
Question identifier: 
SMK_Q202, SMK_202  
At the present time, do you 
smoke cigarettes every 
day, occasionally or not at 
all? 
1: Daily 
2: Occasionally 
3: Not at all 
8: RF 
9: DK 
 
Variable: regular users 
(daily), occasional user, 
other options   
S6-Q5.  
What is your cigarette 
(tobacco) smoking history? 
I am currently a regular 
smoker 
I smoke occasionally 
I am a former smoker 
I have never been a smoker  
DK 
PNTA 
a) smoke cigarette 
currently  
Yes  
No   
 
b) Current pattern of 
cigarette smoking  
regular or daily  
occasionally  
others (never, former) 
Number of cigarette 
per day or month  
Question identifier: 
SMK_Q204, SMK_204 
How many cigarettes do 
you smoke each day now? 
NO: ….. 
 
Variable: an ordinal 
variable will be created 
based on pack per day  
S6-Q6.  
How many cigarettes do you 
normally smoke? 
 
Indicate number of cigarettes 
….. per day/or per month 
 
Indicate number of packs: …. 
Per day / or per moth 
Number of cigarettes per 
day:  
This will be an ordinal 
variable such as:  
20+ cigarette/day 
16-20 cigarette/day  
11-15 cigarette/day 
6-10 cigarette/day 
1-5 cigarette/day 
None  
Social determinants     
    
Food security  FSC_Q010, FSC_010 
Which of the following 
statements best describes 
the food eaten in your 
household in the past 12 
months, that is, since 
S1-Q22. Which of the 
following statements best 
describes the food eaten in 
your household in the past 12 
months, that is since [current 
month] of last year?  Select 
Q1) Last year 
household food eaten 
status:  
Enough /the kind wanted 
Enough /not kind wanted 
Sometimes/often not 
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current month of last year? 
1. You and other 
household members always 
had enough of the kinds of 
food you wanted to eat. 
2 you and other household 
members had enough to 
eat, but not always the 
kinds of food you wanted. 
3 Sometimes you and other 
household member did not 
have enough to eat. 
4 Often you and other 
household members didn’t 
have enough to eat. 
DK, RF 
one. 
- In the past 12 months, you 
and other household members 
always had enough of the 
kinds of food you wanted to 
eat 
- In the past 12 months, you 
and other household members 
had enough to eat, but not 
always the kinds of food you 
want 
- Sometimes you and other 
household members did not 
have enough to eat 
- Often you and other 
household members didn’t 
have enough to eat 
- Don't know 
- Prefer not to answer 
have enough  
 
Q2-4) Description of 
food situations  
Often true=2, sometimes 
true=1, never true =0; 
Score range 0 to 6 
Food secure 0-1 / food 
insecure 2-6 
FSC_Q020, FSC_020 
You and other members 
worried that food would 
run out before you got 
money to buy more. Was 
that often true, sometimes 
true, or never true in the 
past 12 months? 
1 Often true 
2 Sometimes true 
3 Never true 
DK, RF 
S1-Q23. 
In the past 12 months, you and 
other household 
members worried that food 
would run out before 
you got money to buy more. 
1 Often true 
2 Sometimes true 
3 Never true 
PNTA 
FSC_Q030, FSC_030 
The food that you and 
other members bought just 
didn’t last, and there 
wasn’t any money to get 
more. Was that often true, 
sometimes true, or never 
true in the past 12 months? 
1 Often true 
2 Sometimes true 
3 Never true 
DK, RF 
S1-Q23. 
In the past 12 months, the 
food that you and other 
household members bought 
just didn’t last, and 
there wasn’t any money to get 
more. 
1 Often true 
2 Sometimes true 
3 Never true 
PNTA 
FSC_Q040, FSC_040 
You and other members 
couldn’t afford to eat 
balanced meals. In the past 
12 months was that often 
true, sometimes true, or 
never true? 
1 Often true 
2 Sometimes true 
3 Never true 
DK, RF 
S1-Q23. 
In the past 12 months, you and 
other household 
members couldn’t afford to eat 
balanced meals.  
1 Often true 
2 Sometimes true 
3 Never true 
PNTA 
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Household income  INC_Q5A 
Can you estimate in which 
of the following groups 
your household income 
falls? Was the total 
household income in the 
past 12 months...? 
1 Less than $50,000 
including income loss 
2 $50,000 and more 
 
INC_Q5B, INC_5B 
Please stop me when I 
have read the category 
which applies to ^YOUR1 
household. Was it...? 
1 Less than $5,000 
2 $5,000 to less than 
$10,000 
3 $10,000 to less than 
$15,000 
4 $15,000 to less than 
$20,000 
5 $20,000 to less than 
$30,000 
6 $30,000 to less than 
$40,000 
7 $40,000 to less than 
$50,000 
DK, RF 
S1-Q11a. How much does 
your household make in a 
year, before taxes (i.e., 
household gross yearly 
income)?  
Less than $10,000 
$10,000 to $19,999 
$20,000 to $29,999 
$30,000 to $39,999 
$40,000 to $49,999 
$50,000 to $59,999 
$60,000 to $69,999 
$70,000 to $79,999 
$80,000 to $99,999 
$100,000 or more 
Don’t know / Prefer to 
estimate by month 
Prefer not to answer 
 
S1-Q11b. If unable to answer 
gross yearly household 
income, prompt for gross 
monthly income: Indicate 
gross monthly income in 
dollars: __ 
Base on the definitions 
used for LICO:  
Less than 20,000  
≥ 20,000  
 
20,000 is not the exact 
cut point, but it is the 
closest cut off point. This 
will be adjusted based on 
the number of 
dependents.  
INC_Q5C, INC_5C 
Please stop me when I 
have read the category 
which applies to your 
household. Was it...? 
1 $50,000 to less than less 
than $60,000 
2 $60,000 to less than less 
than $70,000 
3 $70,000 to less than less 
than $80,000 
4 $80,000 to less than less 
than $90,000 
5 $90,000 to less than less 
than $100,000 
6 $100,000 to less than less 
than $150,000 
7 $150,000 and over 
DK, RF 
  
Personal income  INC_Q8B 
Can you estimate in which 
of the following groups 
^YOUR1 personal income 
falls? Was ^YOUR1 total 
S1-Q12a. How much do you 
make in a year, before taxes 
(i.e., personal gross yearly 
income)? 
Less than $10,000 
Base on the definitions 
used for LICO:  
Less than 20,000  
≥ 20,000  
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personal income in the past 
12 months...? 
1 Less than $30,000 
including income loss 
2 $30,000 and more 
 
INC_Q8C, INC_8C 
Please stop me when I 
have read the category 
which applies to you Was 
it...? 
1 Less than $5,000 
2 $5,000 to less than 
$10,000 
3 $10,000 to less than 
$15,000 
4 $15,000 to less than 
$20,000 
5 $20,000 to less than 
$25,000 
6 $25,000 to less than 
$30,000 
DK, RF 
$10,000 to $19,999 
$20,000 to $29,999 
$30,000 to $39,999 
$40,000 to $49,999 
$50,000 to $59,999 
$60,000 to $69,999 
$70,000 to $79,999 
$80,000 to $99,999 
$100,000 or more 
Don’t know / Prefer to 
estimate by month 
Prefer not to answer 
 
S1-Q12b. If unable to answer 
gross yearly household 
income, prompt for gross 
monthly income: Indicate 
gross monthly income in 
dollars: __ 
 
20,000 is not the exact 
cut point, but it is the 
closest cut off point 
INC_Q8D, INC_8D 
Please stop me when I 
have read the category 
which applies to you Was 
it...? 
01 $30,000 to less than 
$40,000 
02 $40,000 to less than 
$50,000 
03 $50,000 to less than 
$60,000 
04 $60,000 to less than 
$70,000 
05 $70,000 to less than 
$80,000 
06 $80,000 to less than 
$90,000 
07 $90,000 to less than 
$100,000 
08 $100,000 and over 
DK, RF 
  
Race and gender 
discrimination  
EDS_Q005, EDS_005 
In your day-to-day life, 
how often do any of the 
following things happen to 
you? 
You are treated with less 
courtesy or respect than 
other people are. 
1 At least once a week 
2 A few times a month 
S5-Q2. These next questions 
ask about your experiences of 
racism. Please think carefully, 
and do your best to answer 
each question 
Q1) You are treated with less 
courtesy 
Q2) You are treated with less 
respect 
Almost everyday  
We found five matched 
questions on contents and 
wordings. These items 
will be summed up to 
create a new continuous 
variable. The range of 
scale for CCHS will be 
5-25, whereas it will be 
6-30 in CHIWOS. We 
will combine two items 
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3 A few times a year 
4 Less than once a year 
5 Never 
DK, RF 
Frequently  
Sometimes  
Not that often  
Almost never  
Never  
of “not that often” and 
“almost never” in 
CHIWOS to create a 
single item conceptually 
close to the item of “less 
than once a year” in 
CCHS. By doing this, 
both scales will have 
matched ranges from 5 to 
25.  
EDS_Q010, EDS_010 
In your day-to-day life, 
how often do any of the 
following things happen to 
you? 
You receive poorer service 
than other people at 
restaurants or stores. 
1 At least once a week 
2 A few times a month 
3 A few times a year 
4 Less than once a year 
5 Never 
DK, RF 
S5-Q2. These next questions 
ask about your experiences of 
racism. Please think carefully, 
and do your best to answer 
each question 
Q3) You receive poorer 
service 
Almost everyday  
Frequently  
Sometimes  
Not that often  
Almost never  
Never 
 
EDS_Q015, EDS_015 
In your day-to-day life, 
how often do any of the 
following things happen to 
you? 
People act as if they think 
you are not smart. 
1 At least once a week 
2 A few times a month 
3 A few times a year 
4 Less than once a year 
5 Never 
DK, RF 
S5-Q2. These next questions 
ask about your experiences of 
racism. Please think carefully, 
and do your best to answer 
each question 
Q4) People act as if you are 
not as smart 
Almost everyday  
Frequently  
Sometimes  
Not that often  
Almost never  
Never 
 
 EDS_Q020, EDS_020 
In your day-to-day life, 
how often do any of the 
following things happen to 
you? 
People act as if they are 
afraid of you. 
1 At least once a week 
2 A few times a month 
3 A few times a year 
4 Less than once a year 
5 Never 
DK, RF 
S5-Q2. These next questions 
ask about your experiences of 
racism. Please think carefully, 
and do your best to answer 
each question 
Q5) People act as if they are 
afraid of you 
Almost everyday  
Frequently  
Sometimes  
Not that often  
Almost never  
Never 
 
EDS_Q025, EDS_025 
In your day-to-day life, 
how often do any of the 
following things happen to 
S5-Q2. These next questions 
ask about your experiences of 
racism. Please think carefully, 
and do your best to answer 
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you? 
You are threatened or 
harassed. 
1 At least once a week 
2 A few times a month 
3 A few times a year 
4 Less than once a year 
5 Never 
DK, RF 
each question 
Q6) You are threatened or 
harassed 
Almost everyday  
Frequently  
Sometimes  
Not that often  
Almost never  
Never 
 
Point: the questionnaire in the 
CHIWOS has two more 
questions in this section, but 
CCHS does not. Then, We 
will remove these two in the 
analysis to make balance in 
terms of the questions  
 
EDS_Q030 What do you 
think the reasons might be 
for you to have had these 
experiences? Was it... 
 
EDS_030A 01 Your race 
EDS_030B 02 Your 
gender 
DK, RF 
Important point:  
In the CHIWOS, participants 
were explicitly asked these 
questions regarding their race 
discrimination and these 
questions once again repeated 
to sex discrimination 
(assumed to be gender 
discrimination). However, in 
the CCHS, participants were 
asked these questions first and 
then were asked the reason for 
such experiences that gender 
and race are among those 
reason. Then, these questions 
will be summed to calculate 
the scores for only those who 
reported the reasons for race 
and gender. Those who did 
not report these experiences 
for both race and gender 
separately, we will assign the 
least possible score for them.  
Additionally, in CHIWOS, 
trans participants were asked 
questions regarding 
discrimination in relation to 
their gender, whereas 
cisgender women were asked 
about discriminating in 
relation to being a woman. 
This will be considered in the 
analysis.  
 
 EDS_Q035, EDS_035 
Of the reasons you just 
mentioned, which one do 
you think is the main 
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reason? 
01 Your race 
02 Your gender 
DK, RF 
Social support    
A) SS-
emotional/informatio
nal  
SPS_Q06, SPS_06 
There is a trustworthy 
person I could turn to for 
advice if I were having 
problems. 
1 Strongly agree 
2 Agree 
3 Disagree 
4 Strongly disagree 
DK, RF 
S9-Q4 (1) 
Someone to turn to for 
suggestions about how to deal 
with a personal problem 
All of the time  
Most of the time  
Some of the time  
A little of the time  
None of the time  
DK 
PNTA 
 
a) We will sum these 
four items and create a 
new continuous variable. 
Total score with current 
version range: 4-20 (in 
CHIWOS) and 4-16 (in 
CCHS) obtained by 
summing each item. We 
will combine “most of 
the time” and “some of 
the time” in the 
CHIWOS study and 
create four-point-Likert 
scale. The new construct 
will have a range from 4 
to 16, matched with 
CCHS data.  
 
B) SS- Tangible 
support  
SPS_Q01, SPS_01 
There are people I can 
depend on to help me if I 
really need it. 
1 Strongly agree 
2 Agree 
3 Disagree 
4 Strongly disagree 
DK, RF 
S9-Q4 (2) 
Someone to help with daily 
chores if you were sick 
All of the time  
Most of the time  
Some of the time  
A little of the time  
None of the time  
DK 
PNTA 
C) SS- affectionate 
support  
SPS_Q08, SPS_08 
I feel a strong emotional 
bond with at least one 
other person. 
1 Strongly agree 
2 Agree 
3 Disagree 
4 Strongly disagree 
DK, RF 
 
S9-Q4 (3) 
Someone to love and make 
you feel wanted 
All of the time  
Most of the time  
Some of the time  
A little of the time  
None of the time  
DK 
PNTA 
D) SS- positive 
social interaction  
SPS_Q02 , SPS_02 
There are people who 
enjoy the same social 
activities I do. 
1 Strongly agree 
2 Agree 
3 Disagree 
4 Strongly disagree 
DK, RF 
S9-Q4 (4) 
Someone to do something 
enjoyable with 
All of the time  
Most of the time  
Some of the time  
A little of the time  
None of the time  
DK 
PNTA 
Housing status  SDC_Q7A, DHH_OWN 
Now a question about the 
dwelling in which you live.  
Is this dwelling… ? 
1 Owned by you or a 
member of this household, 
S1-Q14.  
Which of the following best 
describes the residence in 
which you currently live? 
House that you own 
Apartment or Condominium 
Housing status  
Owned a house or an 
apartment  
Others (rented, not 
rented, under-housed, 
homeless) 
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even if it is still being paid 
for 
2 Rented, even if no cash 
rent is paid 
DK, RF 
that you own 
House that you rent 
Floor in a house that you rent 
A basement apartment that 
you rent 
Apartment or Condominium 
that you rent 
Self-contained room in a 
house with other people 
Self-contained room in an 
apartment with other people 
Self-contained room with 
amenities  
Self-contained room with no 
amenities  
An HIV care group home 
where you have your own 
room but share a kitchen and 
bathroom and where you 
receive care and support 
related to HIV 
A housing facility (such as a 
group home) where you have 
your own room but share a 
kitchen and bathroom 
and where you receive care 
and support related to your 
older age, physical health, 
mental health, substance 
use, disability or rehabilitation  
Outdoors, on the street, parks, 
or in a car  
Couch Surfing  
Transition house/Halfway 
house/Safe House  
Shelter  
Jail  
Other, please specify: 
________________ 
Don’t know  
Prefer not to answer  
Relationship 
(marital) status 
MSNC_Q01  
What is [respondent 
name]’s marital status? Is 
[he/she]: 
INTERVIEWER: Read 
categories to respondent. 
1 ... married? 
2 ... living common-law? 
3 ... widowed? 
4 ... separated? 
5 ... divorced? 
6 ... single, never married? 
S1-Q4.  
What is your current legal 
relationship status? 
Legally married 
Common-law 
In a relationship, not living  
together 
Single 
Separated / Divorced 
Widowed 
Other, please specify:  
Prefer not to answer  
Marital status  
Married/ Common-law 
Others type of marital 
status (separated, 
divorced, widowed) 
Single/never married  
 
 
Education  EHG2_Q01, EDU_1  S1-Q9. What is the highest Educational status 
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What is the highest grade 
of elementary or high 
school [respondent name] 
has ever completed? 
 
1 Grade 8 or lower 
(Québec: Secondary II or 
lower)  
2 Grade 9 - 10 (Québec: 
Secondary III or IV, 
Newfoundland and 
Labrador: 1st year 
secondary)  
3. Grade 11 - 13 (Québec: 
Secondary V, 
Newfoundland and 
Labrador: 2nd to 3rd year 
of secondary) 
 
EHG2_Q02, EDU_2 
Did [respondent 
name]complete a high 
school diploma or its 
equivalent? 
1 Yes 
2 No 
 
EHG2_Q03, EDU_3 
Has [respondent name] 
received any other 
education that could be 
counted towards a 
certificate, diploma or 
degree from an educational 
institution? 
1 Yes  
2 No 
 
EHG2_Q04, EDU_1 
What is the highest 
certificate, diploma or 
degree that [respondent 
name] has completed? 
1 Less than high school 
diploma or its equivalent 
2 High school diploma or a 
high school equivalency 
certificate 
3. Trade certificate or 
diploma 
4. College, CEGEP or 
other non-university 
certificate or diploma 
(other than trades 
level of formal education you 
have completed? 
Select one. 
No formal education 
Elementary / Grade school 
High school / Secondary 
GED (General Education 
Diploma) 
Trade or Technical training 
CEGEP / College 
Undergraduate university 
Post-graduate education 
Other, please specify 
___________ 
Don’t know 
Prefer not to answer 
Secondary and below  
Above secondary   
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certificates or diplomas) 
5. University certificate or 
diploma below the 
bachelor's level 
6. Bachelor's degree (e.g. 
B.A., B.Sc., LL.B.) 
7. University certificate, 
diploma, degree above the 
bachelor's level 
 
EDU_Q05, SDC_8 
^ARE_C ^YOU1 currently 
attending a school, college, 
cégep or university? 
1 Yes 
2 No (Go to EDU_END) 
DK, RF (Go to 
EDU_END) 
 
 
EDU_Q06, SDC_9 
^ARE_C ^YOU1 enrolled 
as...? 
1 A full-time student 
2 A part-time student 
3 Both full-time and part-
time student 
Job status  Have you worked at a job 
or business at any time in 
the past 12 months? 
1 Yes  
2 No 
S1-Q10a. People make money 
in a variety of ways; for 
instance, a regular job, and 
some under-the-table work. 
Over the last year, what were 
the different ways you’ve 
made money? 
Paid job, taxes paid  
Paid job, taxes unpaid / 
"Under-the-table work"  
Social assistance  
Pension  
Sex work  
Selling drugs / drugs 
paraphernalia  
Pan-handling/ 'squeegeeing' / 
recycling  
Worker’s compensation 
(WCB)  
Employment Insurance (EI)  
Personal savings  
Loan(s) / Student Loan(s)  
Parent / friend / relative / 
partner income  
Honoraria (workshops, 
trainings)  
Other, please specify: ____ 
Categories:  
- Yes (paid job with or 
without tax) 
- No (others) 
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Household size 
(probably useful for 
income adjustments) 
Hhsz  S1-Q13a. How many people 
are financially dependent on 
you, not including yourself? 
…..  
 
 
 
Selected list of variables available in CHIWOS for the first and second waves used in 
objectives 1 and 2 
 Wave 1 Wave 2  
Variables on substance 
use 
Variable ID, question  Variable ID, question  
Alcohol consumption 
questionnaire  
Definition: A standard drink was considered to be contained 13.45 grams of pure 
alcohol or the equivalent of 0.6 ounces (oz) of 100% alcohol and was defined as 
341 ml (12-oz) bottle of 5% alcohol "beer, cider or cooler", 142 ml (5-oz) glass of 
12% alcohol "wine", and 43 ml (1.5-oz) serving of "liquor or spirits". 
S6-Q1 
How often in the last year have 
you had a drink containing 
alcohol? 
Never  
Monthly or less  
2-4 times a month  
2-3 times a week  
4 or more times a week 
DK 
PNTA 
 
This item is also indicative of the 
frequency measure  
S7-01.  
How often in the last year have you had a 
drink containing alcohol? 
Never  
Monthly or less 
2-4 times a month 
2-3 times a week 
4 or more times a week 
DK 
PNTA 
 
S6-Q2 
How many drinks containing 
alcohol do you have on a typical 
day when you are drinking? 
1 or 2 
3 or 4 
5 or 6 
7, 8 or 9 
10 or more 
Don’t know 
Prefer not to answer 
S7-02.  
How many drinks containing alcohol do 
you have on a typical day when you are 
drinking?  
1 or 2 
3 or 4 
5 or 6 
7, 8 or 9 
10 or more 
Don’t know 
Prefer not to answer 
S6-Q3.  
Considering all types of alcoholic 
beverages (e.g., wine, beer, etc), 
have you had 4 or more drinks on 
any one single occasion in the 
past month? 
 
S7-03. 
How often do you have six or more drinks 
on one occasion? 
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And  
 
S6-Q4.  
How many times in the past 
month have you had 4 or more 
drinks on any one single 
occasion? 
Stimulant use  
 
 
S6-Q10b.  
[3 months before HIV diagnose] 
Within three months before your 
HIV diagnosis, did you use any of 
the following drugs? 
- Cocaine 
- Crack [crack cocaine] 
- Methamphetamine,  
- Speed [amphetamine/MDA]  
---  
S6-Q11b.  
[3 months after HIV diagnose] 
Within three months after your 
HIV diagnosis, did you use any of 
the following drugs? 
- Cocaine 
- Crack [crack cocaine] 
- Methamphetamine,  
- Speed [amphetamine/MDA] 
---  
S6-Q12b.  
[Last three months] Over the last 
three months (current), did you 
use any of the following drugs? 
- Cocaine 
- Crack [crack cocaine] 
- Methamphetamine,  
- Speed [amphetamine/MDA] 
S7-11. And S7-14   
Within six months before your HIV 
diagnosis, did you use any of the following 
drugs? 
- Cocaine 
- Crack [crack cocaine] 
- Methamphetamine,  
- Speed [amphetamine/MDA]  
- Goofballs (heroin + crystal meth) (only 
in w2; then, removed) 
Opiate/Opioids  
 
 
S6-Q10b.  
[3 months before HIV diagnose] 
Within three months before your 
HIV diagnosis, did you use any of 
the following drugs? 
- Heroin 
- Speedball  
- Morphine 
- Methadone  
- OxyContin/Oxycodone 
- Codeine (t3 & T4) 
- Fentanyl  
- Dilaudid (hydromorphone) 
- Talwin & Ritalin (T & R)) 
---  
S6-Q11b.  
[3 months after HIV diagnose] 
Within three months after your 
HIV diagnosis, did you use any of 
the following drugs? 
- Heroin 
- Speedball  
---  
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- Morphine 
- Methadone  
- OxyContin/Oxycodone 
- Codeine (t3 & T4) 
- Fentanyl  
- Dilaudid (hydromorphone) 
- Talwin & Ritalin (T & R)) 
S6-Q12b.  
[Last three months] Over the last 
three months (current), did you 
use any of the following drugs? 
- Heroin 
- Speedball  
- Morphine 
- Methadone  
- OxyContin/Oxycodone 
- Codeine (t3 & T4) 
- Fentanyl  
- Dilaudid (hydromorphone) 
- Talwin & Ritalin (T & R)) 
S7-11. And S7-14   
Over the last six months (current), did 
you use any of the following drugs? 
- Heroin 
- Speedball  
- Morphine 
- Methadone  
- OxyContin/Oxycodone 
- Codeine (t3 & T4) 
- Fentanyl  
- Dilaudid (hydromorphone) 
- Talwin & Ritalin (T & R)) 
Clinical outcomes   
Current ART use  S2-Q8.  
Are you currently taking ARVs? 
S2-02d.  
Are you currently taking ARVs for your 
own health?  
 
Treatment adherence  
Last month 
S2-Q9b.  
We understand that many people 
on HIV medications find it 
difficult to take…. 
 
Optimal adherence:  
Yes if ≥95%  
No if  <95% 
 
S2-06.  
We understand that many people on HIV 
medications find it difficult to take…. 
 
Viral load suppression 
status 
S2-Q12b.  
What was your most recent viral 
load, undetectable or detectable? 
Undetectable (i.e. below 40 
copies/mL)  
Detectable (i.e. over 40 copies/mL) 
DK 
PNTA 
 
S2-Q12c.  
Do you remember the exact 
result? 
Indicate result: ______ copies/mL 
S2-11a. 
What was your most recent viral load, 
undetectable or detectable? 
 
 
 
 
S2-11a. 
Do you remember the exact result? 
Indicate result: ______ copies/mL 
Other variables (social 
determinants and 
exploratory variables) 
  
Age at interview  Participant’s Date of Birth --- 
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Biological sex at birth S1-Q1.  
What was your biological sex at 
birth? 
Male 
Female 
Intersex 
Undetermined 
Other, please specify:  
Don’t know 
Prefer not to answer 
--- 
Current gender identity  S1-Q2a.  
With respect to your gender, how 
do you currently identify? 
 
Woman 
Trans Man (Female to Male) 
(excluded)  
Trans Woman (Male to Female) 
Two-spirited 
Intersex 
Gender Queer 
Other,  
Man (excluded) 
S1-01 
With respect to your gender, how do you 
currently identify? 
 
Woman 
Trans Man (Female to Male) (excluded)  
Trans Woman (Male to Female) 
Two-spirited 
Intersex 
Gender Queer 
Other,  
Man (excluded) 
Sexual orientation  S1-Q3.  
With respect to your sexual 
orientation, how do you currently 
identify? 
 
Heterosexual / Straight 
Lesbian 
Gay 
Queer 
Bisexual 
Two-spirited 
Questioning 
Others  
DK 
PNTA 
S1-04. 
With respect to your sexual orientation*, 
how do you currently identify? 
 
Marital status  S1-Q4.  
What is your current legal 
relationship status? 
Legally married 
Common-law 
In a relationship, not living  
together 
Single 
Separated / Divorced 
Widowed 
Other, please specify:  
Prefer not to answer 
S1-05.   
What is your current legal relationship 
status?  
 
Legal status   
 
 
S1-Q6.  
What is your current legal status 
in Canada? 
Canadian citizen 
Landed Immigrant/Permanent 
Resident 
S1-06. 
What is your current legal status in 
Canada? 
Canadian citizen 
Landed Immigrant/Permanent Resident 
Refugee/Protected Person 
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Refugee/Protected Person 
Refugee claimant/Person in need of 
protection 
Here with Temporary Work Papers 
Here with Humanitarian and 
Compassionate approval 
Here as a visitor 
Here on a Student Visa 
Undocumented/Illegal Immigrant 
Other, please specify:  
Don’t know 
Prefer not to answer 
Refugee claimant/Person in need of 
protection 
Here with Temporary Work Papers 
Here with Humanitarian and Compassionate 
approval 
Here as a visitor 
Here on a Student Visa 
Undocumented/Illegal Immigrant 
Other, please specify:  
Don’t know 
Prefer not to answer 
Ethno-racial  S1-Q7.  
What do you consider to be your 
racial and/or ethnic background? 
 
Many groups …  
--- 
Educational attainment  S1-Q9.  
What is the highest level of 
formal education you have 
completed? 
 
Many groups … 
S1-23.  
What is the highest level of formal 
education you have completed*? 
Employment status  S1-Q10a.  
People make money in a variety 
of ways; for instance, a regular 
job, and some under-the-table 
work. Over the last year, what 
were the different ways you’ve 
made money? 
 
Many groups …  
S1-24. 
Are you currently employed? 
Household income  S1-Q11a.  
How much does your household 
make in a year, before taxes (i.e., 
household gross yearly income)? 
Less than 10,000 
10,000 to 19,999 
20,000 to 29,999 
30,000 to 39,999 
40,000 to 49,999 
….  
S1-27.   
Considering all income sources, how 
much does your household make in a 
year, before taxes (i.e., household gross 
yearly income*)? 
Household income  S1-Q11b.  
If unable to answer gross yearly 
household income, prompt for 
gross monthly income: 
 
Indicate gross monthly income in 
dollars: ……….  
--- 
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Personal income  S1-Q12a.  
How much do you make in a 
year, before taxes (i.e., personal 
gross yearly income)? 
Less than 10,000 
10,000 to 19,999 
20,000 to 29,999 
30,000 to 39,999 
40,000 to 49,999 
…. 
S1-28.  
Considering all income sources, how 
much do you make in a year, before taxes 
(i.e., personal gross yearly income*)? 
Personal income S1-Q12b.  
If unable to answer gross yearly 
personal income, prompt for 
gross monthly income: 
 
Indicate gross monthly income in 
dollars: ………. 
--- 
Difficulty in meeting 
monthly housing costs 
S1-Q18.  
Given your total household 
income, how difficult is it to meet 
your monthly housing costs 
including rent/mortgage, 
property taxes, and utilities (e.g., 
heat, electricity, water and gas)? 
Would you say that it is 
S1-36. 
Given your total household income, how 
difficult is it to meet your monthly 
housing costs   (including rent, mortgage, property taxes, heat, electricity, water and/or gas)? 
Number of dependents  S1-Q13a.  
How many people are financially 
dependent on you, not including 
yourself? 
 
Indicate the number of people: 
……… 
--- 
Housing status  S1-Q14.  
Which of the following best 
describes the residence in which 
you currently live? 
 
Many groups … 
S1-29.  
Since your last visit, have you been 
homeless*? 
 
 
S1-30.   
Do you have a regular place to stay right 
now? 
 
 
 
S1-33. 
What type of place are you currently 
living in? 
 
 
 
 
S1-37. 
My current housing situation is stable 
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Geographic location  S1-Q19.  
What are the first three digits of 
the postal code at which you are 
currently living? 
Only record first three digits Postal 
Code: ……  
S1-31. 
What is the postal code for the place 
where you are currently living or 
regularly sleep? 
Food insecurity  
 
In past 12 months  
S1-Q23. 
Item 1 
Item 2 
Item 3  
---  
Specific addiction 
treatment enrollment  
 
 
Ever status which makes it 
difficult to use, but since 
occur before baseline time 
point, we can use it.  
S6-Q17.  
Now I am going to ask you some 
questions about your use of 
substance related services, as they 
relate to your use of drugs or 
alcohol (not tobacco). 
 
Have you ever used any of the 
following substance-related 
services? 
S7-17. 
Since your last CHIWOS interview, have 
you used any of the following substance-
related services? 
Addiction treatment 
enrollment (overall) 
S6-Q17.  
Now I am going to ask you some 
questions about your use of 
substance related services, as they 
relate to your use of drugs or 
alcohol (not tobacco). 
 
Have you ever used any of the 
following substance-related 
services? 
S7-17. 
Since your last CHIWOS interview, have 
you used any of the following substance-
related services? 
Time since HIV diagnosis  
(HIV duration) 
S2-Q4a.  
When were you diagnosed with 
HIV? 
 
---  
Age at HIV diagnose  S2-Q4a.  
When were you diagnosed with 
HIV? 
 
---  
Time since ART 
initiation  
 
(duration of ART uptake) 
S2-Q7.  
When was the first time you ever 
took ARVs? 
---  
Time for last CD4 count  
 
Current status 
S2-Q10a.  
When did you last receive your 
CD4 count results? 
S2-07.   
When did you last receive your CD4 
count results? 
CD4 count measure  
 
Current status! 
S2-Q10b.  
What was your most recent CD4 
count? 
 
S2-Q10c.  
Are you able to estimate your 
most recent CD4 
count? 
S2-08a.   
What was your most recent CD4 count? 
 
S2-08b. 
Are you able to estimate your most recent 
CD4 count? 
Time since nadir CD4 S2-Q11a.  ---  
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count  When did you receive your lowest 
(nadir) CD4 count results? 
Results of nadir CD4 
count  
S2-Q11b.  
What was your lowest (nadir) 
CD4 count? 
 
S2-Q11c.  
Are you able to estimate your 
lowest (nadir) CD4 count? 
---  
CD4 count first time 
diagnosed with HIV  
---  S2-09b. 
Are you able to estimate your CD4 count 
when you were first diagnosed with HIV? 
CD4 count at time ART 
initiated 
---  S2-09c.   
Are you able to estimate your CD4 count 
when you first started taking ARVs (i.e., 
for the first time ever)?  
Change ART since last 
CHIWOS wave  
--- S2-03. 
Since your last CHIWOS interview, have 
there been any changes in your HIV 
antiretroviral therapy medications (i.e. 
ARVs*)? 
Viral load last result 
(time) 
S2-Q12a.  
When did you last receive your 
HIV viral load results? 
 
Indicate Year: ….. 
Indicate Month: ….  
 
Never received viral load results  
DK 
PNTA 
S2-10.   
When did you receive your most recent 
HIV viral load* results?  
Indicate Year: ….. 
Indicate Month: ….  
 
Never received viral load results  
DK 
PNTA 
Time takes to travel to 
HIV clinic [where 
primarily receive HIV 
medical care]  
S3-Q19.  
How much time does it take to 
travel one-way from your 
residence to this clinic? 
Between 0 and <30 min 
Between 30 and <60 min 
Between 1 and <3 hours 
Between 3 and <5 hours 
Five hours or more 
Don't know 
Prefer not to answer 
---  
HIV medical care 
satisfaction  
S3-Q30  
All 6 items  
S3-30  
All 6 items  
HCV infection and 
medication  
S2-Q15a.  
Have you ever been told by a 
doctor or nurse that you have or 
had hepatitis C (Hep C)? 
S2-15.   
Have you ever been told by a doctor or 
nurse that you have hepatitis C (Hep C)? 
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S2-Q15b.  
Have you ever taken medication 
for hepatitis C? 
S2-16 
Have you ever taken medication for 
hepatitis C? 
HBV  S2-Q16.  
Have you ever been told by a 
doctor or nurse that you have 
hepatitis B (Hep B)? 
S2-17  
Since your last CHIWOS interview, have 
you been told by a doctor or nurse that 
you have hepatitis B (Hep B)? 
Quality of life  
 
Last 4 weeks 
Using SF-12  
S9-Q5. (both items) 
S9-Q6. (both items) 
S9-Q7. (both items)  
S9-Q8.  
S9-Q9. (all three items) 
S9-Q10. 
S9-Q11. 
Using SF-12  
S4-04 (both items) 
S4-05 (both items) 
S4-06 (both items) 
S4-07  
S4-08 (all three items) 
S4-09  
S4-10  
Social support  
 
MOS-SS scale  
 
S9-Q4 
Item 1  
Item 2 
Item 3 
Item 4  
--- 
Resilience  
 
Connor-Davidson 
resilience scale (CDRS) 
 
Without time limit!  
S9-Q12 
All items in this scale  
--- 
HIV stigma  
 
Berger HIV stigma scale  
 
Without time limit! 
S5-Q1 
All items under this scale  
S6-01  
All items under this scale 
Experience of Racial 
discrimination (time: 
day-to-day) 
 
Detroit Area study (EDS) 
scale  
S5-Q2  
All items under this scale  
 
Experience of sexism 
(time: day-to-day) 
 
S5-Q3 
All items under this scale  
 
Willingness to HIV status 
disclosure  
 
S5-Q5  
All items under this scale  
S6-02  
All items under this scale 
Depressive symptoms  
 
CES-D 10 scale – past 
week  
S9-Q2 
All items under this scale  
S4-02  
All items under this scale  
Distress  
 
Kessler Psychological 
Distress scale (K6) – 
during past 30 days  
--- S4-03  
All items under this scale  
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PTSD  
 
PTSD checklist (PCL-C) 
 
S9-Q3  
All items under this scale  
---  
Mental health conditions 
(overall) 
 
Ever  
S9-Q1a.  
Have you ever been diagnosed 
with a mental health condition by 
a care provider? 
S4-01 
Which, if any, of the following mental 
health conditions are you currently living 
with? Please only include conditions that 
have been diagnosed by a healthcare 
provider 
Specific mental health 
conditions  
S9-Q1b.  
Which ones [mental health 
conditions]? 
S4-01 
Which, if any, of the following mental 
health conditions are you currently living 
with? Please only include conditions that 
have been diagnosed by a healthcare 
provider 
Recent incarceration  S1-Q29.  
In the last year, have you been 
incarcerated, or held in custody 
overnight or longer, in Canada? 
 
S1-38. 
Since your last CHIWOS interview, have 
you been incarcerated*, or held in 
custody overnight or longer, in Canada? 
Any experience of 
violence in the past 3 
months (adulthood 
violence, ≥ 16 years)  
S7-Q2c. 
Has this [physical violence] 
happened in the last 3 months? 
 
S7-Q3c.  
Has this [insulted, threatened, 
screamed, or cursed] happened in 
the last 3 months? 
 
S7-Q4c.  
Has this [restricted your actions 
by controlling] happened in the 
last 3 months? 
 
S7-Q5c.  
Has this [sexually forced] 
happened in the last 3 months? 
S8-02 
In the last 3 months, has someone ever 
physically hurt you?  
 
S8-08. 
In the last 3 months, has someone 
insulted, threatened, screamed, or cursed 
at you? 
 
 
S8-12. 
In the last three months, has someone 
restricted your actions by controlling 
where you can go and what you can do? 
 
S8-16 
In the last three months, has someone 
sexually forced themselves on you, or 
forced you to have sex? 
Adverse childhood 
experiences 
i) Any experience of violence in 
childhood  (< 16 years) 
S7-Q6a. This second series of 
questions are about experiences you 
had as a child. For our purposes, 
child is defined as less than 16 
years of age. During your 
childhood, did an adult ever 
physically hurt you? 
 
S7-Q8a. During your childhood, did 
someone ever sexually force 
themselves on you, or forced you to 
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have sex? 
 
ii) S1-Q25. Have you ever been 
under the care of Child Protection 
Services? Select one.   
Yes  
No  
Don’t know   
Prefer not to answer 
 
iii) S1-Q26. Have you ever been 
in foster care? Select one.  
Yes  
No   
Don’t know   
Prefer not to answer   
Barriers to care scale  S3-42. Please indicate to what 
extent each of the following 
circumstances have made it 
difficult for you to receive the 
care, services, or opportunities 
you wish to obtain over the past 
year  
1. Long distances to medical 
facilities and personnel 
2. Medical personnel (e.g. 
physicians, nurses), who decline to 
provide direct care to persons with 
HIV/AIDS 
3. The lack of health care 
professionals who are adequately 
trained and competent in HIV/ care 
4. The lack of transportation to 
access the services you need 
5. The shortages of psychologists, 
social workers and mental health 
counselors who can help address 
mental health issues 
6. The lack of psychological 
support groups for persons with 
HIV/AIDS 
7. The level of knowledge about 
HIV/AIDS among residents in the 
community 
8. Community residents' stigma 
against persons living with 
HIV/AIDS 
9. The lack of employment 
opportunities for people living with 
HIV/AIDS 
10. The lack of supportive and 
understanding work environments 
for people living with HIV/AIDS 
11. Your personal financial 
resources 
12. Lack of adequate and affordable 
Please indicate to what extent each of the 
following circumstances have made it 
difficult for you to receive the care, 
services, or opportunities you wish to 
obtain over the past year  
1. Long distances to medical facilities and 
personnel 
2. Medical personnel (e.g. physicians, 
nurses), who decline to provide direct care to 
persons with HIV/AIDS 
3. The lack of health care professionals who 
are adequately trained and competent in 
HIV/AIDS care 
4. The lack of transportation to access the 
services you need 
5. The shortages of psychologists, social 
workers and mental health counselors who 
can help address mental health issues 
6. The lack of psychological support groups 
for persons with HIV/AIDS 
7. The level of knowledge about HIV/AIDS 
among residents in the community 
8. Community residents' stigma against 
persons living with HIV/AIDS 
9. The lack of employment opportunities for 
people living with HIV/AIDS 
10. The lack of supportive and 
understanding work environments for people 
living with HIV/AIDS 
11. Your personal financial resources 
12. Lack of adequate and affordable housing 
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housing 
Access to medical care  S2-Q4b. After receiving your 
HIV diagnosis, when did you first 
access HIV medical care? 
Indicate Year: …………  
Indicate Month: ………… 
 
I have never accessed HIV medical 
care  
Don’t know 
Prefer not to answer 
 
Access to medical care S3-Q41a. Have you ever tried to 
access HIV support services and 
been unable to?   
Select one.  
Yes  
No  
Don’t know  
Prefer not to answer 
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